NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Santaguida PL, Balion C, Hunt D, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep. (Evidence Reports/Technology Assessments, No. 128.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose

Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose.

Show details

Appendix F. Bibliography

References

  1. Abbott WGH, Thuillez P, Howard BV. Body composition, adipocyte size, free fatty acid concentration, and glucose tolerance in children of diabetic pregnancies. Diabetes. 1986;35(10):1077–1080. [PubMed: 3530841]
  2. Abel ED, Ledingham JG. Impaired glucose tolerance in hypertension is associated with impaired insulin release independently of changes in insulin sensitivity. J Hypertens. 1994;12(11):1265–1273. [PubMed: 7868874]
  3. Acosta P, Jimenez-Balderas E, Juarez-Oropeza MA, Diaz-Zagoya JC. Hypoglycemic action of Cucurbita ficifolia on Type 2 diabetic patients with moderately high blood glucose levels. J Ethnopharmacol. 2001;77(1):99–101. [PubMed: 11483384]
  4. Adachi H, Hashimoto R, Tsuruta M, Jacobs DR Jr., Crow RS, Imaizumi T. Hyperinsulinemia and the development ST-T electrocardiographic abnormalities: An 11-year follow-up study. Diabetes Care. 1997;20(11):1688–1692. [PubMed: 9353609]
  5. Adachi H, Hirai Y, Tsuruta M, Fujiura Y, Imaizuml T. Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. Diabetes Res Clin Pract. 2001;51(3):215–223. [PubMed: 11269894]
  6. Adegbenro SA, Dada OA, Olanrewaju DM, Fafunso MA. Glycosylated haemoglobin levels in children with protein-energy malnutrition. Ann Trop Paediatr. 1991;11(4):337–341. [PubMed: 1721790]
  7. Adler AI, Boyko EJ, Schraer CD, Murphy NJ. Lower prevalence of impaired glucose tolerance and diabetes associated with daily seal oil or salmon consumption among Alaska Natives. Diabetes Care. 1994;17(12):1498–1501. [PubMed: 7882827]
  8. Adler AI, Boyko EJ, Schraer CD, Murphy NJ. The negative association between traditional physical activities and the prevalence of glucose intolerance in Alaska Natives. Diabet Med. 1996;13(6):555–560. [PubMed: 8799660]
  9. Agardh CD, Aberg A, Norden NE. Glucose levels and insulin secretion during a 75 g glucose challenge test in normal pregnancy. J Intern Med. 1996;240(5):303–309. [PubMed: 8946813]
  10. Agewall S, Persson B, Samuelsson O, Ljungman S, Herlitz H, Fagerberg B. Microalbuminuria in treated hypertensive men at high risk of coronary disease. J Hypertens. 1993;11(4):461–469. [PubMed: 8390516]
  11. Agner E, Thorsteinsson B, Eriksen M. Impaired glucose tolerance and diabetes mellitus in elderly subjects. Diabetes Care. 1982;5(6):600–604. [PubMed: 6927730]
  12. Ai M, Tanaka A, Ogita K, Sekine M, Numano F, Numano F. et al. Relationship between hyperinsulinemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2000;85(10):3557–3560. [PubMed: 11061501]
  13. Akanji AO, Bruce M, Frayn K. Oral glucose tolerance and ambient temperature in non-diabetic subjects. Diabetologia. 1987;30(6):431–433. [PubMed: 3678662]
  14. Al Lawati JA, Mohammed AJ. Diabetes in Oman: Comparison of 1997 American diabetes association classification of diabetes mellitus with 1985 WHO classification. Annals of Saudi Medicine. 2000;20(1):12–15. [PubMed: 17322734]
  15. Al Lawati JA, Al Riyami AM, Mohammed AJ, Jousilahti P. Increasing prevalence of diabetes mellitus in Oman. Diabet Med. 2002;19(11):954–957. [PubMed: 12421434]
  16. Al Shoumer KAS, Beshyah SA, Niththyananthan R, Johnston DG. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol (Oxf) 1995;42(1):85–90. [PubMed: 7889636]
  17. Alderman BW, Marshall JA, Boyko EJ, Markham KA, Baxter J, Hamman RF. Reproductive history, glucose tolerance, and NIDDM in Hispanic and non-Hispanic white women. The San Luis Valley Diabetes Study. Diabetes Care. 1993;16(12):1557–1564. [PubMed: 8299451]
  18. Alemzadeh R, Langley G, Upchurch L, Smith P, Slonim AE. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J Clin Endocrinol Metab. 1998;83(6):1911–1915. [PubMed: 9626118]
  19. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000;86(9):897–902. [PubMed: 11053695]
  20. Algvere P, Efendic S, Luft R, Wajngot A. Retinal microangiopathy and pigment epithelial lesions in subjects with normal, borderline, and decreased oral glucose tolerance. Br J Ophthalmol. 1985;69(6):416–419. [PMC free article: PMC1040618] [PubMed: 4005209]
  21. Allegra V, Amendolagine F, Mengozzi G, Jesu L, Vasile A. Metabolic and hormonal assessment of patients on maintenance hemodialysis for 10 years or more and their importance in long-term survival. Nephron. 1988;49(2):107–113. [PubMed: 3288886]
  22. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Glucose-induced insulin secretion in uremia: effects of aminophylline infusion and glucose loads. Kidney Int. 1990;38(6):1146–1150. [PubMed: 1963648]
  23. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr. 2002;76(1):148–155. [PubMed: 12081828]
  24. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis.[see comment] Am J Clin Nutr. 2002;76(1):148–155. [PubMed: 12081828]
  25. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: Pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother. 2003;52(3):435–440. [PubMed: 12917247]
  26. Amin P, Shah S, Walker D, Page SR. Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review. Diabet Med. 2001;18(10):849–853. [PubMed: 11678978]
  27. Amin R, Ross K, Acerini CI, Edge JA, Warner J, Dunger DB. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: Use of continuous glucose monitoring system. Diabetes Care. 2003;26(3):662–667. [PubMed: 12610018]
  28. Ammari F, Batieha A, Jaddou PHH, Okashi M, Ajlouni K. A natural history of impaired glucose tolerance in North Jordan. Practical Diabetes International. 1998;15(5):139–140.
  29. Amoah AG, Schuster DP, Gaillard T, Osei K. Insulin resistance, beta cell function and cardiovascular risk factors in Ghanaians with varying degrees of glucose tolerance. Ethn Dis. 2002;12(4):S3–S7. [PubMed: 12477148]
  30. Amoah AG, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. Diabetes Res Clin Pract. 2002;56(3):197–205. [PubMed: 11947967]
  31. Amoah AGB. Undiagnosed diabetes and impaired glucose regulation in adult Ghanaians using the ADA and WHO diagnostic criteria. Acta Diabetol. 2002;39(1):7–13. [PubMed: 12043940]
  32. Anand SS, Yusuf S. Risk factors for cardiovascular disease in Canadians of South Asian and European origin: a pilot study of the Study of Heart Assessment and Risk in Ethnic Groups (SHARE) Clin Invest Med. 1997;20(4):204–210. [PubMed: 9258575]
  33. Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q. et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care. 2003;26(2):290–296. [PubMed: 12547851]
  34. Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr. 1991;54(5):909–916. [PubMed: 1951165]
  35. Andronico G, Piazza G, Mangano MT, Mule G, Carone MB, Cerasola G. Nifedipine vs. enalapril in treatment of hypertensive patients with glucose intolerance. J Cardiovasc Pharmacol. 1991;18(Suppl 10):S52–S54. [PubMed: 1725004]
  36. Andronico G, Mangano M, Ferrara L, Lamanna D, Mule G, Cerasola G. In vivo relationship between insulin and endothelin role of insulin-resistance. J Hum Hypertens. 1997;11(1):63–66. [PubMed: 9111160]
  37. Angelopoulos TJ, Schultz RM, Denton JC, Jamurtas AZ. Significant enhancements in glucose tolerance and insulin action in centrally obese subjects following ten days of training. Clinical Journal of Sport Medicine. 2002;12(2):113–118. [PubMed: 11953558]
  38. Annuzzi G, Rivellese A, Vaccaro O. The relationship between blood glucose concentration and beat-to-beat variation in asymptomatic subjects. Acta Diabetol Lat. 1983;20(1):57–62. [PubMed: 6858543]
  39. Anonymous Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039–1057. [PubMed: 510803]
  40. Anonymous From the NIH: New standards for classification and diagnosis of diabetes. JAMA. 1980;243(22):2296–2297. [PubMed: 6892828]
  41. Anonymous Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71(5):393–400. [PubMed: 8430625]
  42. Anonymous Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–1197. [PubMed: 9203460]
  43. Anonymous Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe.[see comment] Diabetologia. 1999;42(6):647–654. [PubMed: 10382583]
  44. Anonymous Diet, exercise delay type 2 diabetes. FDA Consum. 2001;35(5):10–11. [PubMed: 11697084]
  45. Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 1997;20(2):188–193. [PubMed: 9118772]
  46. Arashiro R, Katsuren K, Fukuyama S, Ohta T. Effect of Trp64Arg mutation of the beta3-adrenergic receptor gene and C161T substitution of the peroxisome proliferator activated receptor gamma gene on obesity in Japanese children. Pediatrics International. 2003;45(2):135–141. [PubMed: 12709137]
  47. Arciero PJ, Vukovich MD, Holloszy JO, Racette SB, Kohrt WM. Comparison of short-term diet and exercise on insulin action in individuals with abnormal glucose tolerance. J Appl Physiol. 1999;86(6):1930–1935. [PubMed: 10368358]
  48. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68(12):873–877. [PMC free article: PMC1040501] [PubMed: 6509007]
  49. Armstrong VW, Buschmann U, Ebert R. Biochemical investigations of CAPD: Plasma levels of trace elements and amino acids and impaired glucose tolerance during the course of treatment. Int J Artif Organs. 1980;3(4):237–241. [PubMed: 7409923]
  50. Arrigo T, Cucinotta D, Conti NS, Di Cesare E, Di Benedetto A, Magazzu G. et al. Longitudinal evaluation of glucose tolerance and insulin secretion in non-diabetic children and adolescents with cystic fibrosis: results of a two-year follow-up. Acta Paediatr. 1993;82(3):249–253. [PubMed: 8495078]
  51. Arroliga AC. Intensive care update: Seven studies that should change your practice. Cleve Clin J Med. 2002;69(6):505–506. [PubMed: 12061466]
  52. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86(1):66–71. [PubMed: 11231980]
  53. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87(4):1555–1559. [PubMed: 11932281]
  54. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. J Clin Endocrinol Metab. 1994;79(1):80–85. [PubMed: 8027259]
  55. Baan CA, Stolk RP, Grobbee DE, Witteman JCM, Feskens EJM. Physical activity in elderly subjects with impaired glucose tolerance and newly diagnosed diabetes mellitus. American Journal of Epidemiology 149(3):219–27, 1999 Fen 1 (28 ref) 1999;(3) 219–227. [PubMed: 9927216]
  56. Bakker SJL, Hoogeveen EK, Nijpels G, Kostense PJ, Dekker JM, Gans ROB. et al. The association of dietary fibres with glucose tolerance is partly explained by concomitant intake of thiamine: The Hoorn Study. Diabetologia. 1998;41(10):1168–1175. [PubMed: 9794103]
  57. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A. et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003;59(4):492–499. [PubMed: 14510913]
  58. Balentine JR, Gaeta TJ, Kessler D, Bagiella E, Lee T. Effect of 50 milliliters of 50% dextrose in water administration on the blood sugar of euglycemic volunteers. Acad Emerg Med. 1998;5(7):691–694. [PubMed: 9678393]
  59. Balfour JA, Faulds D, Wolffenbuttel BHR, Mooradian AD. Repaglinide. Drugs & Aging. 1998;13(2):173–181. [PubMed: 9739505]
  60. Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44(6):465–474. [PubMed: 2037851]
  61. Balkau B, Eschwege E, Fontbonne A, Claude JR, Warnet JM. Cardiovascular and alcohol-related deaths in abnormal glucose tolerant and diabetic subjects. Diabetologia. 1992;35(1):39–44. [PubMed: 1541380]
  62. Balkau B, Eschwege E, Papoz L, Richard JL, Claude JR, Warnet JM. et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ. 1993;307(6899):295–299. [PMC free article: PMC1678578] [PubMed: 8374376]
  63. Balkau B, Eschwege E, Tichet J, Marre M. Proposed criteria for the diagnosis of diabetes: Evidence from a French epidemiological study (D.E.S.I.R.) Diabetes Metab. 1997;23(5):428–434. [PubMed: 9416436]
  64. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care. 1999;22(5):696–699. [PubMed: 10332668]
  65. Balkau B. Consequences of the new diagnostic criteria for diabetes in older men and women: The DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) Diabetes Care. 1999;22(10):1667–1671. [PubMed: 10526732]
  66. Balkau B. et al. Consequences of the new diagnostic criteria for diabetes in older men and women: the DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) Diabetes Care. 1999;22(10):1667–1671. [PubMed: 10526732]
  67. Balkau B. The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab. 2000;26(4):282–286. [PubMed: 11011220]
  68. Balkau B, Forhan A, Eschwege E. Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia. 2002;45(9):1224–1230. [PubMed: 12242454]
  69. Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW. Efficacy of Rosuvastatin 10 mg in patients with the Metabolic Syndrome. Am J Cardiol. 2003;91(5A):25C–28C. [PubMed: 12646342]
  70. Bancroft K, Tuffnell D, Mason G, Rogerson L, Mansfield M. A randomized controlled study of the management of impaired glucose intolerance in pregnancy. British Journal of Obstetrics and Gynaecology. 1998;105(Suppl 17):53–54.
  71. Bancroft K, Tuffnell DJ, Mason GC, Rogerson LJ, Mansfield M. A randomised controlled pilot study of the management of gestational impaired glucose tolerance.[comment] BJOG. 2000;107(8):959–963. [PubMed: 10955425]
  72. Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath M Jr. Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes. 1990;39(12):1527–1533. [PubMed: 2245877]
  73. Baral N, Koner BC, Karki P, Ramaprasad C, Lamsal M, Koirala S. Evaluation of new WHO diagnostic criteria for diabetes on the prevalence of abnormal glucose tolerance in a heterogeneous Nepali population--the implications of measuring glycated hemoglobin. Singapore Med J. 2000;41(6):264–267. [PubMed: 11109341]
  74. Bardet S, Joseph MG, Maugendre D, Matthieu E, Chaillous L, Semana G. et al. Predictive value of age-related acute insulin response to glucose in subjects at risk for type 1 diabetes: results of a 6-year follow-up study from west-France.[erratum appears in Diabete Metab 1993 Nov-Dec;19(6):602] Diabete Metab. 1993;19(4):372–380. [PubMed: 8293864]
  75. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol. 2001;88(2 SUPPL. 2):16H–19H. [PubMed: 11576521]
  76. Barrett-Connor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older adults: The Rancho Bernardo Study. Diabetes Care. 1996;19(12):1441–1444. [PubMed: 8941481]
  77. Barriga KJ, Hamman RF, Hoag S, Marshall JA, Shetterly SM. Population screening for glucose intolerant subjects using decision tree analyses. Diabetes Res Clin Pract. 1996;34 Suppl:S17–S29. [PubMed: 9015666]
  78. Barzilay J, Spiekerman C. Comparing ADA and WHO diabetes criteria for predicting cardiovascular risk. Cardiology Review. 2000;17(11):22–25.
  79. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD. et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria... including commentary by Davies M. Lancet. 1999;354(9179):622–625. [PubMed: 10466662]
  80. Barzilay JI, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS. et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care. 2001;24(7):1233–1239. [PubMed: 11423508]
  81. Batty GD, Shipley MJ, Marmot M, Smith GD. Physical activity and cause-specific mortality in men with Type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. Diabet Med. 2002;19(7):580–588. [PubMed: 12099962]
  82. Bavirti S, Tayek JA. Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose. Metabolism. 2003;52(4):407–412. [PubMed: 12701050]
  83. Bazaes RA, Petry CJ, Ong KK, Avila A, Dunger DB, Mericq MV. Insulin gene VNTR genotype is associated with insulin sensitivity and secretion in infancy. Clin Endocrinol (Oxf) 2003;59(5):599–603. [PubMed: 14616883]
  84. Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor CCM, Breier A. Treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biol Psychiatry. 2001;49(8):121S.
  85. Beer SF, Heaton DA, Alberti KG, Pyke DA, Leslie RD. Impaired glucose tolerance precedes but does not predict insulin-dependent diabetes mellitus: a study of identical twins. Diabetologia. 1990;33(8):497–502. [PubMed: 2210123]
  86. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A. et al. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003;52(8):1926–1934. [PubMed: 12882907]
  87. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T. et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13(10):F63–F70. [PubMed: 10416516]
  88. Beks PH, Mackaay AJ, de Vries H, De Neeling JN, Bouter LM, Heine RJ. Carotid artery stenosis is related to blood glucose level in an elderly Caucasian population: the Hoorn Study. Diabetologia. 1997;40(3):290–298. [PubMed: 9084966]
  89. Beks PJ, Mackaay AJ, De Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia. 1995;38(1):86–96. [PubMed: 7744233]
  90. Benfield MR. Current status of kidney transplant: Update 2003. Pediatr Clin North Am. 2003;50(6):1301–1334. [PubMed: 14710782]
  91. Berenson GS, Radhakrishnamurthy B, Srinivasan S. Plasma glucose and insulin levels in relation to cardiovascular risk factors in children from a biracial population - the Bogalusa heart study. J Chronic Dis. 1981;34(8):379–391. [PubMed: 7021577]
  92. Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW, Fujimoto WY. Association of plasma triglyceride and C-peptide with coronary heart disease in Japanese-American men with a high prevalence of glucose intolerance. Diabetologia. 1990;33(8):489–496. [PubMed: 2210122]
  93. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME. et al. Effect of troglitazone on insulin sensitivity and pancreatic b-cell function in women at high risk of NIDDM. Diabetes. 1996;45(11):1572–1579. [PubMed: 8866563]
  94. Berntorp K, Lindgarde F, Mattiasson I. Platelet sodium kinetics, blood pressure and serum urate: aberrations in non-obese men at risk for type 2 diabetes mellitus. Clin Sci (Colch ) 1987;73(1):109–116. [PubMed: 3608370]
  95. Bertin E, Rich N, Schneider N, Larbre H, Marcus C, Durlach V. et al. Insulin and body fat distribution have no direct effect on plasma leptin levels in obese Caucasian women with and without type 2 diabetes mellitus. Diabetes Metab. 1998;24(3):229–234. [PubMed: 9690055]
  96. Bertolini S, Cordera R, Marcenaro A, Versari G, Cuzzolaro S, Carniel M. et al. Metabolic effects of gemfibrozil in patients with primary hypertriglyceridaemia. Diabetes Nutr Metab. 1990;3(1):23–33.
  97. Bevier WC, Fischer R, Jovanovic L. Treatment of women with an abnormal glucose challenge test (but a normal oral glucose tolerance test) decreases the prevalence of macrosomia. Am J Perinatol. 1999;16(6):269–275. [PubMed: 10586979]
  98. Bitzen P-O, Melander A, Schersten B, Wahlin-Boll E. The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia. Eur J Clin Pharmacol. 1988;35(1):31–37. [PubMed: 3065086]
  99. Bitzen P-O, Melander A, Schersten B, Svensson M. Efficacy of dietary regulation in primary health care patients with hyperglycaemia detected by screening. Diabet Med. 1988;5(7):640–647. [PubMed: 2975547]
  100. Bitzen PO, Schersten B. Assessment of laboratory methods for detection of unsuspected diabetes in primary health care. Scand J Prim Health Care. 1986;4(2):85–95. [PubMed: 3726333]
  101. Bjorklund K, Lind L, Andren B, Lithell H. The majority of nondipping men do not have increased cardiovascular risk: a population-based study.[see comment] J Hypertens. 2002;20(8):1501–1506. [PubMed: 12172310]
  102. Bjornholt JV, Erikssen G, Kjeldsen SE, Bodegard J, Thaulow E, Erikssen J. Fasting blood glucose is independently associated with resting and exercise blood pressures and development of elevated blood pressure. J Hypertens. 2003;21(7):1383–1389. [PubMed: 12817188]
  103. Blaak EE, Kemerink GJ, Pakbiers MTW, Wolffenbuttel BHR, Heidendal GA, Saris WH. Microdialysis assessment of local adipose tissue lipolysis during beta-adrenergic stimulation in upper-body-obese subjects with type II diabetes. Clin Sci (Colch ) 1999;97(4):421–428. [PubMed: 10491342]
  104. Bloomgarden ZT. Pharmacologic treatment of type 2 diabetes. Diabetes Care. 2003;26(2):526–533. [PubMed: 12547894]
  105. Bluher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia. 2002;45(2):210–216. [PubMed: 11935152]
  106. Boer JM, Feskens EJ, Kromhout D. Characteristics of non-insulin-dependent diabetes mellitus in elderly men: effect modification by family history. Int J Epidemiol. 1996;25(2):394–402. [PubMed: 9119566]
  107. Boes U, Wallner S, Wascher TC. Acute effects of nicorandil on glucose tolerance in subjects with borderline fasting blood glucose levels. Wien Klin Wochenschr. 2001;113(3-4):127–129. [PubMed: 11253738]
  108. Bogardus C, Lillioja S, Howard BV. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest. 1984;74(4):1238–1246. [PMC free article: PMC425290] [PubMed: 6384267]
  109. Bolk J, van der PT, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79(2-3):207–214. [PubMed: 11461743]
  110. Bolli G, Compagnucci P, Cartechini MG. HbA1 in subjects with abnormal glucose tolerance but normal fasting plasma glucose. Diabetes. 1980;29(4):272–277. [PubMed: 7358227]
  111. Bonen A, Ball-Burnett M, Russel C. Glucose tolerance is improved after low- and high-intensity exercise in middle-age men and women. Can J Appl Physiol. 1998;23(6):583–593. [PubMed: 9822794]
  112. Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M. et al. Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia. 2000;43(2):156–164. [PubMed: 10753036]
  113. Boonsiri B, Virutamasen P, Tangkeo P, Wongsrichanalai C. Effects of daily 30 MCG norgestrel on glucose, insulin, cholesterol and triglycerides during 1 year's time of use. Asia Oceania J Obstet Gynaecol. 1983;9(2):180–184. [PubMed: 6351820]
  114. Bor MV, Bor P, Cevik C. Serum fructosamine and fructosamine - Albumin ratio as screening tests for gestational diabetes mellitus. Arch Gynecol Obstet. 1999;262(3-4):105–111. [PubMed: 10326628]
  115. Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care. 1994;17(11):1269–1272. [PubMed: 7821166]
  116. Bos G, Dekker JM, Nijpels G, de Vegt F, Diamant M, Stehouwer CDA. et al. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism - The Hoorn Study. Diabetologia. 2003;46(7):910–916. [PubMed: 12819906]
  117. Bosi EP, Garancini MP, Poggiali F, Bonifacio E, Gallus G. Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. Diabetologia. 1999;42(7):840–844. [PubMed: 10440126]
  118. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM. et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem. 2003;49(1):1–6. [PubMed: 12507953]
  119. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM. et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem. 2003;49(1):7–18. [PubMed: 12507954]
  120. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJW. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia. 1995;38(10):1239–1245. [PubMed: 8690178]
  121. Bougneres P-F, Artavia-Loria E, Ferre P. Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. J Clin Endocrinol Metab. 1985;61(6):1152–1157. [PubMed: 3902870]
  122. Bourn D, Mann J. Screening for noninsulin dependent diabetes mellitus and impaired glucose tolerance in a Dunedin general practice--is it worth it? N Z Med J. 1992;105(935):208–210. [PubMed: 1598139]
  123. Bourn DM, Mann JI, McSkimming BJ, Waldron MA, Wishart JD. Impaired glucose tolerance and NIDDM: does a lifestyle intervention program have an effect? Diabetes Care. 1994;17(11):1311–1319. [PubMed: 7821173]
  124. Bourn DM, Mann JI. The 3-yr follow-up of subjects with impaired glucose tolerance or non-insulin dependent diabetes mellitus in a diet and exercise intervention programme. Diabetes Nutr Metab. 1996;9(5):240–246.
  125. Boyko EJ, Court de, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23(9):1242–1248. [PubMed: 10977013]
  126. Braun B, Zimmermann MB, Kretchmer N, Spargo RM, Smith RM, Gracey M. Risk factors for diabetes and cardiovascular disease in young Asutralian Aborigines. Diabetes Care. 1996;19(5):472–479. [PubMed: 8732712]
  127. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism. 1995;44(12):1570–1576. [PubMed: 8786726]
  128. Brown DC, Byrne CD, Clark PM, Cox BD, Day NE, Hales CN. et al. Height and glucose tolerance in adult subjects [see comments] Diabetologia. 1991;34(7):531–533. [PubMed: 1916060]
  129. Brown DW, Giles WH, Greenlund KJ, Valdez R, Croft JB. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk. 2001;8(4):227–233. [PubMed: 11551001]
  130. Brown MD, Lau J, Nelson RD, Kline JA. Turbidimetric D-dimer test in the diagnosis of pulmonary embolism: a metaanalysis. Clin Chem. 2003;49(11):1846–1853. [PubMed: 14578316]
  131. Bruno A, Pagano G, Benzi L, Di Ciani G, Spallone V, Calabrese G. et al. Change in glucose metabolism after long-term treatment with deflazacort and betamethasone. Eur J Clin Pharmacol. 1992;43(1):47–50. [PubMed: 1505608]
  132. Bruno A, Fornengo P, Gruden G, Cavallo-Perin P, Cassader M, Milani S. et al. Serum glucose, insulin, C-peptide and plasma glucagon response to oral glucose after intravenous injection of different glucocorticoids at increasing doses in man. Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1997;10(1):18–23.
  133. Brustman L, Langer O, Engel S, Anyaegbunam A, Mazze R. Verified self-monitored blood glucose data versus glycosylated hemoglobin and glycosylated serum protein as a means of predicting short- and long-term metabolic control in gestational diabetes. Am J Obstet Gynecol. 1987;157(3):699–703. [PubMed: 3631170]
  134. Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK. Antepartum predictors of the development of type 2 diabetes in Latino women 11-26 months after pregnancies complicated by gestational diabetes. Diabetes. 1999;48(12):2430–2436. [PubMed: 10580433]
  135. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A. et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000;49(5):782–788. [PubMed: 10905487]
  136. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796–2803. [PubMed: 12196473]
  137. Bulow B, Erfurth EM. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance. Clin Endocrinol (Oxf) 1999;50(1):45–55. [PubMed: 10341855]
  138. Burchfiel CM, Hamman RF, Marshall JA, Baxter J, Kahn LB, Amirani JJ. Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study. Am J Epidemiol. 1990;131(1):57–70. [PubMed: 2293753]
  139. Burchfiel CM, Shetterly SM, Baxter J, Hamman RF. The roles of insulin, obesity, and fat distribution in the elevation of cardiovascular risk factors in impaired glucose tolerance: The San Luis Valley Diabetes Study. Am J Epidemiol. 1992;136(9):1101–1109. [PubMed: 1462970]
  140. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence: The Honolulu Heart Program. Stroke. 1994;25(5):951–957. [PubMed: 8165689]
  141. Buse JB, Ahroni JH, Bakris GL. Summary of revisions for the 2004 clinical practice recommendations. Diabetes Care. 2004;27:S3–S10.
  142. Butler WJ, Ostrander LD Jr.,, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol. 1985;121(4):541–547. [PubMed: 4014143]
  143. Buysschaert M, Vandenbroucke C, Barsoum S. A type 2 diabetes screening program by general practioners in a Belgian at risk population. Diabetes Metab. 2001;27(2 Pt 1):109–114. [PubMed: 11353875]
  144. Byrne CD, Wareham NJ, Brown DC, Clark PM, Cox LJ, Day NE. et al. Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia. 1994;37(9):889–896. [PubMed: 7806018]
  145. Byrne JJ, Leon BH. DHEA-PC Slows the progression of type 2 diabetes (Non-Insulin-Dependent Diabetes Mellitus) in the ZDF/Gmi-fa/fa rat. Diabetes Technology & Therapeutics. 2001;3(2):211–219. [PubMed: 11478327]
  146. Cacciari E, Coccheri S, Bergamaschi R, Fortunato G, Balsamo A, Poggi M. et al. Hemostatic balance alterations in obese children. Acta Paediatr Scand. 1982;71(3):479–484. [PubMed: 6814176]
  147. Calle-Pascual AL, Rodriguez C, Martin-Alvarez PJ, Camacho F, Calle JR, Yuste E. et al. Effect of weight loss on insulin sensitivity and cardiovascular risk factors in glucose tolerant and intolerant obese subjects. Diabete Metab. 1991;17(4):404–409. [PubMed: 1915998]
  148. Calle-Pascual AL, Saavedra A, Benedi A, Martin-Alvarez PJ, Garcia-Honduvilla J, Calle JR. et al. Changes in nutritional pattern, insulin sensitivity and glucose tolerance during weight loss in obese patients from a Mediterranean area. Horm Metab Res. 1995;27(11):499–502. [PubMed: 8770626]
  149. Campbell KL, Borde-Perry WC, Murtaugh KH, Gidding SS, Falkner B. Glucose tolerance and cardiovascular risk in young adult African Americans. Am J Med Sci. 2002;323(5):231–237. [PubMed: 12018664]
  150. Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres PF. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun. 1996;9(6):739–745. [PubMed: 9115576]
  151. Carlstrom S, Sartor G. Plasma glycerol and free fatty acids at oral glucose tests in subjects with impaired glucose tolerance. Journal of the Kuwait Medical Association. 1985;19(2):119–126.
  152. Carneiro DM, Levi JU, Irvin III GL. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery. 2002;132(6):937–943. [PubMed: 12490839]
  153. Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: Importance of insulin secretion and resistance. Diabetes Care. 2003;26(5):1333–1337. [PubMed: 12716784]
  154. Casiglia E, Pauletto P, Mazza A, Ginocchio G, di Menza G, Pavan L. et al. Impaired glucose tolerance and its co-variates among 2079 non-diabetic elderly subjects. Ten year mortality and morbidity in the CASTEL study. Acta Diabetol. 1996;33(4):284–290. [PubMed: 9033969]
  155. Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol. 2003;189(6):1698–1704. [PubMed: 14710101]
  156. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100(3):530–537. [PMC free article: PMC508219] [PubMed: 9239399]
  157. Cavallo-Perin P, Bruno A, Scaglione L, Gruden G, Cassader M, Pagano G. Feedback inhibition of insulin and glucagon secretion by insulin is altered in abdominal obesity with normal or impaired glucose tolerance. Acta Diabetol. 1993;30(3):154–158. [PubMed: 8111076]
  158. Caviezel F, Cattaneo AG, Pozza G. Long-term administration of acetylsalicylic acid in impaired glucose tolerance in addition to the diet: effects and limits. Acta Diabetol Lat. 1981;18(3):225–233. [PubMed: 7029988]
  159. Cederholm J. Short-term treatment of glucose intolerance in middle-aged subjects by diet, exercise and sulfonylurea. Upsala Journal of Medical Sciences. 1985;90(3):229–242. [PubMed: 4095819]
  160. Cederholm J, Wibell L. What causes impaired glucose tolerance to deteriorate or normalize? Scand J Clin Lab Invest. 1992;52(6):491–496. [PubMed: 1411261]
  161. Chae B-J, Kang B-J. The effect of clozapine on blood glucose metabolism. HUM. 2001;16(3):265–271. [PubMed: 12404579]
  162. Chae BJ, Kang BJ. The effect of clozapine on blood glucose metabolism. Human-Psychopharmacology-Clinical-and-Experimental. 2001;16(3):265–271. [PubMed: 12404579]
  163. Chaisiri K, Pongpaew P, Tungtrongchitr R, Phonrat B, Kulleap S, Kuhathong C. et al. Prevalence of abnormal glucose tolerance in Khon Kaen Province and validity of urine stick and fasting blood sugar as screening tools. J Med Assoc Thai. 1997;80(6):363–371. [PubMed: 9240010]
  164. Chapin BL, Medina S, Le D, Bussell N, Bussell K. Prevalence of undiagnosed diabetes and abnormalities of carbohydrate metabolism in a U.S. Army population. Diabetes Care. 1999;22(3):426–429. [PubMed: 10097923]
  165. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes. 1991;40(7):796–799. [PubMed: 2060716]
  166. Charles MA, Eschwege E, Thibult N, Claude JR, Warnet JM, Rosselin GE. et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia. 1997;40(9):1101–1106. [PubMed: 9300248]
  167. Charlton KE, Levitt NS, Lombard CJ. The prevalence of diabetes mellitus and associated risk factors in elderly coloured South Africans. S Afr Med J. 1997;87(3 Suppl):364–367. [PubMed: 9137356]
  168. Chaturvedi N, McKeigue PM, Marmot MG. Relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans. Diabetologia. 1994;37(8):765–772. [PubMed: 7988778]
  169. Chen KT, Chen CJ, Gregg EW, Williamson DF, Narayan KM. High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic? Diabetes Res Clin Pract. 1999;44(1):59–69. [PubMed: 10414941]
  170. Chen KT, Chen CJ, Gregg EW, Imperatore G, Narayan KM. Impaired fasting glucose and risk of diabetes in Taiwan: follow-up over 3 years. Diabetes Res Clin Pract. 2003;60(3):177–182. [PubMed: 12757990]
  171. Chi C-S, Mak S-C, Shian W-J, Chen C-H. Oral glucose lactate stimulation test in mitochondrial diseases. Pediatr Neurol. 1992;8(6):445–449. [PubMed: 1476574]
  172. Chiaretti A, De Benedictis R, Langer A, Di Rocco C, Bizzarri C, Iannelli A. et al. Prognostic implications of hyperglycaemia in paediatric head injury. Childs Nervous System. 1998;14(9):455–459. [PubMed: 9808254]
  173. Chiasson J, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C. et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19(11):1190–1193. [PubMed: 8908378]
  174. Chiasson J-L. The potential use of acarbose in the prevention of type 2 diabetes and cardiovascular disease. European Heart Journal Supplements. 2000;2(D):35.
  175. Chiasson JL. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet Med. 1996;13(3 Suppl 2):S23–S24. [PubMed: 8689858]
  176. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C. et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19(11):1190–1193. [PubMed: 8908378]
  177. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998;21(10):1720–1725. [PubMed: 9773737]
  178. Chiasson JL, Naditch L. Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.[comment] Diabetes Care. 2001;24(6):989–994. [PubMed: 11375358]
  179. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077. [PubMed: 12086760]
  180. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494. [PubMed: 12876091]
  181. Cho NH, Silverman BL, Rizzo TA, Metzger BE. Correlations between the intrauterine metabolic environment and blood pressure in adolescent offspring of diabetic mothers. Journal of Pediatrics 136(5):587–92, 2000 May (32 ref) 2000;(5):587–592. [PubMed: 10802488]
  182. Choi KM, Lee J, Kim DR, Kim SK, Shin DH, Kim NH. et al. Comparison of ADA and WHO criteria for the diagnosis of diabetes in elderly Koreans. Diabet Med. 2002;19(10):853–857. [PubMed: 12358874]
  183. Choi YH, Ahn YB, Yoon KH, Kang MI, Cha BY, Lee KW. et al. New ADA criteria in the Korean population: fasting blood glucose is not enough for diagnosis of mild diabetes especially in the elderly. Korean J Intern Med. 2000;15(3):211–217. [PMC free article: PMC4531770] [PubMed: 11242809]
  184. Chong SA, Mythily, Lum A, Huak CY, Kane J. Tardive dyskinesia and impaired glucose tolerance. HUM. 2002;17(6):305–307. [PubMed: 12404676]
  185. Chong SA, Mythily, Lum A, Huak CY, Kane J. Tardive dyskinesia and impaired glucose tolerance. Human-Psychopharmacology-Clinical-and-Experimental. 2002;17(6):305–307. [PubMed: 12404676]
  186. Chou P, Li CL, Kuo HS, Hsiao KJ, Tsai ST. Comparison of the prevalence in two diabetes surveys in Pu-Li, Taiwan, 1987-1988 and 1991-1992. Diabetes Res Clin Pract. 1997;38(1):61–67. [PubMed: 9347247]
  187. Chou P, Li CL, Wu GS, Tsai ST. Progression to type 2 diabetes among high-risk groups in Kin-Chen, Kinmen. Exploring the natural history of type 2 diabetes. Diabetes Care. 1998;21(7):1183–1187. [PubMed: 9653617]
  188. Chu N, Rimm EB, Wang D, Liou H, Shieh S. Clustering of cardiovascular disease risk factors among obese schoolchildren: the Taipei Children Heart Study. Am J Clin Nutr. 1998;67(6):1141–1146. [PubMed: 9625086]
  189. Chu N-F, Lee MMS, Wang D-J, Chen L-M, Ding Y-A, Shieh S-M. The interrelationship between impaired glucose tolerance and other risk factors for cardiovascular disease: Is it a predictor for cardiovascular disease? J Clin Epidemiol. 1994;47(5):485–493. [PubMed: 7730874]
  190. Clark CV, Mapstone R. Progression of impaired glucose tolerance to diabetes mellitus in patients with primary glaucoma and ocular hypertension. Diabet Med. 1986;3(3):226–229. [PubMed: 2951174]
  191. Clark CV. Diabetes mellitus in primary glaucomas. Ann Acad Med Singapore. 1989;18(2):190–194. [PubMed: 2751236]
  192. Carke R. Review: glucose levels are associated with cardiovascular risk in persons without diabetes mellitus... commentary on Coutinho M, Wang Y, Gerstein HC et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. DIABETES CARE 1999 Feb;22:233–40. ACP Journal Club 131(1):23, 1999 Jul-Aug (3 ref) 1999;(1):23. [PubMed: 10333939]
  193. Clausen JO, Ibsen H, Ibsen KK, Borch-Johnsen K. Association of body mass index, blood pressure and serum levels of triglycerides and high-density lipoprotein cholesterol in childhood with the insulin sensitivity index in young adulthood: a 13-year follow-up. J Cardiovasc Risk. 1996;3(5):427–433. [PubMed: 9048257]
  194. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement. 1960;20:37–46.
  195. Colagiuri S, Colagiuri R, Na'ati S, Muimuiheata S, Hussain Z, Palu T. The prevalence of diabetes in the kingdom of Tonga. Diabetes Care. 2002;25(8):1378–1383. [PubMed: 12145238]
  196. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P. et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85(1):193–199. [PubMed: 10634386]
  197. Collins V, Taylor R, Zimmet P. Impaired glucose tolerances in Kiribati. N Z Med J. 1984;97(768):809–812. [PubMed: 6334253]
  198. Colman E, Katzel LI, Rogus E, Coon P, Muller D, Goldberg AP. Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Metabolism. 1995;44(11):1502–1508. [PubMed: 7476341]
  199. Colman E, Katzel LI, Sorkin J, Coon PJ, Engelhardt S, Rogus E. et al. The role of obesity and cardiovascular fitness in the impaired glucose tolerance of aging. Exp Gerontol. 1995;30(6):571–580. [PubMed: 8867526]
  200. Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P, Moore MP. New classification and criteria for diagnosis of diabetes mellitus. The Australasian Working Party on Diagnostic Criteria for Diabetes Mellitus.[see comment] N Z Med J. 1999;112(1086):139–141. [PubMed: 10340693]
  201. Cononie CC, Goldberg AP, Rogus E, Hagberg JM. Seven consecutive days of exercise lowers plasma insulin responses to an oral glucose challenge in sedentary elderly. Journal of the American Geriatrics Society 42(4):394–8, 1994 Apr (40 ref) 1994;(4):394–398. [PubMed: 8144824]
  202. Cook JT, Page RC, Levy JC, Hammersley MS, Walravens EK, Turner RC. Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function. Diabet Med. 1993;10(4):321–326. [PubMed: 8508613]
  203. Cooper DE, Goff DC Jr.,, Bell RA, Zaccaro D, Mayer-Davis EJ, Karter AJ. Is insulin sensitivity a causal intermediate in the relationship between alcohol consumption and carotid atherosclerosis?: the insulin resistance and atherosclerosis study. Diabetes Care. 2002;25(8):1425–1431. [PubMed: 12145245]
  204. Cornu C, Mercier C, Ffrench P, Bully C, Pugeat M, Cousin P. et al. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Maturitas. 2000;37(2):95–104. [PubMed: 11137328]
  205. Costa A, Conget I, Gomis R. Impaired glucose tolerance: Is there a case for pharmacologic intervention? Treatments in Endocrinology. 2002;1(4):205–210. [PubMed: 15799213]
  206. Costa A, Iguala I, Bedini J, Quinto L, Conget I. Uric acid concentration in subjects at risk of type 2 diabetes mellitus: Relationship to components of the metabolic syndrome. Metabolism. 2002;51(3):372–375. [PubMed: 11887176]
  207. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X. et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med. 2003;20(9):743–745. [PubMed: 12925055]
  208. Costa A, Fernandez-Real JM, Vendrell J, Broch M, Casamitjana R, Ricart W. et al. Lower rate of tumor necrosis factor-alpha -863A allele and higher concentration of tumor necrosis factor-alpha receptor 2 in first-degree relatives of subjects with type 2 diabetes. Metabolism. 2003;52(8):1068–1071. [PubMed: 12898475]
  209. Coulston A, Greenfield MS, Kraemer FB. Effect of differences in source of dietary carbohydrate on plasma glucose and insulin responses to meals in patients with impaired carbohydrate tolerance. Am J Clin Nutr. 1981;34(12):2716–2720. [PubMed: 7032274]
  210. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233–240. [PubMed: 10333939]
  211. Crapo P.A., Kolterman O.G., Waldeck N. et al. Postprandial hormonal responses to different types of complex carbohydrate in individuals with impaired glucose tolerance. AM J CLIN NUTR. 1980;33(8):1723–1728. [PubMed: 6996472]
  212. Crapo PA, Scarlett JA, Kolterman OG. Comparison of the metabolic responses to fructose and sucrose sweetened foods. Am J Clin Nutr. 1982;36(2):256–261. [PubMed: 7048890]
  213. Crawford JF. Proportional versus projected glucose tolerance values: a quality control program. Clinical Laboratory Science 13(3):151-9, 2000 Summer (8 ref) 2000;13(3):151–159. [PubMed: 14989326]
  214. Crivaro M, Celentano A, Palmieri V, Oliviero M, Tammaro P, Pietropaolo I. et al. Mild arterial hypertension and impaired glucose tolerance: Short-term effects of manidipine hydrochloride. Advances in Therapy. 1996;13(6):365–372.
  215. Crook M, Cartwright K, Lumb P, Worsley A. Serum sialic acid in young type-1 diabetic patients. Diabetes Res Clin Pract. 2000;47(2):119–122. [PubMed: 10670911]
  216. Crowther NJ, Cameron N, Trusler J, Gray IP. Association between poor glucose tolerance and rapid post natal weight gain in seven-year-old children. Diabetologia. 1998;41(10):1163–1167. [PubMed: 9794102]
  217. Croxson SCM, Absalom S, Burden AC. Fructosamine in diabetes screening of the elderly. ANN CLIN BIOCHEM. 1991;28(3):279–282. [PubMed: 1872575]
  218. Croxson SCM, Thomas PH. Glucose tolerance test results reappraised using recent ADA criteria. Practical Diabetes International. 1998;15(6):178–180.
  219. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106(16):2085–2090. [PubMed: 12379578]
  220. Csabi G, Torok K, Jeges S, Molnar D. Presence of metabolic cardiovascular syndrome in obese children. Eur J Pediatr. 2000;159(1-2):91–94. [PubMed: 10653338]
  221. Cucinotta D, De Luca F, Arrigo T, Di Benedetto A, Sferlazzas C, Gigante A. et al. First-phase insulin response to intravenous glucose in cystic fibrosis patients with different degrees of glucose tolerance. J Pediatr Endocrinol. 1994;7(1):13–17. [PubMed: 8186820]
  222. Cucinotta D, De Luca F, Gigante A, Arrigo T, Di Benedetto A, Tedeschi A. et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. European Journal of Endocrinology. 1994;130(3):253–258. [PubMed: 8156098]
  223. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation. 1995;91(10):2591–2595. [PubMed: 7743621]
  224. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH. et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999;52(5):971–975. [PubMed: 10102414]
  225. D'Agostino RB, Jr., Burke G, O'Leary D, Rewers M, Selby J, Savage PJ et al. Ethnic differences in carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Stroke 27(10):1744–9, 1996 Oct (54 ref) 1996;(10):1744–1749. [PubMed: 8841322]
  226. Dagogo-Jack S, Santiago JV. Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157(16):1802–1817. [PubMed: 9290539]
  227. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 1999;22(5):789–794. [PubMed: 10332683]
  228. Daniel M, O'Dea K, Rowley KG, McDermott R, Kelly S. Glycated hemoglobin as an indicator of social environmental stress among indigenous versus westernized populations.[see comment] Prev Med. 1999;29(5):405–413. [PubMed: 10564632]
  229. Davalos A, Fernandez-Real JM, Ricart W, Soler S, Molins A, Planas E. et al. Iron-related damage in acute ischemic stroke. Stroke. 1994;25(8):1543–1546. [PubMed: 8042204]
  230. Davidson MB, Schriger DL, Peters AL, Lorber B. Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. J Gen Intern Med. 2000;15(8):551–555. [PMC free article: PMC1495578] [PubMed: 10940146]
  231. Davidson MB. Diagnosing diabetes: Cutoffs vs. tradeoffs. Endocrinologist. 2000;10(2):90–96.
  232. Davies M, Rayman G, Day J. Increased incidence of coronary disease in people with impaired glucose tolerance: Link with increased lipoprotein(a) concentrations? British Medical Journal. 1992;304(6842):1610–1611. [PMC free article: PMC1881985] [PubMed: 1385748]
  233. Davies MJ, Rayman G, Gray IP, Day JL, Hales CN. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med. 1993;10(4):313–320. [PubMed: 8508612]
  234. Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med. 1994;11(5):432–436. [PubMed: 8088119]
  235. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med. 2000;17(6):433–440. [PubMed: 10975211]
  236. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med. 2004;21(5):403–414. [PubMed: 15089783]
  237. Court, de, Pettitt DJ, Knowler WC. Hypertension in Pima Indians: prevalence and predictors. Public Health Rep. 1996;111(Suppl 2):40–43. [PMC free article: PMC1381662] [PubMed: 8898771]
  238. De Luca F, Arrigo T, Conti NS, Sferlazzas C, Gigante A, Di Cesare E. et al. Insulin secretion, glycosylated haemoglobin and islet cell antibodies in cystic fibrosis children and adolescents with different degrees of glucose tolerance. Horm Metab Res. 1991;23(10):495–498. [PubMed: 1761281]
  239. De Michele M, Panico S, Celentano E, Covetti G, Intrieri M, Zarrilli F. et al. Association of impaired glucose homeostasis with preclinical carotid atherosclerosis in women: Impact of the new American Diabetes Association criteria. Metabolism. 2002;51(1):52–56. [PubMed: 11782872]
  240. De Neeling JN, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn study. Diabet Med. 1996;13(11):960–966. [PubMed: 8946154]
  241. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension: The MAVI study. Hypertension. 2002;40(4):470–476. [PubMed: 12364349]
  242. de Simone G, Devereux RB, Palmieri V, Roman MJ, Celentano A, Welty TK. et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutr Metab Cardiovasc Dis. 2003;13(3):140–147. [PubMed: 12955795]
  243. de Vegt F, Dekker JM, Stehouwer CDA, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: Poor agreement in the Hoorn Study. Diabetes Care. 1998;21(10):1686–1690. [PubMed: 9773731]
  244. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care. 2000;23(1):40–44. [PubMed: 10857966]
  245. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD. et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285(16):2109–2113. [PubMed: 11311100]
  246. Dean HJ, Mundy RL, Moffatt M. Non-insulin-dependent diabetes mellitus in Indian children in Manitoba. CMAJ. 1992;147(1):52–57. [PMC free article: PMC1336119] [PubMed: 1393888]
  247. Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. Lancet. 1998;352(9139):1523–1524. [PubMed: 9820307]
  248. DECODE Study Group; European Diabetes Epidemiology Group. Age, body mass index and glucose tolerance in 11 European population-based surveys. Diabet Med. 2002;19(7):558–565. [PubMed: 12099958]
  249. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. [see comment] BMJ. 1998;317(7155):371–375. [PMC free article: PMC28629] [PubMed: 9694750]
  250. DECODE Study Group tEDEG. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397–405. [PubMed: 11176766]
  251. Decsi T, Molnar D. Insulin resistance syndrome in children: Pathophysiology and potential management strategies. Paediatric Drugs. 2003;5(5):291–299. [PubMed: 12716216]
  252. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387–395. [PubMed: 2657323]
  253. Delahanty LM. Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus. Diabetes Spectrum. 1995;8(2):102–103. [PubMed: 8382712]
  254. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M. et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57(3):474–480. [PubMed: 11502916]
  255. Dessi-Fulgheri P, Pacifico A, Bandiera F, Rubattu S, Madeddu P, Glorioso N. et al. Effect of nifedipine and verapamil on carbohydrate metabolism in hypertensive patients with impaired glucose tolerance. J Cardiovasc Pharmacol. 1987;10(Suppl 10):S195–S198. [PubMed: 2455132]
  256. Dessi-Fulgheri P, Zanna C, Di NG, Baldinelli A, Paci MV, Espinosa E. et al. Antihypertensive and metabolic effects of ketanserin in patients with hypertension and impaired glucose tolerance: A double-blind, randomized, placebo-controlled, crossover study. CURR THER RES CLIN EXP. 1991;49(2):249–255.
  257. Dhawan J, Bray CL, Warburton R, Ghambhir DS, Morris J. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect? [see comments] Br Heart J. 1994;72(5):413–421. [PMC free article: PMC1025607] [PubMed: 7818957]
  258. Di Giulio R, Gaddi A, Ciarrocchi A, Barozzi G, Fraticelli G, Sangiorgi Z. et al. Effects of coenzyme A in massive hypertriglyceridaemia (phenotype IV) and in patients with hypertriglyceridaemia associated with impaired glucose tolerance or diabetes mellitus. Acta Therapeutica. 1993;19(1):23–34.
  259. Di Simone N, Ronsisvalle E, Fulghesu AM, Lanzone A, Caruso A. Insulin plasma levels in pregnant patients with impaired glucose tolerance: relationship with pregnancy outcome. Gynecol Obstet Invest. 1996;42(1):16–20. [PubMed: 8840171]
  260. Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22(4):623–634. [PMC free article: PMC1351026] [PubMed: 10189543]
  261. Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679–686. [PMC free article: PMC2516377] [PubMed: 12411462]
  262. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26(4):977–980. [PMC free article: PMC1360737] [PubMed: 12663559]
  263. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology. 1996;103(8):1271–1275. [PubMed: 8764798]
  264. Dinneen SF, Maldonado D III, Leibson CL, Klee GG, Li H, Melton LJ III. et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care. 1998;21(9):1408–1413. [PubMed: 9727885]
  265. Dinsmoor RS. Diabetes definitions. Diabetes Self-Management 14(5):70–1, 1997 Sep-Oct 1997;(5):70–71.
  266. DiPietro L, Seeman TE, Stachenfeld NS, Katz LD, Nadel ER. Moderate-intensity aerobic training improves glucose tolerance in aging independent of abdominal adiposity. Journal of the American Geriatrics Society 46(7):875–9, 1998 Jul (36 ref) 1998;(7):875–879. [PubMed: 9670875]
  267. Doggrell SA. Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Expert Opin Pharmacother. 2002;3(7):1011–1013. [PubMed: 12084000]
  268. Dolecek R, Kubis M, Sajnar J, Zavada M. Bromocriptine and glucose tolerance in acromegalics. Pharmatherapeutica. 1982;3(2):100–106. [PubMed: 7048336]
  269. Dowse GK, Zimmet PZ, Gareeboo H, George K, Alberti MM, Tuomilehto J. et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care. 1991;14(4):271–282. [PubMed: 2060430]
  270. Dowse GK, Zimmet PZ, Finch CF, Collins VR. Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the “thrifty genotype” Am J Epidemiol. 1991;133(11):1093–1104. [PubMed: 2035513]
  271. Dowse GK, Zimmet PZ, King H. Relationship between prevalence of impaired glucose tolerance and NIDDM in a population. Diabetes Care. 1991;14(11):968–974. [PubMed: 1797510]
  272. Dowse GK, Collins VR, Alberti KG, Zimmet PZ, Tuomilehto J, Chitson P. et al. Insulin and blood pressure levels are not independently related in Mauritians of Asian Indian, Creole or Chinese origin. The Mauritius Non-communicable Disease Study Group. J Hypertens. 1993;11(3):297–307. [PubMed: 8387088]
  273. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes. 1996;45(10):1367–1372. [PubMed: 8826973]
  274. Dowse GK. Incidence of NIDDM and the natural history of IGT in Pacific and Indian Ocean populations. Diabetes Res Clin Pract. 1996;34 Suppl:S45–S50. [PubMed: 9015669]
  275. Dowse GK, Humphrey AR, Collins VR, Plehwe W, Gareeboo H, Fareed D. et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol. 1998;147(5):448–457. [PubMed: 9525531]
  276. Drzewoski J, Czupryniak L. Concordance between fasting and 2-h post-glucose challenge criteria for the diagnosis of diabetes mellitus and glucose intolerance in high risk individuals. Diabet Med. 2001;18(1):29–31. [PubMed: 11168338]
  277. Duffy TJ, Ray R. Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance. Contraception. 1984;30(3):197–208. [PubMed: 6509976]
  278. Dunn PJ, Cole RA, Soeldner JS, Gleason RE. Reproducibility of hemoglobin A(Ic) and sensitivity to various degrees of glucose intolerance. Annals of Internal Medicine. 1979;91(3):390–396. [PubMed: 475166]
  279. Dunstan DW, Zimmet PZ, Welborn TA, Court, de, Cameron AJ, Sicree RA. et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829–834. [PubMed: 11978676]
  280. Ebert R, Frerichs H, Creutzfeldt W. Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance. Eur J Clin Invest. 1979;9(2 Pt 1):129–135. [PubMed: 111943]
  281. Eccles M, Hawthorne G, Whitty P, Steen N, Vanoli A, Grimshaw J. et al. A randomised controlled trial of a patient based Diabetes Recall and Management System: the DREAM trial: a study protocol [ISRCTN32042030] BMC Health Serv Res. 2002;2(1):5. [PMC free article: PMC101376] [PubMed: 11914161]
  282. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46(4):701–10, 1997 Apr (49 ref) 1997;(4):701–710. [PMC free article: PMC2517225] [PubMed: 9075814]
  283. Efendic S, Wajngot A, Cerasi E, Luft R. Insulin release, insulin sensitivity, and glucose intolerance. Proc Natl Acad Sci U S A. 1980;77(12):7425–7429. [PMC free article: PMC350516] [PubMed: 7012840]
  284. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–146. [PubMed: 10333916]
  285. El Hazmi MA, Al Deeb ABM, Warsy AS, Al Swailem A, Al Swailem A, Al Meshari A. et al. Diabetes mellitus and IGT in relation to gender and age in Najran, Saudi Arabia. Bahrain Medical Bulletin. 1997;19(2):40–44.
  286. El Hazmi MAF, Al Swailem A, Al Fawaz I, Warsey AS, Al Swailem A. Diabetes mellitus in children suffering from beta-thalassaemia. J Trop Pediatr. 1994;40(5):261–266. [PubMed: 7807619]
  287. Elbein SC, Wegner K, Miles C, Yu L, Eisenbarth G. The role of late-onset autoimmune diabetes in white familial NIDDM pedigrees. Diabetes Care. 1997;20(8):1248–1251. [PubMed: 9250448]
  288. Elliott T.G., Viberti G. ., and Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. [Review] Baillieres Clinical Endocrinology & Metabolism. 1993;7(4):1079–1103. [PubMed: 8304914]
  289. Elliott RB, Chase HP. Prevention or delay of Type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia. 1991;34(5):362–365. [PubMed: 1830860]
  290. Engfeldt P, Tyden G, Gunnarsson R. Impaired glucose tolerance with cyclosporine. Transplant Proc. 1986;18(1):65–66.
  291. Erenus M, Gurler AD, Elter K. Should we consider performing oral glucose tolerance tests more frequently in postmenopausal women for optimal screening of impaired glucose tolerance? Menopause. 2002;9(4):296–301. [PubMed: 12082367]
  292. Ergun Y, Oksuz M, Isiksal FY, Kocak F, Abayli B. Frequency of impaired glucose tolerance test and diabetes mellitus in patients with cirrhosis due to hepatitis B virus infection. Annals of Medical Sciences. 2003;12(1):15–18.
  293. Eriksson J, Saloranta C, Widen E, Ekstrand A, Franssila-Kallunki A, Schalin C. et al. Non-esterified fatty acids do not contribute to insulin resistance in persons at increased risk of developing Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34(3):192–197. [PubMed: 1884892]
  294. Eriksson J, Tuominen J, Valle T, Sundberg S, Sovijarvi A, Lindholm H. et al. Aerobic endurance exercise or circuit-type resistance training for individuals with impaired glucose tolerance? Horm Metab Res. 1998;30(1):37–41. [PubMed: 9503037]
  295. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P. et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999;42(7):793–801. [PubMed: 10440120]
  296. Eriksson J, Valle T, Lindstrom J, Haffner S, Louheranta A, Uusitupa M. et al. Leptin concentrations and their relation to body fat distribution and weight loss--a prospective study in individuals with impaired glucose tolerance. DPS-study group. Horm Metab Res. 1999;31(11):616–619. [PubMed: 10598830]
  297. Eriksson JG, Forsen T, Tuomilehto J, Jaddoe VWV, Osmond C, Barker DJP. Effects of size at birth and childhood growth on the insulin resistance syndrome in elderly individuals. Diabetologia. 2002;45(3):342–348. [PubMed: 11914739]
  298. Eriksson K-F, Lindgarde F. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34(12):891–898. [PubMed: 1778354]
  299. Eriksson K-F, Saltin B, Lindgarde F. Increased skeletal muscle capillary density precedes diabetes development in men with impaired glucose tolerance: A 15-year follow-up. Diabetes. 1994;43(6):805–808. [PubMed: 8194667]
  300. Eriksson K-F, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia. 1998;41(9):1010–1016. [PubMed: 9754818]
  301. Eriksson KF, Lindgarde F. Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases [see comments] Diabetologia. 1990;33(9):526–531. [PubMed: 2253828]
  302. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34(12):891–898. [PubMed: 1778354]
  303. Eriksson KF, Saltin B, Lindgarde F. Increased skeletal muscle capillary density precedes diabetes development in men with impaired glucose tolerance. A 15-year follow-up. Diabetes. 1994;43(6):805–808. [PubMed: 8194667]
  304. Eriksson KF, Nilsson H, Lindgarde F, Osterlin S, Dahlin LB, Lilja B. et al. Diabetes mellitus but not impaired glucose tolerance is associated with dysfunction in peripheral nerves. Diabet Med. 1994;11(3):279–285. [PubMed: 8033527]
  305. Eriksson KF, Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia. 1998;41(9):1010–1016. [PubMed: 9754818]
  306. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress - Activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1–8. [PubMed: 12502486]
  307. Evans MF. Can we prevent high-risk patients from getting type 2 diabetes? Canadian Family Physician. 2002;48(FEB.):279–281. [PMC free article: PMC2213974] [PubMed: 11889887]
  308. Fagerberg B, Berglund A, Holme E, Wilhelmsen L, Elmfeldt D. Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: A comparison with atenolol. J Intern Med. 1990;227(1):37–43. [PubMed: 2405089]
  309. Fagot-Campagna A, Saaddine JB, Flegal KM, Beckles GL. Diabetes, impaired fasting glucose, and elevated HbA1c in U.S. adolescents: the Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24(5):834–837. [PubMed: 11347739]
  310. Fagundes NU, Affonso S I. Escherichia coli infections and malnutrition. Lancet. 2000;356(9248):s27. [PubMed: 11191483]
  311. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Medica Scandinavica. 1983;213(1):27–30. [PubMed: 6338681]
  312. Falko JM, Parr JH, Simpson RN, Wynn V. Lipoprotein analysis in varying degrees of glucose tolerance. Comparison between non-insulin-dependent diabetic, impaired glucose tolerant, and control populations. American Journal of Medicine. 1987;83(4):641–647. [PubMed: 3674053]
  313. Fantus IG, Dupre J. Prevention of diabetes: goal for the twenty-first century: part one. Canadian Journal of Diabetes Care. 1995;19(3):9–17.
  314. Farrer M, Game FL, Albers CJ, Neil HA, Winocour PH, Laker MF. et al. Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease [see comments] BMJ. 1993;307(6908):832–836. [PMC free article: PMC1678874] [PubMed: 8401124]
  315. Farrer M, Fulcher G, Albers CJ, Neil HA, Adams PC, Alberti KG. Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism. 1995;44(8):1016–1027. [PubMed: 7637643]
  316. Farrer M, Albers CJ, Neil HA, Adams PC, Laker MF, Alberti KG. Assessing the impact of blood sample type on the estimated prevalence of impaired glucose tolerance and diabetes mellitus in epidemiological surveys. Diabet Med. 1995;12(4):325–329. [PubMed: 7600748]
  317. Fasching P, Ratheiser K, Waldhausl W, Rohac M, Osterrode W, Nowotny P. et al. Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes. 1991;40(5):583–589. [PubMed: 2022303]
  318. Felber JP, Ferrannini E, Golay A, Meyer HU, Theibaud D, Curchod B. et al. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes. 1987;36(11):1341–1350. [PubMed: 3311856]
  319. Felber JP, Golay A, Jequier E, Curchod B, Temler E, DeFronzo RA. et al. The metabolic consequences of long-term human obesity. Int J Obes. 1988;12(5):377–389. [PubMed: 3069764]
  320. Feriozzi S, Meschini L, Costantini S, Gomes V, Ranalli T, Perez M. et al. Fatal intestinal tuberculosis in a uremic patient with a renal transplant. Jn Journal of Nephrology. 2002;15(5):593–596. [PubMed: 12455729]
  321. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: Safety considerations. DRUG SAF. 2003;26(9):643–659. [PubMed: 12814332]
  322. Fernando MR, Wickramasinghe SMDN, Thabrew MI, Ariyananda PL, Karunanayake EH. Effect of Artocarpus heterophyllus and Asteracanthus longifolia on glucose tolerance in normal human subjects and in maturity-onset diabetic patients. J Ethnopharmacol. 1991;31(3):277–282. [PubMed: 2056756]
  323. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16(7):895–906. [PubMed: 9794728]
  324. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A. et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003;46(9):1211–1219. [PubMed: 12879253]
  325. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance. Diabetes. 2004;53(1):160–165. [PubMed: 14693710]
  326. Ferro A, Hall JA, Dickerson JEC, Brown MJ. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Br J Clin Pharmacol. 1997;43(3):301–308. [PMC free article: PMC2042735] [PubMed: 9088585]
  327. Feskens EJ, Bowles CH, Kromhout D. Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol. 1991;44(9):947–953. [PubMed: 1890437]
  328. Feskens EJ, Bowles CH, Kromhout D. Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women. Diabetes Care. 1991;14(11):935–941. [PubMed: 1797505]
  329. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol. 1992;45(11):1327–1334. [PubMed: 1432012]
  330. Feskens EJ, Bowles CH, Kromhout D. Association between fish intake and coronary heart disease mortality. Differences in normoglycemic and glucose intolerant elderly subjects. Diabetes Care. 1993;16(7):1029–1034. [PubMed: 8359097]
  331. Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J. et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care. 1995;18(8):1104–1112. [PubMed: 7587845]
  332. Feskens EJ, Tuomilehto J, Stengard JH, Pekkanen J, Nissinen A, Kromhout D. Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetologia. 1995;38(7):839–847. [PubMed: 7556987]
  333. Feskens EJM, Kromhout D. Glucose tolerance and the risk of cardiovascular diseases: The Zutphen Study. J Clin Epidemiol. 1992;45(11):1327–1334. [PubMed: 1432012]
  334. Feskens EJM, Bowles CH, Kromhout D. Glucose tolerance and mortality from ischemic heart disease in an elderly population: Impact of repeated glucose measurements. Ann Epidemiol. 1993;3(4):336–342. [PubMed: 8275208]
  335. Festa A, D'Agostino R Jr.,, Mykkanen L, Tracy RP, Hales CN, Howard BV. et al. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22(10):1688–1693. [PubMed: 10526736]
  336. Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J. 2001;141(3):485–490. [PubMed: 11231448]
  337. Flanagan DE, Moore VM, Godsland IF, Cockington RA, Robinson JS, Phillips DI. Fetal growth and the physiological control of glucose tolerance in adults: a minimal model analysis. Am J Physiol Endocrinol Metab. 2000;278(4):E700–E706. [PubMed: 10751205]
  338. Fleiss JL, Cohen J, Everitt BS. Large-sample standard errors of kappa and weighted kappa. Psychological Bulletin. 1969;72:323–327.
  339. Fliser D, Rett K, Hubinger A, Ritz E. Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure. Nephrol Dial Transplant. 1995;10(5):643–647. [PubMed: 7566576]
  340. Flock EV, Bennett PH, Savage PJ. Bimodality of glycosylated hemoglobin distribution in Pima indians: Relationship to fasting hyperglycemia. Diabetes. 1979;28(11):984–989. [PubMed: 488548]
  341. Flores-Saenz JL, Trujillo-Arriaga HM, Rivas-Vilchis JF, Mendez-Francisco JD, Alarcon-Aguilar FJ, Roman-Ramos R. Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects. Proc West Pharmacol Soc. 2003;46:143–147. [PubMed: 14699913]
  342. Fluckey JD, Hickey MS, Brambrink JK, Hart KK, Alexander K, Craig BW. Effects of resistance exercise on glucose tolerance in normal and glucose-intolerant subjects. J Appl Physiol. 1994;77(3):1087–1092. [PubMed: 7836108]
  343. Folsom AR, Jacobs DR Jr.,, Wagenknecht LE, Winkhart SP, Yunis C, Hilner JE. et al. Increase in fasting insulin and glucose over seven years with increasing weight and inactivity of young adults: the CARDIA Study. Am J Epidemiol. 1996;144(3):235–246. [PubMed: 8686692]
  344. Fontbonne A, Eschwege E. Diabetes, hyperglycaemia, hyperinsulinaemia and atherosclerosis: epidemiological data. Diabete Metab. 1987;13(3 Pt 2):350–353. [PubMed: 3308563]
  345. Fontbonne A, Tchobroutsky G, Eschwege E, Richards JL, Claude JR, Rosselin GE. Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes. 1988;12(6):557–565. [PubMed: 3069769]
  346. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N. et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32(5):300–304. [PubMed: 2666216]
  347. Fontbonne A, Eschwege E. Insulin-resistance, hypertriglyceridaemia and cardiovascular risk: the Paris Prospective Study. Diabete Metab. 1991;17(1 Pt 2):93–95. [PubMed: 1936489]
  348. Fontbonne A, Thibult N, Eschwege E, Ducimetiere P. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia. 1992;35(5):464–468. [PubMed: 1521729]
  349. Fontbonne A, Charles A, Balkau B, Eschwege E. The insulin resistance syndrome and the Paris Prospective Study. Cardiovascular Risk Factors. 1993;3(1):36–43.
  350. Fontbonne A, Charles MA, Juhan-Vague I, Bard J, Andre P, Isnard F. et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care. 1996;19(9):920–926. [PubMed: 8875083]
  351. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care. 1991;14(6):461–469. [PubMed: 1864219]
  352. Ford ES, Will JC, Bowman BA, Narayan KM. Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 1999;149(2):168–176. [PubMed: 9921962]
  353. Forrest RD, Jackson CA, Yudkin JS. The abbreviated glucose tolerance test in screening for diabetes: The Islington Diabetes Survey. Diabet Med. 1988;5(6):557–561. [PubMed: 2974779]
  354. Foucan L, Bangou-Bredent J, Ekouevi DK, Deloumeaux J, Roset JE, Kangambega P. Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI) Eur J Epidemiol. 2002;17(12):1089–1095. [PubMed: 12530767]
  355. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ. et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135(4):331–340. [PubMed: 1550087]
  356. Foyle WJ, Carstensen E, Fernandez MC, Yudkin JS. Longitudinal study of associations of microalbuminuria with the insulin resistance syndrome and sodium-lithium countertransport in nondiabetic subjects. Arterioscler Thromb Vasc Biol. 1995;15(9):1330–1337. [PubMed: 7670946]
  357. Fragachan F, Perez-Acuna F, Monsalve P, Sanabria A. Impaired glucose metabolism in hypertensive patients. Clin Physiol Biochem. 1990;8(4):188–203. [PubMed: 2078921]
  358. Frape DL, Williams NR, Rajput-Williams J, Maitland BW, Scriven AJ, Palmer CR. et al. Effect of breakfast fat content on glucose tolerance and risk factors of atherosclerosis and thrombosis. Br J Nutr. 1998;80(4):323–331. [PubMed: 9924274]
  359. Fraser GC. Biological variation: from principles to practice. Washington: AACC press, 2001.
  360. Frati Munari AC, Fernandez Harp JA, De La RH. Effects of nopal (Opuntia sp.) on serum lipids, glycemia and body weight. Arch Invest Med (Mex ) 1983;14(2):117–125. [PubMed: 6314922]
  361. Frayn KN, Whyte PL, Benson HA, Earl DJ, Smith HA. Changes in forearm blood flow at elevated ambient temperature and their role in the apparent impairment of glucose tolerance. Clin Sci (Colch ) 1989;76(3):323–328. [PubMed: 2494016]
  362. Freedman DS, Serdula MK, Percy CA, Ballew C, White L. Obesity, levels of lipids and glucose, and smoking among Navajo adolescents. J Nutr. 1997;127(10 SUPPL.):2120S–2127S. [PubMed: 9339179]
  363. Freemark M. Clinical perspective: Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab. 2003;88(1):3–13. [PubMed: 12519819]
  364. French LR, Boen JR, Martinez AM, Bushhouse SA, Sprafka JM, Goetz FC. Population-based study of impaired glucose tolerance and type II diabetes in Wadena, Minnesota. Diabetes. 1990;39(9):1131–1137. [PubMed: 2384192]
  365. Freyschuss U, Gentz J, Noack G, Persson B. Circulatory adaptation in newborn infants of strictly controlled diabetic mothers. Acta Paediatr Scand. 1982;71(2):209–215. [PubMed: 7136629]
  366. Fujimoto WY, Leonetti DL, Kinyoun JL. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes. 1987;36(6):730–739. [PubMed: 3569672]
  367. Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris L, Shuman WP, Stolov WC. et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes. 1987;36(6):721–729. [PubMed: 3569671]
  368. Fujimoto WY, Leonetti DL, Bergstrom RW, Kinyoun JL, Stolov WC, Wahl PW. Glucose intolerance and diabetic complications among Japanese-American women. Diabetes Res Clin Pract. 1991;13(1-2):119–129. [PubMed: 1773709]
  369. Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance. Diabetologia. 1994;37(5):524–532. [PubMed: 8056192]
  370. Fujimoto WY. Diabetes Prevention Program Research Group. Background and recruitment data for the U.S. Diabetes Prevention Program.[erratum appears in Diabetes Care 2000 Jun;23(6):876] Diabetes Care. 2000;23(Suppl 2):B11–B13. [PMC free article: PMC2505054] [PubMed: 10860185]
  371. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K. et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes. 1996;45(Suppl3):S14–S16. [PubMed: 8674881]
  372. Fujita H, Narita T, Ito S. Abnormality in urinary protein excretion in Japanese men with impaired glucose tolerance. Diabetes Care. 1999;22(5):823–826. [PubMed: 10332689]
  373. Fujiwara R, Kutsumi Y, Hayashi T, Nishio H, Koshino Y, Shimada Y. et al. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol. 1995;75(2):122–126. [PubMed: 7810485]
  374. Fukuda H, Muto T, Kawamori R. Evaluation of a diabetes patient education program consisting of a three-day hospitalization and a six-month follow-up by telephone counseling for mild type 2 diabetes and IGT. Environmental Health & Preventive Medicine. 1999;4(3):122–129. [PMC free article: PMC2723521] [PubMed: 21432184]
  375. Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A. et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med. 2001;40(10):987–992. [PubMed: 11688841]
  376. Fulghesu AM, Cucinelli F, Pavone V, Murgia F, Guido M, Caruso A. et al. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome. Hum Reprod. 1999;14(3):611–617. [PubMed: 10221684]
  377. Fuller JH, Shipley MJ. Hyperglycaemia as a cardiovascular risk factor. Postgrad Med J. 1989;65(SUPPL. 1):S30–S32. [PubMed: 2622811]
  378. Fuller J, Shipley M, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease and impaired glucose tolerance. The Whitehall Study. The Lancet. 1980;315(8183):1373–1376. [PubMed: 6104171]
  379. Gabbay RA. New developments in home glucose monitoring: Minimizing the pain. Canadian Journal of Diabetes. 2003;27(3):271–276.
  380. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH. et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23(8):1108–1112. [PubMed: 10937506]
  381. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH. et al. Plasma glucose and prediction of microvascular disease and mortality: Evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care. 2000;23(8):1113–1118. [PubMed: 10937507]
  382. Gafni A. Economic implications of IGT intervention: the case of a "phantom alternative'? Diabet Med. 1996;13(3 Suppl 2):S25–S28. [PubMed: 8689859]
  383. Gale EA. European Nicotinamide Diabetes Intervention Trial Group. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Diabetologia. 2003;46(3):339–346. [PubMed: 12687331]
  384. Gale EAM. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Diabetologia. 2003;46(3):339–346. [PubMed: 12687331]
  385. Galli-Tsinopoulou A, Karamouzis M, Nousia-Arvanitakis S. Insulin resistance and hyperinsulinemia in prepubertal obese children. J Pediatr Endocrinol Metab. 2003;16(4):555–560. [PubMed: 12793608]
  386. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes. 1978;27(7):715–725. [PubMed: 658617]
  387. Ganda OP. A 2-hour oral glucose tolerance test result is greater than or equal to 11.1 mmol/L predicted all-cause mortality better than a fasting glucose level greater than or equal to 7.0 mmol/L... commentary on The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. LANCET 1999 Aug 21;354:617–21. ACP Journal Club 132(2):70, 2000 Mar-Apr (4 ref) 2000;(2):70.
  388. Gans DA, Harper AE, Bachorowski J-A, Newman JP, Shrago ES, Taylor SL. Sucrose and delinquency: Oral sucrose tolerance test and nutritional assessment. Pediatrics. 1990;86(2):254–262. [PubMed: 2196523]
  389. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality.[see comment] JAMA. 2000;283(19):2552–2558. [PubMed: 10815119]
  390. Gapstur SM, Gann PH, Colangelo LA, Barron-Simpson R, Kopp P, Dyer A. et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States) Cancer Causes Control. 2001;12(8):763–772. [PubMed: 11562117]
  391. Garagorri JM, Rodriguez G, Ros L, Sanchez A. Early detection of impaired glucose tolerance in patients with cystic fibrosis and predisposition factors. J Pediatr Endocrinol Metab. 2001;14(1):53–60. [PubMed: 11220706]
  392. Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E. et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia. 1995;38(3):306–313. [PubMed: 7758877]
  393. Garcia GV, Freeman RV, Supiano MA, Smith MJ, Galecki AT, Halter JB. Glucose metabolism in older adults: A study including subjects more than 80 years of age. J Am Geriatr Soc. 1997;45(7):813–817. [PubMed: 9215331]
  394. Gartaganis SP, Psyrojannis AJ, Koliopoulos JX, Mela EK. Contrast sensitivity function in patients with impaired oral glucose tolerance. Optometry & Vision Science. 2001;78(3):157–161. [PubMed: 11327677]
  395. Gatling W, Begley JP. Diagnosing diabetes mellitus in clinical practice: Is fasting plasma glucose a good initial test? Practical Diabetes International. 2001;18(3):89–93.
  396. Gautam VK, Vasavada JP, Khanijo SK. A study of oral glucose tolerance test in patients of hypertension receiving propranolol. Indian Heart J. 1989;41(4):261–264. [PubMed: 2807363]
  397. Gavella M, Lipovac V, Car A, Vucic M. Baseline diene conjugation in LDL lipids from newly diagnosed type 2 diabetic patients. Diabetes Metab. 2002;28(5):391–396. [PubMed: 12461476]
  398. Gelmini G, Butturini L, Cucinotta D, Delsignore R, Coiro V. Whole blood filterability in elderly obese women. Acta Diabetol Lat. 1987;24(3):199–203. [PubMed: 3687312]
  399. Geloneze B, Tambascia MA, Pareja JC, Repetto EM, Magna LA, Pereira SG. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11(6):693–698. [PubMed: 11775566]
  400. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R. et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–3167. [PubMed: 14578255]
  401. Gerard J, Luyckx AS, Lefebvre PJ. Acarbose in reactive hypoglycemia: a double-blind study. Int J Clin Pharmacol Ther Toxicol. 1984;22(1):25–31. [PubMed: 6698657]
  402. Gerich JE. Novel insulins: Expanding options in diabetes management. American Journal of Medicine. 2002;113(4):308–316. [PubMed: 12361817]
  403. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD. et al. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia. 2000;43(5):561–570. [PubMed: 10855530]
  404. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999;33(3):612–619. [PubMed: 10080459]
  405. Giacca A, Groenewoud Y, Tsui E, McClean P, Zinman B. Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia. Diabetes. 1998;47(11):1763–1770. [PubMed: 9792546]
  406. Giannarelli RA. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29(4):28–35. [PubMed: 14502098]
  407. Gimenez-Perez G, Gonzales-Clemente JM, Mauricio D. Lifestyle interventions for prevention type 2 diabetes mellitus [Protocol]. Cochrane Database Syst Rev 2004; 1.
  408. Ginsberg-Fellner F, Witt ME, Franklin BH, Yagihashi S, Toguchi Y, Dobersen MJ. et al. Triad of markers for identifying children at high risk of developing insulin-dependent diabetes mellitus. JAMA. 1985;254(11):1469–1472. [PubMed: 3897593]
  409. Ginsberg HN. Treatment for Pateints with the Metabolic Syndrome. Am J Cardiol. 2003;91(7A):Suppl 29E–9E. [PubMed: 12679201]
  410. Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M. Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol. 1980;18(5):395–398. [PubMed: 7002569]
  411. Giugliano D, Quatraro A, Minei A, De Rosa N, Coppola L, D'Onofrio F. Hyperinsulinemia in hypertension: increased secretion, reduced clearance or both? J Endocrinol Invest. 1993;16(5):315–321. [PubMed: 8320421]
  412. Giugliano D, Quatraro A, Acampora R, De Rosa N, Ceriello A, D'Onofrio F. Hyperinsulinemia in glucose intolerance: is it true? J Endocrinol Invest. 1994;17(6):391–396. [PubMed: 7930385]
  413. Glorioso N, Bandiera F, Fulgheri PD. Once-a-day fenquizone in the treatment of hypertensive patients with impaired glucose tolerance. Current Therapeutic Research, Clinical & Experimental. 1984;35(3):483–490.
  414. Godsland IF, Shennan NM, Wynn V. Insulin action and dynamics modelled in patients taking the anabolic steroid methandienone (Dianabol) Clin Sci (Colch ) 1986;71(6):665–673. [PubMed: 3539458]
  415. Goedecke JH, Elmer-English R, Dennis SC, Schloss I, Noakes TD, Lambert EV. Effects of medium-chain triacylglycerol ingested with carbohydrate on metabolism and exercise performance. Int J Sport Nutr. 1999;9(1):35–47. [PubMed: 10036340]
  416. Goetz FC, French LR, Thomas W, Gingerich RL, Clements JP. Are specific serum insulin levels low in impaired glucose tolerance and type II diabetes?: measurement with a radioimmunoassay blind to proinsulin, in the population of Wadena, Minnesota. Metabolism. 1995;44(10):1371–1376. [PubMed: 7476300]
  417. Goetz FC, Jacobs DR Jr.,, Chavers B, Roel J, Yelle M, Sprafka JM. Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study. Am J Epidemiol. 1997;145(2):91–102. [PubMed: 9006305]
  418. Goff DC Jr.,, D'Agostino RB Jr., Haffner SM, Saad MF, Wagenknecht LE. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: Results from the insulin resistance atherosclerosis study. Diabetes Care. 2000;23(7):1006–1011. [PubMed: 10895855]
  419. Gokcel A, Ozsahin AK. High prevalence of diabetes in Adana, a southern province of Turkey. Diabetes Care. 2003;26(11):3031–3034. [PubMed: 14578235]
  420. Golay A, Felber JP, Meyer HU, Curchod B, Maeder E, Jequier E. Study on lipid metabolism in obesity diabetes. Metabolism. 1984;33(2):111–116. [PubMed: 6694554]
  421. Golay A, Chen N, Chen YD, Hollenbeck C, Reaven GM. Effect of central obesity on regulation of carbohydrate metabolism in obese patients with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1990;71(5):1299–1304. [PubMed: 2229287]
  422. Golay A, Felber JP. Evolution from obesity to diabetes. Diabete Metab. 1994;20(1):3–14. [PubMed: 8056132]
  423. Golay A, Munger R, Assimacopoulos-Jeannet F, Bobbioni-Harsch E, Habicht F, Felber J-P. Progressive defect of insulin action on glycogen synthase in obesity and diabetes. Metabolism. 2002;51(5):549–553. [PubMed: 11979384]
  424. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98(23):2513–2519. [PubMed: 9843456]
  425. Gomez-Perez FJ, Aguilar-Salinas CA, Lopez-Alvarenga JC, Perez-Jauregui J, Guillen-Pineda LE, Rull JA. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care. 1998;21(11):1886–1888. [PubMed: 9802737]
  426. Gonzalez C, Stern MP, Gonzalez E, Rivera D, Simon J, Islas S et al. The Mexico City Diabetes Study: a population-based approach to the study of genetic and environmental interactions in the pathogenesis of obesity and diabetes... including commentary by Gutierez-Cortina A, Toussiant T, Gonzalez-Barranco J, Bastarrachea R, Zavala J, Perusse L and Valencia M with author response... Second Nestle Conference on Nutrition: Nutrition-Gene Interactions in Human Populations: the Amerindian Case, Mexico City, Mexico, January 29–30, 1998. Nutrition Reviews 57(5 part 2):S71–7, 1999 May (21 ref) 1999;(5 part 2):S71–S77.
  427. Gonzalez VC, Stern MP, Haffner S, Arredondo PB, Martinez DS, Islas AS. The insulin resistance syndrome in Mexico. Prevalence and clinical characteristics: a population based study. Arch Med Res 1995; 26 Spec No:S9–15. [PubMed: 8845665]
  428. Goodstein MH, Herman JH, Smith JF, Rubenstein SD. Metabolic consequences in very low birth weight infants transfused with older AS-1-preserved erythrocytes. Pediatric Pathology & Molecular Medicine. 1998;18(2):173–185.
  429. Gopinath R. Role of pharmacologic agents in the prevention of diabetes in pateints with impaired glucose intolerance. Medscape 2004.
  430. Gorogawa S-I, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuroda A. et al. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2002;57(1):1–10. [PubMed: 12007724]
  431. Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Medicine & Science in Sports & Exercise. 1997;29(8):992–998. [PubMed: 9268955]
  432. Grant P. Insulin resistance and cardiovascular disease: Redefining type 2 diabetes. British Journal of Cardiology. 2001;8(SUPPL. 4):S1–S3.
  433. Grant PT, Oats JN, Beischer NA. The long-term follow-up of women with gestational diabetes. Aust N Z J Obstet Gynaecol. 1986;26(1):17–22. [PubMed: 3460570]
  434. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F. et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens. 2003;21(9):1761–1769. [PubMed: 12923410]
  435. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes. 1996;45(11):1631–1634. [PubMed: 8866571]
  436. Griffiths J, Springuel P. Reports on Individual Drugs. WHO Drug Information. 2001;15(3/4):152–154.
  437. Grimberg A, Ferry RJ Jr.,, Kelly A, Koo-Mccoy S, Polonsky K, Glaser B. et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes. 2001;50(2):322–328. [PMC free article: PMC3313678] [PubMed: 11272143]
  438. Grinker JA, Tucker KL, Vokonas PS, Rush D. Changes in patterns of fatness in adult men in relation to serum indices of cardiovascular risk: The Normative Aging Study. Int J Obes. 2000;24(10):1369–1378. [PubMed: 11093301]
  439. Grobin W. A longitudinal study of impaired glucose tolerance and diabetes mellitus in the aged. J Am Geriatr Soc. 1989;37(12):1127–1134. [PubMed: 2592720]
  440. Groop L, Forsblom C, Lehtovirta M. Characterization of the prediabetic state. Am J Hypertens. 1997;10(9 II SUPPL.):172S–180S. [PubMed: 9324118]
  441. Guazzarotti L, Fumelli P, Testa I, Pecora R, Panicri F, Bellanne-Chantelot C. et al. Diagnosis of MODY in the offspring of parents with insulin-dependent and non-insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab. 2001;14(SUPPL. 1):611–617. [PubMed: 11393552]
  442. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non- insulin-dependent diabetes mellitus. Stroke. 1999;30(9):1787–1791. [PubMed: 10471424]
  443. Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose values. J Diabetes Complications. 2000;14(5):272–276. [PubMed: 11113690]
  444. Guerrero-Romero F, Rodriguez-Moran M. Glucose intolerance is predicted by the high Fasting Insulin-to-Glucose ratio. Diabetes Metab. 2001;27(2 Pt 1):117–121. [PubMed: 11353876]
  445. Guerrero-Romero F, Rodriguez-Moran M. Impaired glucose tolerance is a more advanced stage of alteration in the glucose metabolism than impaired fasting glucose. J Diabetes Complications. 2001;15(1):34–37. [PubMed: 11259924]
  446. Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003;29(1):65–71. [PubMed: 12629450]
  447. Guerrero-Romero F, Rodriguez-Moran M. Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial. Experimental & Clinical Endocrinology & Diabetes. 2003;111(2):91–96. [PubMed: 12746760]
  448. Guichard-Rode S, Charrie A, Penet D, Teboul F, Thivolet C. Massive weight loss does not restore normal insulin secretory pulses in obese patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Metab. 1997;23(6):506–510. [PubMed: 9496556]
  449. Guillaume M, Lapidus L, Beckers F, Lambert A, Bjorntorp P. Cardiovascular risk factors in children from the Belgian province of Luxembourg. The Belgian Luxembourg Child Study. Am J Epidemiol. 1996;144(9):867–880. [PubMed: 8890665]
  450. Gulbas Z, Erdogan Y, Balci S. Impaired glucose tolerance in pulmonary tuberculosis. Eur J Respir Dis. 1987;71(5):345–347. [PubMed: 3443157]
  451. Guney E, Ozgen AG, Kisakol G. Impact of new diagnostic criteria on the frequency of diabetes mellitus and prediabetic conditions. International Journal of Diabetes & Metabolism. 2002;10(1):22–28.
  452. Gupta AG. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract. 2003;61(1):69–76. [PubMed: 12849925]
  453. Guthrie JR, Ball M, Dudley EC, Garamszegi CV, Wahlqvist ML, Dennerstein L. et al. Impaired fasting glycaemia in middle-aged women: a prospective study. Int J Obes Relat Metab Disord. 2001;25(5):646–651. [PubMed: 11360146]
  454. Haeusler G, Frisch H. Growth hormone treatment in Turner's syndrome: Short and long-term effects on metabolic parameters. Clin Endocrinol (Oxf) 1992;36(3):247–254. [PubMed: 1563078]
  455. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism. 1988;37(4):338–345. [PubMed: 3282148]
  456. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes. 1990;39(3):283–288. [PubMed: 2407581]
  457. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? [see comments] JAMA. 1990;263(21):2893–2898. [PubMed: 2338751]
  458. Haffner SM, Valdez R, Morales PA, Mitchell BD, Hazuda HP, Stern MP. Greater effect of glycemia on incidence of hypertension in women than in men. Diabetes Care. 1992;15(10):1277–1284. [PubMed: 1425089]
  459. Haffner SM, Gonzales C, Valdez RA, Mykkanen L, Hazuda HP, Mitchell BD. et al. Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia. 1993;36(10):1002–1006. [PubMed: 8243847]
  460. Haffner SM, Bowsher RR, Mykkanen L, Hazuda HP, Mitchell BD, Valdez RA. et al. Proinsulin and specific insulin concentration in high-and low-risk populations for NIDDM. Diabetes. 1994;43(12):1490–1493. [PubMed: 7958504]
  461. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44(12):1386–1391. [PubMed: 7589843]
  462. Haffner SM, Agil A, Mykkanen L, Stern MP, Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Diabetes Care. 1995;18(5):646–653. [PubMed: 8586002]
  463. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia. 1996;39(10):1201–1207. [PubMed: 8897008]
  464. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996;19(10):1138–1141. [PubMed: 8886564]
  465. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087–1092. [PubMed: 9203442]
  466. Haffner SM. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med. 1997;14(SUPPL. 3):S12–S18. [PubMed: 9272608]
  467. Haffner SM, Miettinen H, Stern MP. Are risk factors for conversion to NIDDM similar in high and low risk populations? Diabetologia. 1997;40(1):62–66. [PubMed: 9028719]
  468. Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care. 1998;21(Suppl3):C3–C6. [PubMed: 9850478]
  469. Haffner SM, D'Agostino R Jr.,, Mykkanen L, Tracy R, Howard B, Rewers M. et al. Insulin sensitivity in subjects with type 2 diabetes: Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22(4):562–568. [PubMed: 10189532]
  470. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR. et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.[comment] Arch Intern Med. 1999;159(22):2661–2667. [PubMed: 10597756]
  471. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975–980. [PubMed: 10704163]
  472. Haffner SM. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials. [Review][33 refs]. Int J Clin Pract 2002; Supplement.(129):33–39. [PubMed: 12166604]
  473. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59(6):294–299. [PubMed: 9671341]
  474. Hallgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Medica Scandinavica. 1983;213(5):351–355. [PubMed: 6880857]
  475. Hamada N, Ito K, Mimura T. Factors predicting the course of diabetes mellitus in hyperthyroid patients. Horm Metab Res. 1986;18(4):260–263. [PubMed: 3519414]
  476. Hamman RF, Marshall JA, Baxter J, Kahn LB, Mayer EJ, Orleans M. et al. Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol. 1989;129(2):295–311. [PubMed: 2912042]
  477. Hammersley MS, Meyer LC, Morris RJ, Manley SE, Turner RC, Holman RR. The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial. Metabolism. 1997;46(12 Suppl 1):44–49. [PubMed: 9439559]
  478. Hanai H, Ikuma M, Sato Y, Iida T, Hosoda Y, Matsushita I. et al. Long-term effects of water-soluble corn bran hemicellulose on glucose tolerance in obese and non-obese patients: improved insulin sensitivity and glucose metabolism in obese subjects. Biosci Biotechnol Biochem. 1997;61(8):1358–1361. [PubMed: 9301120]
  479. Hanas R, Adolfsson P, Elfvin-Akesson K, Hammaren L, Ilvered R, Jansson I. et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr. 2002;140(3):315–320. [PubMed: 11953729]
  480. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med. 1997;14(SUPPL. 3):S6–S11. [PubMed: 9272607]
  481. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med. 1999;16(3):212–218. [PubMed: 10227566]
  482. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: The RIAD study. Diabet Med. 2000;17(12):835–840. [PubMed: 11168325]
  483. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: The risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care. 2003;26(3):868–874. [PubMed: 12610051]
  484. Hanley AJ, McKeown-Eyssen G, Harris SB, Hegele RA, Wolever TM, Kwan J. et al. Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition.[erratum appears in Diabetes Care 2001 Oct;24(10):1851] Diabetes Care. 2001;24(7):1240–1247. [PubMed: 11423509]
  485. Hanley AJ, McKeown-Eyssen G, Harris SB, Hegele RA, Wolever TM, Kwan J. et al. Cross-sectional and prospective associations between abdominal adiposity and proinsulin concentration. J Clin Endocrinol Metab. 2002;87(1):77–83. [PubMed: 11788626]
  486. Hara-Nakamura N, Kohara K, Sumimoto T, Lin M, Hiwada K. Glucose intolerance exaggerates left ventricular hypertrophy and dysfunction in essential hypertension. Am J Hypertens. 1994;7(12):1110–1114. [PubMed: 7702807]
  487. Harris MI, Hadden WC, Knowler WC, Bennett PH. International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care. 1985;8(6):562–567. [PubMed: 4075941]
  488. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987;36(4):523–534. [PubMed: 3817306]
  489. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care. 1989;12(7):464–474. [PubMed: 2758951]
  490. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of Diabetes diagnostic categories in the U.S. population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care. 1997;20(12):1859–1862. [PubMed: 9405907]
  491. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care. 1998;21(8):1230–1235. [PubMed: 9702425]
  492. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4):518–524. [PubMed: 9571335]
  493. Harris MK. Gestational diabetes may represent discovery of preexisting glucose intolerance. Diabetes Care. 1988;11(5):402–411. [PubMed: 3391090]
  494. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.[see comment]. [Review] [138 refs] Annals of Internal Medicine. 2003;138(3):215–229. [PubMed: 12558362]
  495. Harris RA, Hardman DT, Brown AR. Cellulitis and the occult diabetic. Australian & New Zealand Journal of Surgery. 1996;66(3):175–177. [PubMed: 8639138]
  496. Harris SB, Perkins BA, Whalen-Brough E. Non-insulin-dependent diabetes mellitus among First Nations children. New entity among First Nations people of north western Ontario. Can Fam Physician. 1996;42:869–876. [PMC free article: PMC2146381] [PubMed: 8688690]
  497. Harris SB, Gittelsohn J, Hanley A, Barnie A, Wolever TMS, Gao J. et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 1997;20(2):185–187. [PubMed: 9118771]
  498. Harris SB, Zinman B, Hanley A, Gittelsohn J, Hegele R, Connelly PW. et al. The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Res Clin Pract. 2002;55(2):165–173. [PubMed: 11796183]
  499. Hartling SG, Lindgren F, Dahlqvist G, Persson B, Binder C. Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes. 1989;38(10):1271–1274. [PubMed: 2792577]
  500. Hauner H, Bognar E, Blum A. Body fat distribution and its association with metabolic and hormonal risk factors in women with angiographically assessed coronary artery disease. Evidence for the presence of a metabolic syndrome. Atherosclerosis. 1994;105(2):209–216. [PubMed: 8003097]
  501. Hayashi K, Kurushima H, Kuga Y, Shingu T, Tanaka K, Yasunobu Y. et al. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance. Cardiovascular Drugs & Therapy. 1998;12(1):3–12. [PubMed: 9607127]
  502. Hays NP. Starling RD.Liu. Effects of an ad libitum low-fat, high-carbohydrate diet on body weight, body composition, and fat distribution in older men and women: a randomized controlled trial. Arch Intern Med. 2004;164(2):210–217. [PubMed: 14744846]
  503. He J, Klag MJ, Caballero B, Appel LJ, Charleston J, Whelton PK. Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med. 1999;159(5):498–503. [PubMed: 10074959]
  504. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A. et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44(3):333–339. [PubMed: 11317665]
  505. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med. 1996;13(3 Suppl 2):S12–S14. [PubMed: 8689855]
  506. Helkala EL, Lakka T, Vanhanen M, Tuomainen TP, Ehnholm C, Kaplan GA. et al. Associations between apolipoprotein E phenotype, glucose metabolism and cognitive function in men. An explorative study in a population sample. Diabet Med. 2001;18(12):991–997. [PubMed: 11903399]
  507. Henkel E, Temelkova-Kurktschiev T, Koehler C, Pietzsch J, Leonhardt W, Hanefeld M. Impaired glucose tolerance is not associated with lipid intolerance. Diabetes Nutr Metab. 2002;15(2):84–90. [PubMed: 12059096]
  508. Henry RMA, Kostense PJ, Spijkerman AMW, Dekker JM, Nijpels G, Heine RJ. et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation. 2003;107(16):2089–2095. [PubMed: 12695300]
  509. Herlihy OM, Barrow BA, Grant PJ, Levy JC. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia. 2002;45(5):635–641. [PubMed: 12107743]
  510. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR. et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.[comment] Diabetes Care. 1999;22(11):1771–1778. [PubMed: 10546006]
  511. Hermann J, Chung H, Arquitt A, Goad C, Burns M, Chan B. Effects of chromium or copper supplementation on plasma lipids, plasma glucose and serum insulin in adults over age fifty. Journal of Nutrition for the Elderly 18(1):27–45, 1998 (48 ref) 1998;(1):27–45.
  512. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes. 1999;48(9):1779–1786. [PubMed: 10480608]
  513. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia. 1999;42(6):678–687. [PubMed: 10382587]
  514. Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE. et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.[comment] Diabetes Care. 2003;26(1):36–47. [PMC free article: PMC1402339] [PubMed: 12502656]
  515. Herranz L, Megia A, Grande C, Gonzalez-Gancedo P, Pallardo F. Dehydroepiandrosterone sulphate, body fat distribution and insulin in obese men. Int J Obes. 1995;19(1):57–60. [PubMed: 7719392]
  516. Herskowitz-Dumont R, Wolfsdorf JI, Jackson RA, Eisenbarth GS. Distinction between transient hyperglycemia and early insulin-dependent diabetes mellitus in childhood: a prospective study of incidence and prognostic factors. J Pediatr. 1993;123(3):347–354. [PubMed: 8355109]
  517. Hetzler RK, Warhaftig-Glynn N, Thompson DL, Dowling E, Weltman A. Effects of acute caffeine withdrawal on habituated male runners. J Appl Physiol. 1994;76(3):1043–1048. [PubMed: 8005843]
  518. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A. et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160(9):1321–1326. [PubMed: 10809036]
  519. Higashi K, Shige H, Ito T, Nakajima K, Ishikawa T, Nakamura H. et al. Impaired glucose tolerance without hypertriglyceridemia does not enhance postprandial lipemia. Horm Metab Res. 2001;33(2):101–105. [PubMed: 11294490]
  520. Hilton CW, Mizuma H, Svec F, Prasad C. Relationship between plasma cyclo (His-Pro), a neuropeptide common to processed protein-rich food, and C-peptide/insulin molar ratio in obese women. Nutritional Neuroscience. 2001;4(6):469–474. [PubMed: 11843266]
  521. Hilton DJ, O'Rourke PK, Welborn TA, Reid CM. Diabetes detection in Australian general practice: a comparison of diagnostic criteria.[see comment] Med J Aust. 2002;176(3):104–107. [PubMed: 11936304]
  522. Hiltunen L, Keinanen-Kiukaanniemi S, Laara E, Kivela SL. Functional ability of elderly persons with diabetes or impaired glucose tolerance. Scand J Prim Health Care. 1996;14(4):229–237. [PubMed: 8956451]
  523. Hiltunen L, Laara E, Kivela S-L, Keinanen-Kiukaanniemi S. Glucose tolerance and mortality in an elderly Finnish population. Diabetes Res Clin Pract. 1998;39(1):75–81. [PubMed: 9597377]
  524. Hiltunen L, Laara E, Keinanen-Kiukaanniemi S. Changes in glucose tolerance during three years' follow-up in an elderly population. Public Health. 1999;113(4):181–184. [PubMed: 10483080]
  525. Hiltunen LA. Does glucose tolerance affect elderly persons' balance, gait or muscle strength? Central European Journal of Public Health. 2001;9(1):22–25. [PubMed: 11243584]
  526. Hiltunen LA, Keinanen-Kiukaanniemi SM, Laara EM. Glucose tolerance and cognitive impairment in an elderly population. Public Health. 2001;115(3):197–200. [PubMed: 11429715]
  527. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26(3):677–682. [PubMed: 12610021]
  528. Hinds A, Sheehan AG, Parsons HG. Tolbutamide causes a modest increase in insulin secretion in cystic fibrosis patients with impaired glucose tolerance. Metabolism. 1995;44(1):13–18. [PubMed: 7854158]
  529. Hirai N, Kawano H, Hirashima O, Motoyama T, Moriyama Y, Sakamoto T. et al. Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C. Am J Physiol Heart Circ Physiol. 2000;279(3):H1172–H1178. [PubMed: 10993781]
  530. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens. 2001;14(9 I):908–913. [PubMed: 11587157]
  531. Hirose T, Mizuno R, Yoshimoto T. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects. Endocr J. 2002;49(6):649–652. [PubMed: 12625415]
  532. Hjalmarsen A, Aasebo U, Birkeland K, Sager G, Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab. 1996;22(1):37–42. [PubMed: 8697294]
  533. Hjelmesaeth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrom J, Morkrid L. et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant. 2001;16(5):1047–1052. [PubMed: 11328915]
  534. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992;36(3):271–279. [PubMed: 1563080]
  535. Hodge AM, Dowse GK, Collins VR, Zimmet PZ. Abnormal glucose tolerance and alcohol consumption in three populations at high risk of non-insulin-dependent diabetes mellitus [published erratum appears in Am J Epidemiol 1993 Aug 15;138(4):279] Am J Epidemiol. 1993;137(2):178–189. [PubMed: 8452122]
  536. Hodge AM, Dowse GK, Zimmet PZ, Gareeboo H, Westerman RA, Tuomilehto J. et al. Factors associated with impaired vibration perception in Mauritians with normal and abnormal glucose tolerance. Mauritius NCD Study Group. J Diabetes Complications. 1995;9(3):149–157. [PubMed: 7548978]
  537. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13(6):1626–1634. [PubMed: 12039992]
  538. Holl RW, Kunze D, Etzrodt H, Teller W, Heinze E. Turner syndrome: Final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr. 1994;153(1):11–16. [PubMed: 8313917]
  539. Holl RW, Heinze E, Wolf A, Rank M, Teller WM. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis. Eur J Pediatr. 1995;154(5):356–361. [PubMed: 7641765]
  540. Holl RW, Wolf A, Thon A, Bernhard M, Buck C, Missel M. et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 1997;25(2):188–193. [PubMed: 9252906]
  541. Holloszy JO, Schultz J, Kusnierkiewicz J. Effects of exercise on glucose tolerance and insulin resistance. Brief review and some preliminary results. Acta Medica Scandinavica. 1986;220(SUPPL. 711):55–65. [PubMed: 3535414]
  542. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of Gastroenterology & Hepatology. 2002;17(6):677–681. [PubMed: 12100613]
  543. Hong Y, Weisnagel SJ, Rice T, Sun G, Mandel SA, Gu C. et al. Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study. Clin Genet. 2001;60(1):22–30. [PubMed: 11531966]
  544. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM. et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study.[see comment] Kidney Int. 1998;54(1):203–209. [PubMed: 9648080]
  545. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM. et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18(1):133–138. [PubMed: 9445267]
  546. Horton ES, Jeanrenaud B. Obesity and diabetes mellitus. In: Rifkin H, Porte D, Jr., editors. Ellenberg and Rifkin's diabetes mellitus: Theory and practice. New York: Elsevir Science, 1990: 457–463.
  547. Hoshino A. Studies on carbohydrate metabolism in infants with congenital heart disease. Part I. Alteration of glucose and lactate metabolism in congenital heart disease. Acta Paediatr Jpn. 1981;23(2):162–171.
  548. Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997;20(2):110–118. [PubMed: 9088667]
  549. Huang TT, Johnson MS, Gower BA, Goran MI. Effect of changes in fat distribution on the rates of change of insulin response in children. Obes Res. 2002;10(10):978–984. [PubMed: 12376577]
  550. Hughes LO, Raval U, Raftery EB. First myocardial infarctions in Asian and white men. Br Med J (Clin Res Ed) 1989;298(6684):1345–1350. [PMC free article: PMC1836652] [PubMed: 2502249]
  551. Hughes VA, Fiatarone MA, Fielding RA, Ferrara CM, Elahi D, Evans WJ. Long-term effects of a high-carbohydrate diet and exercise on insulin action in older subjects with impaired glucose tolerance. Am J Clin Nutr. 1995;62(2):426–433. [PubMed: 7625352]
  552. Husband DJ, Alberti KGMM, Julian DG. ‘Stress’ hyperglycaemia during acute myocardial infarction: An indicator of pre-existing diabetes. Lancet. 1983;2(8343):179–181. [PubMed: 6135025]
  553. Husseini A, Abdul-Rahim H, Awartani F, Jervell J, Bjertness E. Prevalence of diabetes mellitus and impaired glucose tolerance in a rural Palestinian population. Eastern Mediterranean Health Journal 6(5/6):1039–45, 2000 Sep-Nov (16 ref) 2000;(5/6):1039–1045. [PubMed: 12197326]
  554. Hwu C-M, Kwok C-F, Kuo BI, Lin Y-T, Lee Y-S, Hsiao L-C. et al. Undiagnosed glucose intolerance encountered in clinical practice: Reappraisal of the use of the oral glucose tolerance test. Chinese Medical Journal (Taipei) 2001;64(8):435–442. [PubMed: 11720141]
  555. Hyltoft PP, Brandslund I, Jorgensen L, Stahl M, de Fine ON, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glucose as the basis for analytical quality specifications in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest. 2001;61(3):191–204. [PubMed: 11386606]
  556. Hyun KS, Song K-H, Ahn Y-B, Yoo S-J, Son H-S, Yoon K-H. et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism. 2003;52(6):731–734. [PubMed: 12800099]
  557. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'grady MJ, Welty TK. et al. Relationship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am Heart J. 2001;141(6):992–998. [PubMed: 11376315]
  558. Inoue I, Takahashi K, Katayama S, Akabane S, Negishi K, Suzuki M. et al. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract. 1994;25(3):199–205. [PubMed: 7851275]
  559. Inoue I, Takahashi K, Katayama S, Harada Y, Negishi K, Ishi J. et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabet Med. 1996;13(4):330–336. [PubMed: 9162608]
  560. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care. 2003;26(1):118–124. [PubMed: 12502667]
  561. Ioka T, Tasaki H, Yashiro A, Yamashita K, Ozumi K, Tsutsui M. et al. Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. Circ J. 2002;66(3):267–271. [PubMed: 11922276]
  562. Islam AH, Yamashita S, Kotani K, Nakamura T, Tokunaga K, Arai T. et al. Fasting plasma insulin level is an important risk factor for the development of complications in Japanese obese children--results from a cross-sectional and a longitudinal study. Metabolism. 1995;44(4):478–485. [PubMed: 7723670]
  563. Istfan NW, Plaisted CS, Bistrian BR, Blackburn GL. Insulin resistance versus insulin secretion in the hypertension of obesity. Hypertension. 1992;19(4):385–392. [PubMed: 1555870]
  564. Ito C, Maeda R, Nakamura K, Sasaki H. Prediction of diabetes mellitus (NIDDM) Diabetes Res Clin Pract. 1996;34 Suppl:S7–11. [PubMed: 9015664]
  565. Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H. Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. Diabetes Res Clin Pract. 2000;49(2-3):181–186. [PubMed: 10963830]
  566. Iwaoka T, Umeda T, Inoue J, Naomi S, Sasaki M, Fujimoto Y. et al. Dietary NaCl restriction deteriorates oral glucose tolerance in hypertensive patients with impairment of glucose tolerance. Am J Hypertens. 1994;7(5):460–463. [PubMed: 8060581]
  567. Iyer SR, Iyer RR, Upasani SV, Baitule MN. Diabetes mellitus in Dombivli--an urban population study. J Assoc Physicians India. 2001;49:713–716. [PubMed: 11573556]
  568. Jaap AJ, Shore AC, Stockman AJ, Tooke JE. Skin capillary density in subjects with impaired glucose tolerance and patients with type 2 diabetes. Diabet Med. 1996;13(2):160–164. [PubMed: 8641122]
  569. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia. 1997;40(2):238–243. [PubMed: 9049487]
  570. Jaber LA, Brown MB, Hammad A, Howak SN, Zhu Q, Ghafoor A. et al. Epidemiology of diabetes among Arab Americans. Diabetes Care. 2003;26(2):308–313. [PubMed: 12547854]
  571. Jackson KG, Taylor GRJ, Clohessy AM, Williams CM. The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br J Nutr. 1999;82(1):23–30. [PubMed: 10655953]
  572. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M. et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001;54(2):189–195. [PubMed: 11207633]
  573. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jequier E. et al. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism. 1990;39(10):1068–1075. [PubMed: 2215253]
  574. Jang HC, Yim CH, Han KO, Yoon HK, Han IK, Kim MY, Yang JH, Cho NH. Gestational diabetes mellitus in Korea: prevalence and prediction of glucose intolerance at early postpartum. Diabetes Res Clin Pract. 2003;61(2):117–124. [PubMed: 12951280]
  575. Jarrett RJ, McCartney P, Keen H. The Bedford survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22(2):79–84. [PubMed: 7060853]
  576. Jarrett RJ, Keen H, McCartney P. The Whitehall study: Ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. DIABETIC MED. 1984;1(4):279–283. [PubMed: 6242817]
  577. Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease-chicken, egg or neither?. [Review] [37 refs] Diabetologia. 1984;26(2):99–102. [PubMed: 6370765]
  578. Jarrett RJ, Keen H, MT Changes in blood pressure and body weight over ten years in men selected for glucose intolerance. [erratum appears in J Epidemiol Community Health 1987 Sep;41(3):242.] Journal of Epidemiology & Community Health. 1987;41(2):145–151. [PMC free article: PMC1052600] [PubMed: 3655634]
  579. Jawad F, Shera AS, Memon R, Ansari G. Glucose intolerance in pulmonary tuberculosis. JPMA J Pak Med Assoc. 1995;45(9):237–238. [PubMed: 8683828]
  580. Jenkins DJ, Wolever TM, Taylor RH, Griffiths C, Krzeminska K, Lawrie JA. et al. Slow release dietary carbohydrate improves second meal tolerance. Am J Clin Nutr. 1982;35(6):1339–1346. [PubMed: 6282105]
  581. Jensen P, Johansen HK, Carmi P, Hoiby N, Cohen IR. Autoantibodies to pancreatic hsp60 precede the development of glucose intolerance in patients with cystic fibrosis. J Autoimmun. 2001;17(2):165–172. [PubMed: 11591125]
  582. Jeon JY, Weiss CB, Steadward RD, Ryan E, Burnham RS, Bell G. et al. Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury. Spinal Cord. 2002;40(3):110–117. [PubMed: 11859437]
  583. Jiao S, Kameda K, Matsuzawa Y, Kubo M, Nonaka K, Tarui S. Influence of endogenous hyperinsulinism on high density lipoprotein2 level in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance. Atherosclerosis. 1986;60(3):279–286. [PubMed: 3730047]
  584. Johnson KC, Graney MJ, Applegate WB, Kitabchi AE, Runyan JW, Rutan GH. Does syndrome X exist in hypertensive elderly persons with impaired glycemic control? Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 1999;54A(11):M571–M576. [PubMed: 10619320]
  585. Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.[see comment]. [Review] [48 refs] Ann Pharmacother. 1998;32(3):337–348. [PubMed: 9533065]
  586. Jorgensen ME, Bjeregaard P, Borch-Johnsen K. Diabetes and impaired glucose tolerance among the inuit population of Greenland.[erratum appears in Diabetes Care. 2002 Dec;25(12):2372] Diabetes Care. 2002;25(10):1766–1771. [PubMed: 12351475]
  587. Kadowaki T, Miyake Y, Hagura R, Kajinuma H, Kuzuya N, Akanuma Y. et al. On the pathogenesis of type II diabetes with special reference to diminished insulin response and obesity: a 5-12 year follow-up study of subjects with borderline glucose tolerance. Tohoku J Exp Med. 1983;141 Suppl:141–146. [PubMed: 6393431]
  588. Kadowaki T, Miyake Y, Hagura R. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26(1):44–49. [PubMed: 6368299]
  589. Kadowaki T, Yoshinaga H. Risk factors for the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japan. Diabetes Res Clin Pract. 1994;24 Suppl:S123–S127. [PubMed: 7859593]
  590. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. New York: Oxford University Press, 1989.
  591. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstom RW, Fujimoto WY. Proinsulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men. Diabet Med. 1996;13(9 Suppl 6):S63–S66. [PubMed: 8894485]
  592. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia. 1995;38(9):1096–1102. [PubMed: 8591825]
  593. Kaltiala KS, Haavisto MV, Heikinheimo RJ. Blood glucose and diabetes mellitus predicting mortality in persons aged 85 years or above. Age & Ageing. 1987;16(3):165–170. [PubMed: 3604798]
  594. Kan H, Fujimoto S, Matsuda I. Erythrocyte insulin receptor and glucose tolerance test in children treated with prednisolone. Endocrinol Jpn. 1985;32(3):347–353. [PubMed: 3899618]
  595. Kanatsuka A, Osegawa M, Makino H. An assessment of the new NIH diagnostic criteria for diabetes mellitus according to insulin response in a 75 g oral tolerance test and levels of hemoglobin AIC. Horm Metab Res. 1982;14(12):626–630. [PubMed: 6759357]
  596. Kanatsuka A, Makino H, Sakurada M, Hashimoto N, Iwaoka H, Yamaguchi T. et al. First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance: Analysis by C-peptide secretion rate. Metabolism. 1988;37(9):878–884. [PubMed: 3047522]
  597. Kaneshige H, Endoh M, Tomino Y. Abnormal glucose tolerance in patients with chronic glomerulonephritis without renal failure. Diabetes Care. 1983;6(4):381–386. [PubMed: 6352211]
  598. Kanigur-Sultuybek G, Hatemi H, Guven M, Ulutin T, Tezcan V, Ulutin ON. The effect of metformin and gliclazide on platelets and red blood cell glucose transport mechanisms in impaired glucose tolerance and type II diabetic patients with vasculopathy. Thrombotic & Haemorrhagic Disorders. 1993;7(1):17–21.
  599. Kankova K, Jansen EH, Marova I, Stejskalova A, Pacal L, Muzik J. et al. Relations among serum ferritin, C282Y and H63D mutations in the HFE gene and type 2 diabetes mellitus in the Czech population. Experimental & Clinical Endocrinology & Diabetes. 2002;110(5):223–229. [PubMed: 12148086]
  600. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham study. J Am Geriatr Soc. 1985;33(1):13–18. [PubMed: 3965550]
  601. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114(2):413–419. [PubMed: 3604900]
  602. Kaplan LA, Cline D, Gartside P, Burstein S, Sperling M, Stein EA. Hemoglobin A1 in hemolysates from healthy and insulin-dependent diabetic children, as determined with a temperature-controlled minicolumn assay. Clin Chem. 1982;28(1):13–18. [PubMed: 7034998]
  603. Karadeniz S, KirYilmaz MT, Ongor E, Dinccag N, Basar D, Akarcay K. et al. Alteration of visual function in impaired glucose tolerance. Eur J Ophthalmol. 1996;6(1):59–62. [PubMed: 8744852]
  604. Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27 485 people. Occupational & Environmental Medicine 58(11):747–52, 2001 Nov (26 ref) 2001;(11):747–752. [PMC free article: PMC1740071] [PubMed: 11600731]
  605. Karvestedt L, Andersson G, Efendic S, Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med. 2002;251(4):307–316. [PubMed: 11952881]
  606. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H. et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52(5):549–555. [PubMed: 10792333]
  607. Kashiwabara H, Inaba M, Maruno Y, Morita T, Awata T, Negishi K. et al. Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension. J Hypertens. 2000;18(1):83–88. [PubMed: 10678547]
  608. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W. et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52(10):2461–2474. [PubMed: 14514628]
  609. Kasperska-Czyzykowa T, Jaskolska K, Galecki A, Trzaski M, Woy-Wojciechowski J. Effect of biguanide derivatives (phenformin) on carbohydrate tolerance in “borderline” and asymptomatic (“chemical”) diabetes. Results of a 5-year prospective study. Acta Med Pol. 1986;27(3-4):141–152. [PubMed: 3445789]
  610. Katona G, Aganovic I. The National diabetes Programme in Malta - Final Report Phases 1 & II. WHO .1983. Geneva, World Health Organization.Ref Type: Generic.
  611. Katsumori K, Wasada T, Kuroki H, Arii H, Saeki A, Aoki K. et al. Prevalence of macro- and microvascular diseases in non-insulin-dependent diabetic and borderline glucose-intolerant subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 1995;29(3):195–201. [PubMed: 8591713]
  612. Katzman PL, Hulthen UL, Hokfelt B. Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension. Acta Endocrinol (Copenh) 1987;116(4):473–478. [PubMed: 3321819]
  613. Kauffman RP, Baker VM, DiMarino P, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: A comparison of two distinct populations. Am J Obstet Gynecol. 2002;187(5):1362–1369. [PubMed: 12439532]
  614. Kaufmann RC, McBride P, Amankwah KS, Huffman DG. The effect of minor degrees of glucose intolerance on the incidence of neonatal macrosomia. [Review] [21 refs] Obstet Gynecol. 1992;80(1):97–101. [PubMed: 1603507]
  615. Kechrid Z, Kenouz R. Determination of Alkaline Phosphatase Activity in Patients with Different Zinc Metabolic Disorders. Turkish Journal of Medical Sciences. 2003;33(6):387–391.
  616. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D. et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes of impaired fasting glucose: Results from the LIPID trial. Diabetes Care. 2003;26(10):2713–2721. [PubMed: 14514569]
  617. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia. 1982;22(2):73–78. [PubMed: 7060852]
  618. Kekalainen P, Sarlund H, Pyorala K, Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care. 1999;22(1):86–92. [PubMed: 10333908]
  619. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in Observational Epidemiology. 2 ed. New York: Oxford University Press, 1996.
  620. Kenkre PV, Lindeman RD, Lillian YC, Baumgartner RN, Garry PJ. Serum insulin concentrations in daily drinkers compared with abstainers in the New Mexico elder health survey. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2003;58(10):M960–M963. [PubMed: 14570866]
  621. Kentala E, Repo UK. Glucose tolerance and sudden death after myocardial infarction. Ann Clin Res. 1982;14(1):57–60. [PubMed: 7137878]
  622. Kentrup H, Bongers H, Spengler M, Kusenbach G, Skopnik H. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr. 1999;158(6):455–459. [PubMed: 10378391]
  623. Kida T, Harino S, Sugiyama T, Kitanishi K, Iwahashi Y, Ikeda T. Change in retinal arterial blood flow in the contralateral eye of retinal vein occlusion during glucose tolerance test. Graefes Archive for Clinical & Experimental Ophthalmology. 2002;240(5):342–347. [PubMed: 12073056]
  624. Kim D-J, Lee M-S, Kim K-W, Lee M-K. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001;50(5):590–593. [PubMed: 11319722]
  625. Kim SG, Yang SW, Jang AS, Seo JP, Han SW, Yeom CH. et al. Prevalence of diabetes mellitus in the elderly of Namwon County, South Korea. Korean J Intern Med. 2002;17(3):180–190. [PMC free article: PMC4531677] [PubMed: 12298429]
  626. Kindmark H, Kohler M, Arkhammar P, Efendic S, Larsson O, Linder S. et al. Oscillations in cytoplasmic free calcium concentration in human pancreatic islets from subjects with normal and impaired glucose tolerance. Diabetologia. 1994;37(11):1121–1131. [PubMed: 7867884]
  627. King H, Zimmet P, Raper LR, Balkau B. The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six-year follow-up study. Diabetologia. 1984;26(1):39–43. [PubMed: 6706044]
  628. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care. 1993;16(1):157–177. [PubMed: 8123057]
  629. Kiyohara Y, Shinohara A, Kato I, Shirota T, Kubo M, Tanizaki Y. et al. Dietary factors and development of impaired glucose tolerance and diabetes in a general Japanese population: the hisayama study. J Epidemiol. 2003;13(5):251–258. [PubMed: 14604220]
  630. Klein-Weigel P, Krall K, Falkensammer J, Heinz-Erian P, Ulmer H, Fraedrich G. Lack of seasonal variation in flow-mediated dilatation of the brachial artery in women with primary Raynaud's phenomenon and healthy controls. Vasa. 2003;32(2):69–73. [PubMed: 12945098]
  631. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N. et al. Fatty liver--an additional and treatable feature of the insulin resistance syndrome. QJM. 1999;92(2):73–79. [PubMed: 10209658]
  632. Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev. 1990;6(1):1–27. [PubMed: 2192853]
  633. Knowler WC, Saad MF, Pettitt DJ, Nelson RG, Bennett PH. Determinants of diabetes mellitus in the Pima Indians. Diabetes Care. 1993;16(1):216–227. [PubMed: 8422779]
  634. Knowler WC, Narayan KM. Prevention of non-insulin-dependent diabetes mellitus. Prev Med. 1994;23(5):701–703. [PubMed: 7845942]
  635. Knowler WC, Narayan KMV, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J. et al. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44(5):483–488. [PubMed: 7729603]
  636. Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia. 1997;40(6):680–686. [PubMed: 9222648]
  637. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. [PMC free article: PMC1370926] [PubMed: 11832527]
  638. Knuuti J, Takala TO, Nagren K, Sipila H, Turpeinen AK, Uusitupa MI. et al. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia. 2001;44(2):184–187. [PubMed: 11270674]
  639. Ko GT, Chan JC, Woo J, Cockram CS. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care. 1998;21(12):2094–2097. [PubMed: 9839099]
  640. Ko GT, Chan JC, Cockram CS. Use of a paired value of fasting plasma glucose and glycated hemoglobin in predicting the likelihood of diabetes in a community. Diabetes Care. 1999;22(11):1908–1909. [PubMed: 10546031]
  641. Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care. 2000;23(12):1770–1773. [PubMed: 11128350]
  642. Ko GT, Chan JC, Yeung VT, Chow CC, Tsang LW, Cockram CS. A low socio-economic status is an additional risk factor for glucose intolerance in high risk Hong Kong Chinese. Eur J Epidemiol. 2001;17(3):289–295. [PubMed: 11680550]
  643. Ko GTC, Chan JCN, Woo J, Lau E, Yeung VTF, Chow C-C. et al. Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk. 1996;3(5):459–463. [PubMed: 9048262]
  644. Ko GTC, Chan JCN, Lau E, Woo J, Cockram CS. Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care. 1997;20(2):170–172. [PubMed: 9118766]
  645. Ko GTC, Chan JCN, Woo J, Lau E, Yeung VTF, Chow C-C. et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. ANN CLIN BIOCHEM. 1998;35(1):62–67. [PubMed: 9463740]
  646. Ko GTC, Chan W-B, Chan JCN, Tsang LWW, Cockram CS. Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus. Diabet Med. 1999;16(8):670–674. [PubMed: 10477212]
  647. Ko GTC, Chan JCN, Tsang LWW, Yeung VTF, Chow CC, Cockram CS. Outcomes of screening for diabetes in high-risk Hong Kong Chinese subjects. Diabetes Care. 2000;23(9):1290–1294. [PubMed: 10977020]
  648. Ko GTC, Chan JCN, Cockram CS. Change of glycaemic status in Chinese subjects with impaired fasting glycaemia. Diabet Med. 2001;18(9):745–748. [PubMed: 11606173]
  649. Koebberling J, Berninger D. Natural history of glucose tolerance in relatives of diabetic patients: Low prognostic value of the oral glucose tolerance test. Diabetes Care. 1980;3(1):21–26. [PubMed: 7408614]
  650. Koh ET, Ard NF, Mendoza F. Effects of fructose feeding on blood parameters and blood pressure in impaired glucose-tolerant subjects. Journal of the American Dietetic Association. 1988;88(8):932–938. [PubMed: 3294273]
  651. Kohner EM, Dollery CT, Lowy C, Schumer B. Effect of diuretic therapy on glucose tolerance in hypertensive patients. Lancet. 1971;1(7707):986–990. [PubMed: 4102452]
  652. Konukoglu D, Celik C, Akcay T, Ozmen M. The effects of lithium treatment on blood glucose, glycosylated haemoglobin and serum citrate levels. Medical Science Research. 1996;24(8):525–526.
  653. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. European Journal of Endocrinology. 1994;130(6):581–586. [PubMed: 8205258]
  654. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A. et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11(8):950–956. [PubMed: 12917499]
  655. Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E. et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arteriosclerosis Thrombosis & Vascular Biology. 2003;23(6):1042–1047. [PubMed: 12714437]
  656. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(5):441–449. [PubMed: 11981359]
  657. Kosaka K, Kuzuya T, Yoshinaga H, Hagura R. A prospective study of health check examinees for the development of non-insulin-dependent diabetes mellitus: relationship of the incidence of diabetes with the initial insulinogenic index and degree of obesity. Diabet Med. 1996;13(9 Suppl 6):S120–S126. [PubMed: 8894495]
  658. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H. Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. Diabet Med. 1996;13(9 Suppl 6):S109–S119. [PubMed: 8894494]
  659. Kothari K, Mathur A, Yadav S. Estimation of fasting and post oral glucose serum insulin levels in hypertensive and obese subjects. J Assoc Physicians India. 1998;46(6):514–517. [PubMed: 11273248]
  660. Kousta E, Lawrence NJ, Penny A, Millauer BA, Robinson S, Dornhorst A. et al. Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes. Diabetes Care. 1999;22(6):933–937. [PubMed: 10372245]
  661. Kovacs EMR, Westerterp-Plantenga MS, Saris WHM, Melanson KJ, Goossens I, Geurten P. et al. Associations between spontaneous meal initiations and blood glucose dynamics in overweight men in negative energy balance. Br J Nutr. 2002;87(1):39–45. [PubMed: 11898769]
  662. Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachorzewska-Gajewska H. et al. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism. 2002;51(6):733–736. [PubMed: 12037726]
  663. Krakoff J, Hanson RL, Kobes S, Knowler WC. Comparison of the effect of plasma glucose concentrations on microvascular disease between Pima Indian youths and adults. Diabetes Care. 2001;24(6):1023–1028. [PubMed: 11375364]
  664. Kral JG, Sjostrom L, Gustafson A. Effects of jejuno-ileal bypass on serum lipoproteins and glucose tolerance in severely obese patients. Eur J Clin Invest. 1980;10(5):363–367. [PubMed: 6777169]
  665. Krempf M, Louvet J-P, Allanic H, Miloradovich T, Joubert J-M, Attali J-R. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes. 2003;27(5):591–597. [PubMed: 12704403]
  666. Krentz AJ, Williams AC, Nattrass M. Abnormal regulation of carbohydrate metabolism in motor neurone disease. Diabetes Research. 1991;16(2):93–99. [PubMed: 1817811]
  667. Kristiansson K, Sigfusson N, Sigvaldason H, Thorgeirsson G. Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study. J Hypertens. 1995;13(6):581–586. [PubMed: 7594413]
  668. Kristof RA, Neuloh G, Redel L, Klingmuller D, Schramm J. Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission. J Neurosurg. 2002;97(6):1282–1286. [PubMed: 12507124]
  669. Kroke A, Liese AD, Keil U, Boeing H. Arterial hypertension and glycemia in non-diabetic subjects: is there an association independent of obesity? Diabetes Metab Res Rev. 1999;15(2):99–105. [PubMed: 10362457]
  670. Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J. et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2003;52(7):1872–1876. [PubMed: 12829659]
  671. Kuhl C, Vandsted M, Olsen PG. Minor physiological relevance of oral glucose tolerance test. Diabete Metab. 1982;8(3):203–207. [PubMed: 6754492]
  672. Kulkarni M, Jones KD, Newbold S. Screening for gestational diabetes: A retrospective audit. Journal of Obstetrics & Gynaecology. 2003;23(2):160–162. [PubMed: 12745560]
  673. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol. 2000;20(3):823–829. [PubMed: 10712409]
  674. Kumar S, Olukoga AO, Gordoni C, Mawer EB, France M, Hosker JP. et al. Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1994;40(1):47–53. [PubMed: 8306480]
  675. Kutnowski M, Daubresse JC, Friedman H, Kolanowski J, Krzentowski G, Scheen A. et al. Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes Relat Metab Disord. 1992;16(Suppl 4):S63–S66. [PubMed: 1338388]
  676. Kutty VR, Soman CR, Joseph A, Pisharody R, Vijayakumar K. Type 2 diabetes in southern Kerala: variation in prevalence among geographic divisions within a region.[see comment] Natl Med J India. 2000;13(6):287–292. [PubMed: 11209482]
  677. Kuusisto J, Koivisto K, Mykkanen L, Helkala E-L, Vanhanen M, Hanninen T. et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. British Medical Journal. 1997;315(7115):1045–1049. [PMC free article: PMC2127678] [PubMed: 9366728]
  678. Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis. 1990;10(2):223–231. [PubMed: 2180396]
  679. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959–965. [PubMed: 8317453]
  680. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Mykkanen L, Deeb SS. Glucokinase gene variants in subjects with late-onset NIDDM and impaired glucose tolerance. Diabetes Care. 1995;18(3):398–400. [PubMed: 7555485]
  681. Laaksonen DE, Lakka TA, Lakka HM, Nyyssonen K, Rissanen T, Niskanen LK. et al. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med. 2002;19(6):456–464. [PubMed: 12060056]
  682. Lakusic N, Mahovic D, Cerovec D, Majsec M. Do patients with coronary heart disease older than seventy benefit from cardiac rehabilitation? Acta Clinica Croatica. 2002;41(1):69–72.
  683. Landin K, Lindgarde F, Saltin B. Skeletal muscle potassium increases after diet weight reduction in obese subjects with normal and impaired glucose tolerance. Acta Endocrinol (Copenh) 1989;121(1):21–26. [PubMed: 2741639]
  684. Langer O. Prevention of macrosomia. Baillieres Clinical Obstetrics & Gynaecology. 1991;5(2):333–347. [PubMed: 1954717]
  685. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311(7006):655–659. [PMC free article: PMC2551427] [PubMed: 7549632]
  686. Lao T, Lai FH, Bancroft K, Gartside MW, Hopkins RE, Chia KV. et al. A randomised controlled pilot study of the management of gestational impaired glucose tolerance [1] (multiple letters) Br J Obstet Gynaecol. 2001;108(7):769.
  687. Lao TT, Lee CP, Wong WM. Placental weight to birthweight ratio is increased in mild gestational glucose intolerance. Placenta. 1997;18(23):227–230. [PubMed: 9089786]
  688. Lao TT, Lee CP. Gestational ‘impaired glucose tolerance’ should the cut-off be raised to 9 mmol l(-1)? Diabet Med. 1998;15(1):25–29. [PubMed: 9472860]
  689. Lao TT, Ho LF. Impaired glucose tolerance and pregnancy outcome in Chinese women with high body mass index. Hum Reprod. 2000;15(8):1826–1829. [PubMed: 10920111]
  690. Lao TT, Ho LF. Perinatal morbidity and placental size in gestational impaired glucose tolerance. J Soc Gynecol Investig. 2001;8(6):347–350. [PubMed: 11750870]
  691. Lapidus L, Bengtsson C, Blohme G, Lindquist O, Nystrom E. Blood glucose, glucose tolerance and manifest diabetes in relation to cardiovascular disease and death in women. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Medica Scandinavica. 1985;218(5):455–462. [PubMed: 4091045]
  692. Larsen ML. The utility of glycated hemoglobin in identification of impaired glucose tolerance. Diabetes Research. 1989;12(2):67–70. [PubMed: 2634508]
  693. Larsson H, Ahren B, Lindgarde F, Berglund G. Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. J Intern Med. 1995;237(6):537–541. [PubMed: 7782724]
  694. Larsson H, Berglund G, Ahren B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J Clin Endocrinol Metab. 1995;80(6):1778–1782. [PubMed: 7775622]
  695. Larsson H, Ahren B. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia. 1996;39(9):1099–1107. [PubMed: 8877295]
  696. Larsson H, Ahren B. Islet dysfunction in obese women with impaired glucose tolerance. Metabolism. 1996;45(4):502–509. [PubMed: 8609839]
  697. Larsson H, Ahren B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab. 1999;84(6):2068–2074. [PubMed: 10372712]
  698. Larsson H, Elmstahl S, Berglund G, Ahren B. Habitual dietary intake versus glucose tolerance, insulin sensitivity and insulin secretion in postmenopausal women. J Intern Med. 1999;245(6):581–591. [PubMed: 10395187]
  699. Larsson H, Daugaard JR, Kiens B, Richter EA, Ahren B. Muscle fiber characteristics in postmenopausal women with normal or impaired glucose tolerance. Diabetes Care. 1999;22(8):1330–1338. [PubMed: 10480779]
  700. Larsson H, Ahren B. Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia. 2000;43(2):194–202. [PubMed: 10753041]
  701. Larsson H, Lindgarde F, Berglund G, Ahren B. Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia. 2000;43(10):1224–1228. [PubMed: 11079739]
  702. Laskarzewski P, Kelly KA, Mellies MJ, Morrison JA, Khoury P, Tillett S. et al. Interrelationships of lipids, lipoproteins, and clinical chemistry measurements in 1605 schoolchildren, ages 6–17: the Princeton Schoolchildren Study. Metabolism. 1980;29(10):916–923. [PubMed: 7421581]
  703. Lattermann R, Geisser W, Georgieff M, Wachter U, Goertz A, Gnann R. et al. Integrated analysis of glucose, lipid, and urea metabolism in patients with bladder cancer: Impact of tumor stage. Nutrition. 2003;19(78):589–592. [PubMed: 12831943]
  704. Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Experimental & Clinical Endocrinology & Diabetes. 1998;106(3):231–233. [PubMed: 9710365]
  705. Law CM, Gordon GS, Shiell AW, Barker DJ, Hales CN. Thinness at birth and glucose tolerance in seven-year-old children. Diabet Med. 1995;12(1):24–29. [PubMed: 7712699]
  706. Laws A, Marcus EB, Grove JS, Curb JD. Lipids and lipoproteins as risk factors for coronary heart disease in men with abnormal glucose tolerance: the Honolulu Heart Program. J Intern Med. 1993;234(5):471–478. [PubMed: 8228791]
  707. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry. 2001;62(Suppl 27):5–9. [PubMed: 11806489]
  708. Lecomte P, Vol S, Caces E, Lasfargues G, Combe H, Laurent S. et al. Impaired fasting glycaemia and undiagnosed diabetes: Prevalence, cardiovascular and behavioural risk factors. Evidence supporting an early preventive strategy. Diabetes Metab. 2002;28(4 I):311–320. [PubMed: 12442069]
  709. Leden I, Schersten B, Svensson B. Glucose metabolism in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology. 1984;13(2):129–132. [PubMed: 6740267]
  710. Lee AJ, MacGregor AS, Hau CM, Price JF, Rumley A, Lowe GD. et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol. 1999;105(3):648–654. [PubMed: 10354125]
  711. Lee ET, Howard BV, Savage PJ, Cowan LD, Fabsitz RR, Oopik AJ. et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45-74 years: the Strong Heart Study. Diabetes Care. 1995;18(5):599–610. [PubMed: 8585996]
  712. Lee ET, Howard BV, Go O, Savage PJ, Fabsitz RB, Robbins DC et al. Prevalence of undiagnosed diabetes in three American Indian populations: a comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care 23(2):181–6, 2000 Feb (13 ref) 2000;(2):181–186. [PubMed: 10868828]
  713. Legido A, Sarria A, Bueno M. Relationships of body fat distribution to metabolic complications in obese prepubertal girls. Clin Pediatr (Phila) 1987;26(6):310–315. [PubMed: 3555941]
  714. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.[see comment] J Clin Endocrinol Metab. 1999;84(1):165–169. [PubMed: 9920077]
  715. Lehrer JF, Poole DC, Seaman M. Identification and treatment of metabolic abnormalities in patients with vertigo. Arch Intern Med. 1986;146(8):1497–1500. [PubMed: 3524492]
  716. Lehtovirta M, Forsen B, Gullstrom M, Haggblom M, Eriksson JG, Taskinen MR. et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18(7):578–583. [PubMed: 11553189]
  717. Lemne C, Efendic S, Hamsten A, de Faire U. Impaired glucose and insulin metabolism in borderline hypertension. Blood Pressure. 1994;3(5):287–294. [PubMed: 7866592]
  718. Leonard D, McDermott R, O'Dea K, Rowley KG, Pensio P, Sambo E. et al. Obesity, diabetes and associated cardiovascular risk factors among Torres Strait Islander people. Australian & New Zealand Journal of Public Health. 2002;26(2):144–149. [PubMed: 12054333]
  719. Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C. et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab. 2003;88(9):4227–4231. [PubMed: 12970291]
  720. Leslie RDG, Volkmann HP, Poncher M. Metabolic abnormalities in children of non-insulin dependent diabetics. British Medical Journal. 1986;293(6551):840–842. [PMC free article: PMC1341633] [PubMed: 3094681]
  721. Lester E, Frazer AD, Shepherd CA, Woodroffe FJ. Glycosylated haemoglobin as an alternative to the glucose tolerance test for the diagnosis of diabetes mellitus. ANN CLIN BIOCHEM. 1985;22(1):74–78. [PubMed: 3985561]
  722. Leung TW, Lao TT. Placental size and large-for-gestational-age infants in women with abnormal glucose tolerance in pregnancy. Diabet Med. 2000;17(1):48–52. [PubMed: 10691159]
  723. Lev-Ran A. Glycohemoglobin. Its use in the follow-up of diabetes and diagnosis of glucose intolerance. Arch Intern Med. 1981;141(6):747–749. [PubMed: 7235783]
  724. Levien TL, Baker DE, White J Jr., Campbell RK. Insulin glargine: A new basal insulin. Ann Pharmacother. 2002;36(6):1019–1027. [PubMed: 12022906]
  725. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1990;131(2):254–262. [PubMed: 2296978]
  726. Levitt NS, Lambert EV, Woods D, Hales CN, Andrew R, Seckl JR. Impaired glucose tolerance and elevated blood pressure in low birth weight, nonobese, young south african adults: early programming of cortisol axis. J Clin Endocrinol Metab. 2000;85(12):4611–4618. [PubMed: 11134116]
  727. Leyva F, Godsland IF, Worthington M, Walton C, Stevenson JC. Factors of the metabolic syndrome: Baseline interrelationships in the first follow-up cohort of the HDDRISC study (HDDRISC-1) Arteriosclerosis Thrombosis & Vascular Biology. 1998;18(2):208–214. [PubMed: 9484985]
  728. Leyva F, Rauchhaus M, Anker SD, Proudler AJ, Godsland IF, Stiefel P. et al. Non-invasive assessment of vascular function. Paradoxical vascular response to intravenous glucose in coronary heart disease. Eur Heart J. 2000;21(1):39–44. [PubMed: 10610742]
  729. Li C-L, Tsai S-T, Chou P. Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6-7.8 mmol/l in Kin-Hu and Kin-Chen, Kinmen, 1991-94. Diabetes Res Clin Pract. 1999;45(1):51–59. [PubMed: 10499885]
  730. Li C-L, Tsai S-T, Chou P. Comparison of metabolic risk profiles between subjects with fasting and 2-hour plasma glucose impairment: The Kinmen Study. J Clin Epidemiol. 2002;55(1):19–24. [PubMed: 11781118]
  731. Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX. et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16(6):477–481. [PubMed: 10391395]
  732. Li CL, Tsai ST, Chou P. Relative role of insulin resistance and beta-cell dysfunction in the progression to type 2 diabetes--The Kinmen Study. Diabetes Res Clin Pract. 2003;59(3):225–232. [PubMed: 12590020]
  733. Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J. et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract. 2002;58(3):193–200. [PubMed: 12413779]
  734. Li Y, Higashiura K, Ura N, Tor IT, Agata J, Wang L. et al. Effects of the Chinese medicine TSJN on insulin resistance and hypertension in fructose-fed rats. Hypertension Research. 2000;23(2):101–107. [PubMed: 10770256]
  735. Liang P, Hughes V, Fukagawa NK. Increased prevalence of mitochondrial DNA deletions in skeletal muscle of older individuals with impaired glucose tolerance: possible marker of glycemic stress.[erratum appears in Diabetes 1997 Sep;46(9):1532] Diabetes. 1997;46(5):920–923. [PubMed: 9133566]
  736. Liao D, Shofer JB, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE. et al. Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care. 2001;24(1):39–44. [PubMed: 11194238]
  737. Liao D, Asberry PJ, Shofer JB, Callahan H, Matthys C, Boyko EJ. et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care. 2002;25(9):1504–1510. [PubMed: 12196418]
  738. Lidfeldt J, Nerbrand C, Samsioe G, Schersten B, Agardh CD. A screening procedure detecting high-yield candidates for OGTT. The Women's Health in the Lund Area (WHILA) study: a population based study of middle-aged Swedish women. Eur J Epidemiol. 2001;17(10):943–951. [PubMed: 12188015]
  739. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G. et al. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J. 2001;22(22):2075–2084. [PubMed: 11686665]
  740. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D. et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med. 1988;318(19):1217–1225. [PubMed: 3283552]
  741. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E. et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329(27):1988–1992. [PubMed: 8247074]
  742. Lim S-C, Tai E-S, Tan B-Y, Chew S-K, Tan C-E. Cardiovascular risk profile in individuals with borderline glycemia: The effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care. 2000;23(3):278–282. [PubMed: 10868851]
  743. Lind L, Lithell H, Wengle B, Wrege U, Ljunghall S. A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. Scandinavian Journal of Urology & Nephrology. 1988;22(3):219–222. [PubMed: 3187441]
  744. Lind L, Lithell H, Skarfors E, Wide L, Ljunghall S. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Medica Scandinavica. 1988;223(3):211–217. [PubMed: 3281411]
  745. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Research. 1989;11(3):141–147. [PubMed: 2697485]
  746. Lind L, Lithell H, Pollare P, Ljunghall S. On the diversity of insulin secretion and sensitivity in subjects with impaired glucose tolerance. Exp Clin Endocrinol. 1993;101(5):311–314. [PubMed: 8299708]
  747. Lind L, Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care. 1994;5(3):100–105. [PubMed: 10150538]
  748. Lind L, Sarabi M, Millgard J, Kahan T. Endothelium-dependent vasodilation is impaired in apparently healthy subjects with a family history of myocardial infarction. J Cardiovasc Risk. 2002;9(1):53–57. [PubMed: 11984218]
  749. Lindahl B, Nilsson TK, Jansson JH, Asplund K, Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med. 1999;246(1):105–112. [PubMed: 10447232]
  750. Linday LA. Trivalent chromium and the diabetes prevention program. [Review] [20 refs] Med Hypotheses. 1997;49(1):47–49. [PubMed: 9247907]
  751. Lindblad U, Lindwall K, Sjostrand A, Ranstam J, Melander A. The NEPI Antidiabetes Sstudy (NANSY). The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes Metab 2001. 3(6):443–451. [PubMed: 11903417]
  752. Lindeman RD, Romero LJ, LaRue A, Yau CL, Schade DS, Koehler KM. et al. A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey. Diabetes Care. 2001;24(9):1567–1572. [PubMed: 11522700]
  753. Lindeman RD, Yau CL, Baumgartner RN, Morley JE, Garry PJ. New Mexico Aging Process Study. Longitudinal study of fasting serum glucose concentrations in healthy elderly. The New Mexico Aging Process Study. J Nutr Health Aging. 2003;7(3):172–177. [PubMed: 12766795]
  754. Lindi VI, Uusitupa MI, Lindstrom J, Louheranta A, Eriksson JG, Valle TT. et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes. 2002;51(8):2581–2586. [PubMed: 12145174]
  755. Lindquist CH, Gower BA, Goran MI. Role of dietary factors in ethnic differences in early risk of cardiovascular disease and type 2 diabetes... including commentary by Kasim-Karakas SE. Am J Clin Nutr. 2000;71(3):725–732. [PubMed: 10702165]
  756. Lindsay RS, Walker JD, Halsall I, Hales CN, Calder AA, Hamilton BA. et al. Insulin and insulin propeptides at birth in offspring of diabetic mothers. J Clin Endocrinol Metab. 2003;88(4):1664–1671. [PubMed: 12679454]
  757. Lindstrom J, Eriksson JG, Valle TT, Aunola S, Cepaitis Z, Hakumaki M. et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol. 2003;14(7 Suppl 2):S108–S113. [PubMed: 12819313]
  758. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236. [PubMed: 14633807]
  759. Little RR, England JD, Wiedmeyer HM, Madsen RW, Pettitt DJ, Knowler WC. et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia. 1994;37(3):252–256. [PubMed: 8174838]
  760. Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sorensen OH. et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance--a prospective randomized double-blind study. Acta Medica Scandinavica. 1987;222(4):361–367. [PubMed: 3321925]
  761. Lo GS, Goldberg AP, Lim A. Soy fiber improves lipid and carbohydrate metabolism in primary hyperlipidemic subjects. Atherosclerosis. 1986;62(3):239–248. [PubMed: 3026411]
  762. Long SD, O'Brien K, MacDonald KG Jr., Leggett-Frazier N, Swanson MS, Pories WJ. et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994;17(5):372–375. [PubMed: 8062602]
  763. Lorentzen B, Birkeland KI, Endresen MJ, Henriksen T. Glucose intolerance in women with preeclampsia. Acta Obstet Gynecol Scand. 1998;77(1):22–27. [PubMed: 9492712]
  764. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The Metabolic Syndrome as Predictor of Type 2 Diabetes: The San Antonio Heart Study. Diabetes Care. 2003;26(11):3153–3159. [PubMed: 14578254]
  765. Lorini R, Alibrandi A, Vitali L, Klersy C, Martinetti M, Betterle C. et al. Risk of type 1 diabetes development in children with incidental hyperglycemia: A multicenter Italian study. Diabetes Care. 2001;24(7):1210–1216. [PubMed: 11423504]
  766. Louheranta AM, Sarkkinen ES, Vidgren HM, Schwab US, Uusitupa MIJ. Association of the fatty acid profile of serum lipids with glucose and insulin metabolism during 2 fat-modified diets in subjects with impaired glucose tolerance. Am J Clin Nutr. 2002;76(2):331–337. [PubMed: 12145003]
  767. Louheranta J. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3–year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236. [PubMed: 14633807]
  768. Lourido J, Ederoth P, Sundvall N, Ungerstedt U, Nordstrom C-H. Correlation between blood glucose concentration and glucose concentration in subcutaneous adipose tissue evaluated with microdialysis during intensive care. Scand J Clin Lab Invest. 2002;62(4):285–292. [PubMed: 12476927]
  769. Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N. The clinical and cost-effectiveness of patient education models for diabetes: A systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2003;7(22):190p. [PubMed: 13678547]
  770. Lu W, Resnick HE, Jain AK, Adams-Campbell LL, Jablonski KA, Gottlieb AM. et al. Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. Ann Epidemiol. 2003;13(3):182–188. [PubMed: 12604162]
  771. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol. 1998;12(5):553–558. [PubMed: 9794154]
  772. Lundell K-H, Sabel K-G, Eriksson BO, Mellgren G. Glucose metabolism and insulin secretion in children with cyanotic congenital heart disease. Acta Paediatr. 1997;86(10):1082–1084. [PubMed: 9350889]
  773. Lunetta M, Di Mauro M, Nicoletti F, Mughini L. Diabetogenic effect of naloxone in subjects with impaired glucose tolerance. Medical Science Research. 1991;19(21):737–738.
  774. Ma S, Cutter J, Tan CE, Chew SK, Tai ES. Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from the 1992 Singapore National Health Survey. Am J Epidemiol. 2003;158(6):543–552. [PubMed: 12965880]
  775. MacGregor AS, Price JF, Hau CM, Lee AJ, Carson MN, Fowkes FG. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study. Diabetes Care. 1999;22(3):453–458. [PubMed: 10097928]
  776. Mackey RH, Sutton-Tyrrell K, Vaitkevicius PV, Sakkinen PA, Lyles MF, Spurgeon HA. et al. Correlates of aortic stiffness in elderly individuals: A subgroup of the cardiovascular health study. Am J Hypertens. 2002;15(1 I):16–23. [PubMed: 11824854]
  777. Maggi S, Zucchetto M, Grigoletto F, Baldereschi M, Candelise L, Scarpini E. et al. The Italian Longitudinal Study on Aging (ILSA): design and methods. Aging (Milano) 1994;6(6):464–473. [PubMed: 7748921]
  778. Mak RHK, Turner C, Haycock GB, Chantler C. Secondary hyperparathyroidism and glucose intolerance in children with uremia. Kidney Int 1983; 24(SUPPL. 16). [PubMed: 6588242]
  779. Mak RHK, Turner C, Thompson T, Haycock G, Chantler C. Glucose metabolism in children with uremia: Effect of dietary phosphate and protein. Kidney Int 1987; 32(SUPPL. 22). [PubMed: 3323625]
  780. Mancini M, Strazzullo P, Trevisan M, Contaldo F, Vaccaro O, Cappuccio FP. Pathophysiological interrelations of obesity, impaired glucose tolerance, and arterial hypertension. Prev Med. 1985;14(4):428–435. [PubMed: 3906627]
  781. Manderson JG, Patterson CC, Hadden DR, Traub AI, Leslie H, McCance DR. Leptin concentrations in maternal serum and cord blood in diabetic and nondiabetic pregnancy. Am J Obstet Gynecol. 2003;188(5):1326–1332. [PubMed: 12748507]
  782. Mangiagli A, Italia S, De S, V, Campisi S. Impaired glucose homeostasis in young adult thalassemic patients: A pilot study with acarbose. J Pediatr Endocrinol Metab. 2002;15(2):205–210. [PubMed: 11874186]
  783. Mannucci E, Bardini G, Ognibene A, Rotella CM. Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. Diabet Med. 1999;16(7):579–585. [PubMed: 10445834]
  784. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E. et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489–494. [PubMed: 11289473]
  785. Mannucci E, Ognibene A, Sposato I, Brogi M, Gallori G, Bardini G. et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2003;40(4):181–186. [PubMed: 14740278]
  786. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN. et al. Liver pathology and the metabolic syndrome X in severe obesity.[see comment] J Clin Endocrinol Metab. 1999;84(5):1513–1517. [PubMed: 10323371]
  787. Marchand E, Grigorescu F, Buysschaert M. The hypoglycemic effect of a sulfonylurea (gliclazide) in moderate type II diabetes and glucose intolerance is not accompanied by changes in insulin action and insulin binding to erythrocytes. Molecular Physiology. 1983;4(12):83–93.
  788. Marchesi E, Baiardini R, Centeleghe P, Covini D, Frattoni A, Muggia C. et al. Structural changes in the heart and carotid arteries in hypertensive patients associated with cardiovascular risk factors. J Cardiovasc Risk. 1997;4(4):283–289. [PubMed: 9477207]
  789. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A. et al. Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol. 1999;94(3):655–662. [PubMed: 10086647]
  790. Mari A. Assessment of insulin sensitivity and secretion with the labelled intravenous glucose tolerance test: Improved modelling analysis. Diabetologia. 1998;41(9):1029–1039. [PubMed: 9754821]
  791. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24(3):539–548. [PubMed: 11289482]
  792. Marshall JA, Hoag S, Shetterly S, Hamman RF. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM: The San Luis Valley Diabetes Study. Diabetes Care. 1994;17(1):50–55. [PubMed: 8112189]
  793. Martin IK, Weber KM, Ward GM, Best JD, Boston RC. Application of the SAAM modeling program to minimal model analysis of intravenous glucose tolerance test data. Computer Methods & Programs in Biomedicine. 1990;33(4):193–203. [PubMed: 2282786]
  794. Marugame T, Lee K, Eguchi H, Oda T, Shinchi K, Kono S. Relation of impaired glucose tolerance and diabetes mellitus to colorectal adenomas in Japan. Cancer Causes Control. 2002;13(10):917–921. [PubMed: 12588087]
  795. Marugame T, Hayasaki H, Lee K, Eguchi H, Matsumoto S. Alveolar bone loss associated with glucose tolerance in Japanese men. Diabet Med. 2003;20(9):746–751. [PubMed: 12925056]
  796. Massari V, Eschwege E, Valleron AJ. Imprecision of new criteria for the oral glucose tolerance test. Diabetologia. 1983;24(2):100–106. [PubMed: 6840420]
  797. Mathai M, Thomas TJ, Kuruvila S, Jairaj P. Random plasma glucose and the glucose challenge test in pregnancy. Natl Med J India. 1994;7(4):160–162. [PubMed: 7950945]
  798. Mathur HC, Gupta SD. Evaluation of correlation of C.S.F. and blood sugar in neurological disorders of childhood. Indian Medical Gazette. 1984;118(10):331–332.
  799. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–1470. [PubMed: 10480510]
  800. Matsuoka K, Tanaka G, Etoh R, Horiuchi A. A 10-year follow-up study of per oral glucose tolerance at annual physical examinations. Tohoku J Exp Med. 1983;141 Suppl:105–109. [PubMed: 6680477]
  801. Matt GE, Cook TD. Threats to the validity of research synthosis. In: Cooper H, Hedges LV, editors. The Handbook of Research Synthesis. New York: Russell Sage Foundation, 1994: 503-520.
  802. Matthews DR, Edge JA, Dunger DB. Un unbiased glucose clamp method using a variable insulin infusion: Its application in diabetic adolescents. Diabet Med. 1990;7(3):246–251. [PubMed: 2139397]
  803. Mayer-Davis EJ, Costacou T, King I, Zaccaro DJ, Bell RA. The Insulin Resistance and Atherosclerosis Study (IRAS). Plasma and dietary vitamin E in relation to incidence of type 2 diabetes: The Insulin Resistance and Atherosclerosis Study (IRAS) Diabetes Care. 2002;25(12):2172–2177. [PubMed: 12453956]
  804. Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur J Epidemiol. 2001;17(12):1097–1104. [PubMed: 12530768]
  805. Mbanya J-C, Cruickshank JK, Forrester T, Balkau B, Ngogang JY, Riste L. et al. Standardized comparison of glucose intolerance in West African-origin populations of rural and urban Cameroon, Jamaica, and Caribbean migrants to Britain. Diabetes Care. 1999;22(3):434–440. [PubMed: 10097925]
  806. Mbanya JCN, Ngogang J, Salah JN, Minkoulou E, Balkau B. Prevalence of NIDDM and impaired glucose tolerance in a rural and an urban population in Cameroon. Diabetologia. 1997;40(7):824–829. [PubMed: 9243104]
  807. McCartney P, Keen H, Jarrett RJ. The Bedford Survey: observations on retina and lens of subjects with impaired glucose tolerance and in controls with normal glucose tolerance. Diabete Metab. 1983;9(4):303–305. [PubMed: 6667765]
  808. McClain MR, Srinivasan SR, Chen W, Steinmann WC, Berenson GS. Risk of type 2 diabetes mellitus in young adults from a biracial community: the Bogalusa Heart Study. Prev Med. 2000;31(1):1–7. [PubMed: 10896837]
  809. McCowen KC, Friel C, Sternberg J, Chan S, Forse RA, Burke PA. et al. Hypocaloric total parenteral nutrition: effectiveness in prevention of hyperglycemia and infectious complications -- a randomized clinical trial. Crit Care Med. 2000;28(11):3606–3611. [PubMed: 11098961]
  810. MCDONALD GW, FISHER GF, BURNHAM C. Reproducibility of the oral glucose tolerance test. Diabetes. 1965;14:473–480. [PubMed: 14334838]
  811. McGill HC Jr.,, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation. 2001;103(11):1546–1550. [PubMed: 11257083]
  812. McIntyre HD, Begg LM, Parry AF, Oats J. Audit of maternal and fetal outcomes in women treated for glucose intolerance during pregnancy. Aust N Z J Obstet Gynaecol. 2002;42(1):23–28. [PubMed: 11926637]
  813. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians [see comments] Lancet. 1991;337(8738):382–386. [PubMed: 1671422]
  814. McKenney JM, Goodman W Jr. Use of antihypertensive agents in patients with glucose intolerance. Clin Pharm. 1985;4(6):649–656. [PubMed: 2866862]
  815. McLellan JAS, Barrow BA, Levy JC, Hammersley MS, Hattersley AT, Gillmer MDG. et al. Prevalence of diabetes mellitus and impaired glucose tolerance in parents of women with gestational diabetes. Diabetologia. 1995;38(6):693–698. [PubMed: 7672491]
  816. McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol. 1990;131(3):443–453. [PubMed: 2301354]
  817. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Annals of Internal Medicine. 1998;128(7):524–533. [PubMed: 9518396]
  818. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283(2):221–228. [PubMed: 10634338]
  819. Meigs JB, D'Agostino RB Sr., Nathan DM, Rifai N, Wilson PW, Framingham OS. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002;25(6):977–983. [PubMed: 12032102]
  820. Meigs JB, Nathan DM, D'Agostino RB Sr.,, Wilson PW, Framingham OS. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25(10):1845–1850. [PubMed: 12351489]
  821. Meigs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep. 2003;3(1):73–79. [PubMed: 12643149]
  822. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. Baltimore Longitudinal Study of Aging. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003;52(6):1475–1484. [PubMed: 12765960]
  823. Mennen LI, Potier dC, Guilland J-C, Ducros V, Bertrais S, Nicolas J-P. et al. Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study. Am J Clin Nutr. 2002;76(6):1279–1289. [PubMed: 12450894]
  824. Menotti A. Cardiovascular risk factors in patients discharged from departments of internal medicine-the Italian FADOI-2 study. European Journal of Internal Medicine. 2002;13(1):44–51. [PubMed: 11836082]
  825. Mensink M, Blaak EE, Vidal H, De Bruin TWA, Glatz JFC, Saris WHM. Lifestyle changes and lipid metabolism gene expression and protein content in skeletal muscle of subjects with impaired glucose tolerance. Diabetologia. 2003;46(8):1082–1089. [PubMed: 12856127]
  826. Mensink M, Feskens E-JM, Saris W-HM, de Bruin T-WA, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): Preliminary results after one year. International-Journal-of-Obesity-and-Related-Metabolic-Disorders. 2003;27(3):377–384. [PubMed: 12629566]
  827. Mensink M, Corpeleijn E. Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract. 2003;61(1):49–58. [PubMed: 12849923]
  828. Mertz W. Chromium in human nutrition: A review. J Nutr. 1993;123(4):626–633. [PubMed: 8463863]
  829. Merz CNB, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol. 2002;40(10):1877–1881. [PubMed: 12446074]
  830. Mescheryakov AV, Kozlov IA, Dementyeva II, Lakhter MA, Ermolyn AJ, Galyibin AA. Glucose metabolism and insulin activity during cardiac surgery. J Cardiothorac Anesth. 1989;3(5):536–543. [PubMed: 2520930]
  831. Messina MF, Lombardo F, Meo A, Miceli M, Wasniewska M, Valenzise M. et al. Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major. J Endocrinol Invest. 2002;25(6):497–501. [PubMed: 12109619]
  832. Mestman JH. Outcome of diabetes screening in pregnancy and perinatal morbidity in infants of mothers with mild impairment in glucose tolerance. Diabetes Care. 1980;3(3):447–452. [PubMed: 7389561]
  833. Metcalf PA, Scragg RKR. Comparison of WHO and ADA criteria for diagnosis of glucose status in adults. Diabetes Res Clin Pract. 2000;49(23):169–180. [PubMed: 10963829]
  834. Metzger BE, Bybee DE, Freinkel N. Gestational diabetes mellitus. Correlations between the phenotypic and genotypic characteristics of the mother and abnormal glucose tolerance during the first year postpartum. Diabetes. 1985;34(SUPPL. 2):111–115. [PubMed: 3888736]
  835. Micic D, Kendereski A, Sumarac-Dumanovic M, Cvijovic G, Popovic V, Dieguez C. et al. Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp. Diabetes Res Clin Pract. 2004;63(1):37–45. [PubMed: 14693411]
  836. Mihara T, Oohashi H, Hirata Y. Mortality of Japanese diabetics in a seven-year follow-up study. Diabetes Res Clin Pract. 1986;2(3):139–144. [PubMed: 3743361]
  837. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891–895. [PubMed: 10988101]
  838. Mincu I, Ionescu-Tirgoviste C, Moldovan A, Mirodon Z, Georgescu M, Ionescu L. et al. Insulin resistance: the link between impaired glucose tolerance, body mass index and plasma lipids. Rom J Intern Med. 1993;31(4):237–243. [PubMed: 8148775]
  839. Mingrone G, De Gaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M. et al. Dodecanedioic acid infusion induces a sparing effect on whole-body glucose uptake, mainly in non-insulin-dependent diabetes mellitus. Br J Nutr. 1997;78(5):723–735. [PubMed: 9389896]
  840. Misra A, Cherukupalli R, Reddy KS, Mohan A, Bajaj JS. Hyperinsulinemia and dyslipidemia in non–obese, normotensive offspring of hypertensive parents in northern India. Blood Pressure. 1998;7(5-6):286–290. [PubMed: 10321441]
  841. Misra A, Reddy RB, Reddy KS, Mohan A, Bajaj JS. Clustering of impaired glucose tolerance, hyperinsulinemia and dyslipidemia in young north Indian patients with coronary heart disease: a preliminary case-control study. Indian Heart J. 1999;51(3):275–280. [PubMed: 10624065]
  842. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J. et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326(1):22–29. [PubMed: 1727062]
  843. Miwa S, Inouye M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R. Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients. Diabetes Res Clin Pract. 2003;61(2):81–88. [PubMed: 12951275]
  844. Miyazaki S. Abnormal glucose tolerance and prognosis after PTCA. Cardiology Review. 2001;18(4):18–22.
  845. Modan M, Halkin H, Karasik A, Lusky A. Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. The Israel Study of Glucose Intolerance, Obesity and Hypertension. Am J Epidemiol. 1984;119(3):431–444. [PubMed: 6702817]
  846. Modan M, Or J, Karasik A, Drory Y, Fuchs Z, Lusky A. et al. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease [see comments] Circulation. 1991;84(3):1165–1175. [PubMed: 1884447]
  847. Molitch ME, Hou SH, Gottesman S. Effects of antihypertensive medications on carbohydrate metabolism. Current Therapeutic Research, Clinical & Experimental. 1986;39(3):398–407.
  848. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. The diabetes prevention program and its global implications. J Am Soc Nephrol. 2003;14(7 Suppl 2):S103–S107. [PMC free article: PMC2560181] [PubMed: 12819312]
  849. Montori V. Changes in diet and physical activity prevented type 2 diabetes mellitus in persons with impaired glucose tolerance. ACP Journal Club 135(3):101, 2001 Nov–Dec (2 ref) 2001;(3):101.
  850. Montori VM. A lifestyle intervention or metformin prevented or delayed the onset of type 2 diabetes in persons at risk. ACP Journal Club. 2002;137(2):55. [PubMed: 12207433]
  851. Montori VM, Guyatt GH. Summarizing studies of diagnostic test performance. Clin Chem. 2003;49(11):1783–1784. [PubMed: 14578309]
  852. Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev. 2003;61(12):397–412. [PubMed: 14968910]
  853. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM. et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39(3):298–305. [PubMed: 8721775]
  854. Morel, Y , Lehmann, T., Vadas, L. et al. Effect of Metformine on insulin-resistance in obese patients with glucose-intolerance TO:=Effet de la Metformine sur la résistance á l'insuline chez des patients obèses avec intolérance au glucose. Schweiz Med Wochenschr. 1996;126(Suppl. 74/I):12.
  855. Morel Y, Golay A, Perneger T, Lehmann T, Vadas L, Pasik C. et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabet Med. 1999;16(8):650–655. [PubMed: 10477209]
  856. Morici ML, Di Marco A, Sestito D, Candore R, Cangemi C, Accardo F. et al. The impact of coexistent diabetes on the prevalence of coronary heart disease. J Diabetes Complications. 1997;11(5):268–273. [PubMed: 9334908]
  857. Motala AA, Omar MA. The value of glycosylated haemoglobin as a substitute for the oral glucose tolerance test in the detection of impaired glucose tolerance (IGT) Diabetes Res Clin Pract. 1992;17(3):199–207. [PubMed: 1425159]
  858. Motala AA, Omar MA, Gouws E. High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. Diabetes. 1993;42(4):556–563. [PubMed: 8454106]
  859. Motala AA, Omar MA. Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Diabet Med. 1994;11(5):437–444. [PubMed: 8088120]
  860. Motala AA, Omar MA. Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Res Clin Pract. 1994;23(2):103–109. [PubMed: 8070301]
  861. Motala AA, Omar MA, Gouws E. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care. 1997;20(7):1101–1107. [PubMed: 9203444]
  862. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B. et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45(6):805–812. [PubMed: 12107724]
  863. Murphy NJ, Schraer CD, Thiele MC, Boyko EJ, Bulkow LR, Doty BJ. et al. Dietary change and obesity associated with glucose intolerance in Alaska Natives. Journal of the American Dietetic Association. 1995;95(6):676–682. [PubMed: 7759744]
  864. Murphy NJ, Schraer CD, Theile MC, Boyko EJ, Bulkow LR, Doty BJ et al. Hypertension in Alaska Natives: association with overweight, glucose intolerance, diet and mechanized activity. Ethnicity & Health 2(4):267–75, 1997 Nov (57 ref) 1997;(4):267-275. [PubMed: 9526689]
  865. Mutch WJ, Stowers JM. Reversible mild diabetes in children after treatment with chlorpropamide. Lancet. 1980;1(8179):1158–1161. [PubMed: 6103984]
  866. Mykkanen L, Laakso M, Penttila I, Pyorala K. Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis. 1991;88(23):153–161. [PubMed: 1892482]
  867. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36(6):553–559. [PubMed: 8335178]
  868. Mykkanen L, Haffner SM, Ronnemaa T, Bergman RN, Laakso M. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol. 1997;146(4):315–321. [PubMed: 9270410]
  869. Nagai T, Tomizawa T, Minamide S, Nakajima K, Mori M. Serum lipid and lipoprotein metabolism after glucose ingestion in NIDDM and IGT patients: Apolipoprotein-containing particles. Diabetes Care. 1996;19(4):365–368. [PubMed: 8729161]
  870. Nagi DK, Knowler WC, Charles MA, Liu QZ, Hanson RL, McCance DR. et al. Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance. Diabetologia. 1995;38(2):187–192. [PubMed: 7713313]
  871. Nagi DK, Ali VM, Walji S, Jain SK, Yudkin JS. Hyperinsulinemia in nondiabetic Asian subjects using specific assays for insulin, intact proinsulin, and des-31, 32-proinsulin. Diabetes Care. 1996;19(1):39–42. [PubMed: 8720531]
  872. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. Diabet Med. 1997;14(6):449–456. [PubMed: 9212309]
  873. Naito H, Ohneda A, Kojima R, Sato T, Sasaki K, Funayama Y. et al. Plasma glicentin in diabetic and gastrectomized patients. Regul Pept. 1999;79(1):55–61. [PubMed: 9930583]
  874. Nakai I, Mizuta N, Nakamura K, Okamoto M, Nakajiama H, Yoshimura N. et al. Effects and limits of renal transplantation in patients with impaired glucose tolerance. Transplant Proc. 1998;30(1):114–115. [PubMed: 9474974]
  875. Nakanishi N, Nakamura K, Matsuo Y, Suzuki K, Tatara K. Cigarette smoking and risk for impaired fasting glucose and Type 2 Diabetes in middle-aged Japanese men. Annals of Internal Medicine. 2000;133(3):183–191. [PubMed: 10906832]
  876. Nakanishi N, Nishina K, Yoshida H, Matsuo Y, Nagano K, Nakamura K. et al. Hours of work and the risk of developing impaired fasting glucose or type 2 diabetes mellitus in Japanese male office workers. Occupational & Environmental Medicine. 2001;58(9):569–574. [PMC free article: PMC1740182] [PubMed: 11511743]
  877. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia. 2002;45(1):42–48. [PubMed: 11845222]
  878. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18(6):523–530. [PubMed: 12908717]
  879. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med. 2003;254(3):287–295. [PubMed: 12930239]
  880. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K. et al. beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation. 2001;71(10):1417–1423. [PubMed: 11391229]
  881. Nannipieri M, Posadas R, Williams K, Politi E, Gonzales-Villalpando C, Stern MP. et al. Association between polymorphisms of the atrial natriuretic peptide gene and proteinuria: a population-based study. Diabetologia. 2003;46(3):429–432. [PubMed: 12687344]
  882. Narayan KM, Hanson RL, Pettitt DJ, Bennett PH, Knowler WC. A two-step strategy for identification of high-risk subjects for a clinical trial of prevention of NIDDM. Diabetes Care. 1996;19(9):972–978. [PubMed: 8875091]
  883. Nasrat AA, Augensen K, Abushal M, Shalhoub JT. The outcome of pregnancy following untreated impaired glucose tolerance. Int J Gynaecol Obstet. 1994;47(1):1–6. [PubMed: 7813745]
  884. Nathan DM. Addressing the 21st Century Diabetes Epidemic. Advanced Studies in Medicine. 2002;2(26):961–965.
  885. Nathan DM. The impact of clinical trials on the treatment of diabetes mellitus. J Clin Endocrinol Metab. 2002;87(5):1929–1937. [PubMed: 11994319]
  886. Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ. et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998;15(11):937–945. [PubMed: 9827848]
  887. Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt W, Kobberling J. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: Association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. Acta Diabetol. 2003;40(4):163–172. [PubMed: 14740275]
  888. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE. et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 1996;335(22):1636–1642. [PubMed: 8929360]
  889. Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler WC, Mitch WE. et al. Changing glomerular filtration with progression from impaired glucose tolerance to Type II diabetes mellitus. Diabetologia. 1999;42(1):90–93. [PubMed: 10027584]
  890. Neufeld ND, Raffel LJ, Landon C, Chen YD, Vadheim CM. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care. 1998;21(1):80–86. [PubMed: 9538974]
  891. Nicholson G, Paton A. Glucose tolerance in alcoholics. J Stud Alcohol. 1979;40(11):997–1002.
  892. Niemi M, Kervinen K, Rantala A, Kauma H, Paivansalo M, Savolainen MJ. et al. The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects. Gut. 1999;44(4):557–562. [PMC free article: PMC1727442] [PubMed: 10075965]
  893. Nijpels G, van der Wal PS, Bouter LM, Heine RJ. Comparison of three methods for the quantification of beta-cell function and insulin sensitivity. Diabetes Res Clin Pract. 1994;26(3):189–195. [PubMed: 7736899]
  894. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia. 1996;39(1):113–118. [PubMed: 8720611]
  895. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Cardiovascular risk factors prior to the development of non-insulin-dependent diabetes mellitus in persons with impaired glucose tolerance: the Hoorn Study. J Clin Epidemiol. 1997;50(9):1003–1009. [PubMed: 9363034]
  896. Niskanen L, Sarlund H, Laakso M. Metabolic defects in persistent impaired glucose tolerance are related to the family history of non-insulin-dependent diabetes mellitus. Metabolism. 1995;44(8):1099–1104. [PubMed: 7637652]
  897. Niskanen LK, Salonen JT, Nyyssonen K, Uusitupa MI. Plasma lipid peroxidation and hyperglycaemia: a connection through hyperinsulinaemia? Diabet Med. 1995;12(9):802–808. [PubMed: 8542741]
  898. Nissinen A, Tervahauta M, Pekkanen J, Kivinen P, Stengard J, Kaarsalo E. et al. Prevalence and change of cardiovascular risk factors among men born 1900-19: The Finnish cohorts of the Seven Countries Study. Age & Ageing. 1993;22(5):365–376. [PubMed: 8237628]
  899. Njolstad I, Arnesen E, Lund-Larsen PG. Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. Am J Epidemiol. 1998;147(1):49–58. [PubMed: 9440398]
  900. Nolan JH, Wright CE. Evidence of impaired glucose tolerance and insulin resistance in patients with Alzheimer's disease. Current-Directions-in-Psychological-Science. 2001;10(3):102–105.
  901. Nord E, Hanson U, Persson B. Blood glucose limits in the diagnosis of impaired glucose tolerance during pregnancy. Acta Obstet Gynecol Scand. 1995;74(8):589–593. [PubMed: 7660761]
  902. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L. et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.[see comment] Lancet. 2002;359(9324):2140–2144. [PubMed: 12090978]
  903. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16(9):1995–1998. [PubMed: 11527911]
  904. Nozaka K, Hamazoe R, Nishimura O. Results of surgical treatment of chronic pancreatitis. Yonago Acta Medica. 1987;30(SUPPL.):105–114.
  905. O'Sullivan JB. Prevalence and course of diabetes modified by fasting blood glucose levels: implications for diagnostic criteria. Diabetes Care. 1979;2(2):85–90. [PubMed: 520134]
  906. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45(7):881–5, 1996 Jul (26 ref) 1996;(7):881–885. [PubMed: 8666137]
  907. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes. 1980;29(11):919–925. [PubMed: 7000589]
  908. Ogawa O, Onuma T, Uchino H, Takayanagi Y, Tanaka Y, Yamasaki Y. et al. Insulin resistance and atherosclerosis in branch retinal vein occlusion. Jpn J Ophthalmol. 2003;47(4):351–355. [PubMed: 12842202]
  909. Ohlson L-O, Larsson B, Eriksson H. Diabetes mellitus in Swedish middle-aged men. The study of men born in 1913 and 1923. Diabetologia. 1987;30(6):386–393. [PubMed: 3678659]
  910. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L. et al. Risk factors for Type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31(11):798–805. [PubMed: 3234634]
  911. Ohlson LO, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Tibblin G. et al. Fasting blood glucose and risk of coronary heart disease, stroke, and all-cause mortality: a 17-year follow-up study of men born in 1913. Diabet Med. 1986;3(1):33–37. [PubMed: 2951132]
  912. Ohlson LO, Bjuro T, Larsson B, Eriksson H, Svardsudd K, Welin L. et al. A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67-year-old men. Diabet Med. 1989;6(2):112–120. [PubMed: 2522851]
  913. Ohneda A, Kobayashi T, Nihei J. Evaluation of new criteria for diagnosis of diabetes mellitus based on follow-up study of borderline diabetes. Tohoku J Exp Med. 1982;137(4):437–444. [PubMed: 6750844]
  914. Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y. et al. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care. 2003;26(2):437–440. [PubMed: 12547876]
  915. Oida E, Kannagi T, Moritani T, Yamori Y. Diabetic alteration of cardiac vago–sympathetic modulation assessed with tone-entropy analysis. Acta Physiol Scand. 1999;165(2):129–134. [PubMed: 10090323]
  916. Oimomi M, Ishikawa K, Kawasaki T. Carbamylation of hemoglobin in renal failure and clinical aspects. Metabolism. 1984;33(11):999–1002. [PubMed: 6493050]
  917. Okamoto F, Sone H, Nonoyama T, Hommura S. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol. 2000;84(10):1097–1102. [PMC free article: PMC1723257] [PubMed: 11004091]
  918. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D. et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49(10):1255–1260. [PubMed: 11079812]
  919. Okubo M, Watanabe H, Fujikawa R, Kawamura T, Egusa G, Yamakido M. Reduced prevalence of diabetes according to 1997 American Diabetes Association criteria. Diabetologia. 1999;42(10):1168–1170. [PubMed: 10525655]
  920. Olatunbosun ST. Diagnosis and follow-up of subjects with impaired glucose tolerance: how reliable is OGTT? Report from a Nigerian survey. Diabetes Res Clin Pract. 1998;41(2):147–148. [PubMed: 9789721]
  921. Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Res Clin Pract. 2001;52(1):29–43. [PubMed: 11182214]
  922. Olsson G, Rehnqvist N. Effects of chronic metoprolol treatment on glucose tolerance after myocardial infarction. Eur J Clin Pharmacol. 1987;33(3):311–313. [PubMed: 3691619]
  923. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle. 1990;71(2):135–138. [PubMed: 2219464]
  924. Oohashi H, Mihara T, Hirata Y. Prevalence of diabetic microangiopathy and neuropathy among Japanese diabetics in the Tokyo area: related to the WHO new diagnostic criteria. Tohoku J Exp Med. 1983;141 Suppl:367–373. [PubMed: 6680509]
  925. Oohashi H, Mihara T, Hirata Y. Prospective follow-up study of diabetic retinopathy in Japanese subjects showing impaired glucose tolerance. J Med Assoc Thai. 1987;70(Suppl 2):144–148. [PubMed: 3598423]
  926. Osei K, Schuster DP. Decreased insulin-mediated but not non-insulin-dependent glucose disposal rates in glucose intolerance and type II diabetes in African (Ghanaian) immigrants. Am J Med Sci. 1996;311(3):113–121. [PubMed: 8615385]
  927. Ostlund IH. Maternal and fetal outcomes if gestational impaired glucose tolerance is not treated. Diabetes Care. 2003;26(7):2107–2111. [PubMed: 12832321]
  928. Otsuka Y, Miyazaki S, Okumura H, Yasuda S, Daikoku S, Morii I. et al. Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balloon coronary angioplasty.[see comment] Eur Heart J. 2000;21(21):1790–1796. [PubMed: 11052844]
  929. Oyibo SO, Prasad YDM, Jackson NJ, Jude EB, Boulton AJM. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: A pilot study. Diabet Med. 2002;19(10):870–873. [PubMed: 12358878]
  930. Ozmert E, Yurdakok K, Aslan D, Yalcin SS, Yardim M. Clinical characteristics of transient glucose intolerance during acute diarrhoea. Acta Paediatr. 1999;88(10):1071–1073. [PubMed: 10565451]
  931. Pablos-Velasco PL, Martinez-Martin FJ, Rodriguez-Perez F, Ania BJ, Losada A, Betancor P. et al. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population - comparison of the 1997 ADA and the 1985 WHO criteria. The Guia Study. Diabet Med. 2001;18(3):235–241. [PubMed: 11318846]
  932. Pagani G, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G. et al. Medical management of acromegaly: Effects of SMS 201-995 in 30 patients. Endocrinol Exp. 1990;24(12):175–185. [PubMed: 2361459]
  933. Page RC, Harnden KE, Cook JT, Turner RC. Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med. 1992;9(6):562–566. [PubMed: 1643806]
  934. Page RC, Harnden KE, Walravens NK, Onslow C, Sutton P, Levy JC. et al. ‘Healthy living’ and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. Q J Med. 1993;86(3):145–154. [PubMed: 8483989]
  935. Page RC, Walravens EK, Levy JC, Stratton IM, Turner RC. Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups. Metabolism. 1993;42(8):932–938. [PubMed: 8345815]
  936. Page RCL, Harnden KE, Cook JTE, Turner RC. Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med. 1992;9(6):562–566. [PubMed: 1643806]
  937. Page RCL, Harnden KE, Walravens NKN, Onslow C, Sutton P, Levy JC. et al. ‘Healthy living’ and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. Q J Med. 1993;86(3):145–154. [PubMed: 8483989]
  938. Pagnan A, Ambrosio GB, Vincenzi M, Mormino P, Maiolino P, Gerin L. et al. Precursors of atherosclerosis in children: the Cittadella study. Follow-up and tracking of total serum cholesterol, triglycerides, and blood glucose. Prev Med. 1982;11(4):381–390. [PubMed: 7122430]
  939. Paivansalo MJ, Merikanto J, Savolainen MJ, Lilja M, Rantala AO, Kauma H. et al. Effect of hypertension, diabetes and other cardiovascular risk factors on kidney size in middle-aged adults. Clin Nephrol. 1998;50(3):161–168. [PubMed: 9776419]
  940. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Colch ) 2000;98(5):619–625. [PubMed: 10781395]
  941. Pallardo F, Herranz L, Garcia-Ingelmo T, Grande C, Martin-Vaquero P, Janez M. et al. Early postpartum metabolic assessment in women with prior gestational diabetes. Diabetes Care. 1999;22(7):1053–1058. [PubMed: 10388966]
  942. Palmer GS, Clancy MC, Hawley JA, Rodger IM, Burke LM, Noakes TD. Carbohyrate ingestion immediately before exercise does not improve 20 km time trial performance in well trained cyclists. Int J Sports Med. 1998;19(6):415–418. [PubMed: 9774209]
  943. Palumbo G, Barantani E, Pozzi F, Azzolini V, Gronda D, Ronchi E. Long-term nifedipine treatment and glucose homeostasis in hypertensive patients. Current Therapeutic Research, Clinical & Experimental. 1988;43(1):171–179.
  944. Pan C-Y, Gao Y, Chen J-W, Luo B-Y, Fu Z-Z, Lu J-M. et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2003;61(3):183–190. [PubMed: 12965108]
  945. Pan CYG. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2003;61(3):183–190. [PubMed: 12965108]
  946. Pan XR, Hu Y-H, Li G-W, Liu P-A, Bennett PH, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese: Da Qing IGT and diabetes study. Diabetes Care. 1993;16(1):150–156. [PubMed: 8422770]
  947. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–544. [PubMed: 9096977]
  948. Panarotto D, Ardilouze JL, Tessier D, Maheux P. The degree of hyperinsulinemia and impaired glucose tolerance predicts plasma leptin concentrations in women only: a new exploratory paradigm. Metabolism. 2000;49(8):1055–1062. [PubMed: 10954026]
  949. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 1995;38(10):1213–1217. [PubMed: 8690174]
  950. Pappas S, Donohue SM, Denver AE, Mohamed-Ali V, Goubet S, Yudkin JS. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism. 1996;45(5):652–657. [PubMed: 8622611]
  951. Park KS, Kim CH, Lee MK, Shin CS, Park DJ, Kim SY. et al. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients. Metabolism. 1999;48(10):1318–1321. [PubMed: 10535397]
  952. Park PJ, Griffin SJ, Duffy SW, Wareham NJ. The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes. Journal of Medical Screening 7(2):91-6, 2000 (47 ref) 2000;(2):91-96. [PubMed: 11002449]
  953. Park Y, Lee H, Koh CS, Min H. Community-based epidemiologic study on atherosclerotic cardiovascular risk factors. Diabetes Res Clin Pract. 1996;34 Suppl:S65–S72. [PubMed: 9015672]
  954. Parulkar AA, Fonseca VA. Recent advances in pharmacological treatment of type 2 diabetes mellitus. Comprehensive Therapy. 1999;25(810):418–426. [PubMed: 10520444]
  955. Passariello N, Giugliano D, Sgambato S, Torella R, D'Onofrio F. Calcitonin, a diabetogenic hormone? J Clin Endocrinol Metab. 1981;53(2):318–323. [PubMed: 7019230]
  956. Passariello N, Giugliano D, Ceriello A. Impaired insulin response to glucose but not to arginine in heroin addicts. J Endocrinol Invest. 1986;9(5):353–357. [PubMed: 3540079]
  957. Pastore G, Saracco P, Brach dP. Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Acta Haematologica. 1984;72(6):384–387. [PubMed: 6442522]
  958. Patandin S, Bots ML, Abel R, Valkenburg HA. Impaired glucose tolerance and diabetes mellitus in a rural population in south India. Diabetes Res Clin Pract. 1994;24(1):47–53. [PubMed: 7924886]
  959. Payne K, Ireland P. Plasma glucose levels in the peri-operative period in children. Anaesthesia. 1984;39(9):868–872. [PubMed: 6545086]
  960. Peart WS, Barnes GR, Broughton P. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of medical research council working party on mild to moderate hypertension. Lancet. 1981;2(8246):539–543. [PubMed: 6115999]
  961. Pennebaker JW. et al. Physical symptoms related to blood glucose in insulin-dependent diabetics. Psychosomatic-Medicine. 1981;43(6):489–500. [PubMed: 7323257]
  962. Peraldo M, Fasulo A, Chiappini E, Milio C, Marianelli L. Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients. Horm Res. 1998;49(2):65–71. [PubMed: 9485173]
  963. Percheron C, Colette C, Avignon A, Monnier L. Metabolic responses to high carbohydrate breakfasts in obese patients with impaired glucose tolerance. Comparison of meals containing dairy products and fruits versus bread. Nutrition Research. 1997;17(5):797–806.
  964. Pereira MA, Jacobs DR, Jr., Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 287(16):2081–9, 2153-4, 2002 Apr 24 (56 ref) 2002;(16):2081-2089. [PubMed: 11966382]
  965. Perlman JA, Russell-briefel R, Ezzati T, Lieberknecht G. Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis. 1985;38(10):857–864. [PubMed: 4044771]
  966. Permert J, Ihse I, Jorfeldt L, Von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159(2):101–107. [PubMed: 8098623]
  967. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD. The Early Diabetes Intervention Program (. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnositc levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP).[comment] Diabetes Care. 2001;24(3):465–471. [PubMed: 11289469]
  968. Persson B, Hanson U. Insulin dependent diabetes in pregnancy: Impact of maternal blood glucose control on the offspring. Journal of Paediatrics & Child Health. 1993;29(1):20–23. [PubMed: 8461173]
  969. Persson L-G, Lindstrom K, Bengtsson C. Oral glucose tolerance and its relationship to overweight and other cardiovascular risk factors in men aged 33-42. A study in the Community of Habo, Sweden. Scand J Prim Health Care. 1994;12(4):261–268. [PubMed: 7863144]
  970. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: An analysis using glycosylated hemoglobin levels. Journal of the American Medical Association. 1996;276(15):1246–1252. [PubMed: 8849753]
  971. Pettitt DJ, Bennett PH, Saad MF, Charles MA, Nelson RG, Knowler WC. Abnormal glucose tolerance during pregnancy in Pima Indian women. Long-term effects on offspring. Diabetes. 1991;40(Suppl 2):126–130. [PubMed: 1748241]
  972. Pettitt DJ, Narayan KM, Hanson RL, Knowler WC. Incidence of diabetes mellitus in women following impaired glucose tolerance in pregnancy is lower than following impaired glucose tolerance in the non-pregnant state. Diabetologia. 1996;39(11):1334–1337. [PubMed: 8933001]
  973. Peyrot M, Rubin RR. Structure and correlates of diabetes-specific locus of control. Diabetes Care. 1994;17(9):994–1001. [PubMed: 7988321]
  974. Pfeffer F, Nauck MA, Drognitz O, Benz S, von Dobschuetz E, Hopt UT. Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. Transplantation. 2003;76(10):1427–1431. [PubMed: 14657680]
  975. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Infertility & Reproductive Medicine Clinics of North America. 2003;14(1):87–102.
  976. Phenekos C. Influence of fetal body weight on metabolic complications in adult life: review of the evidence. J Pediatr Endocrinol Metab. 2001;14(Suppl 5):1361–1363. [PubMed: 11964035]
  977. Phillips DI, Barker DJ, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37(2):150–154. [PubMed: 8163048]
  978. Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C, Clark PM. Fetal growth and impaired glucose tolerance in men and women [see comments] Diabetologia. 1993;36(3):225–228. [PubMed: 8462770]
  979. Phipps K, Barker DJP, Hales CN, Fall CHD, Osmond C, Clark PMS. Fetal growth and impaired glucose tolerance in men and women. Diabetologia. 1993;36(3):225–228. [PubMed: 8462770]
  980. Piatti P, Di Mario C, Monti LD, Fragasso G, Sgura F, Caumo A. et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108(17):2074–2081. [PubMed: 14530196]
  981. Piatti PM, Monti LD, Zavaroni I, Valsecchi G, Van Phan C, Costa S. et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab. 2000;85(7):2416–2420. [PubMed: 10902787]
  982. Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M. et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 2000;49(6):748–752. [PubMed: 10877200]
  983. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes. 2000;49(1):32–38. [PubMed: 10615947]
  984. Piette JD, Weinberger M, Kraemer FB, McPhee SJ. Impact of automated calls with nurse follow-up on diabetes treatment outcomes in a Department of Veterans Affairs health care system: A randomized controlled trial. Diabetes Care. 2001;24(2):202–208. [PubMed: 11213866]
  985. Pietzsch J, Julius U, Hanefeld M. Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance. Ann N Y Acad Sci. 1999;892(pp 323326):-326. [PubMed: 10842675]
  986. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of type 2 diabetes. [Review] [69 refs] Expert Opin Pharmacother. 2002;3(5):529–540. [PubMed: 11996632]
  987. Piva I, Erle G, Thiella M, Lora L, Strazzabosco M, Sicolo N. et al. A study on the hyperinsulinism of late pregnancy. J Endocrinol Invest. 1991;14(10):807–814. [PubMed: 1802920]
  988. Poinoosawmy D, Gloster J, Nagasubramanian S, Hitchings RA. Association between optic disc haemorrhages in glaucoma and abnormal glucose tolerance. Br J Ophthalmol. 1986;70(8):599–602. [PMC free article: PMC1040780] [PubMed: 3741826]
  989. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19(8):1429–1435. [PubMed: 11518851]
  990. Pokela ML. Effect of opioid-induced analgesia on beta-endorphin, cortisol and glucose responses in neonates with cardiorespiratory problems. Biol Neonate. 1993;64(6):360–367. [PubMed: 8286562]
  991. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA. 2003;290(10):1371–1376. [PubMed: 12966130]
  992. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52(5):1098–1103. [PubMed: 12716738]
  993. Pomerleau J, McKeigue PM, Chaturvedi N. Relationships of fasting and postload glucose levels to sex and alcohol consumption: are American Diabetes Association criteria biased against detection of diabetes in women? Diabetes Care. 1999;22(3):430–433. [PubMed: 10097924]
  994. Pontiroli AE, Perfetti MG, Pozza G. Acute effect of glipizide on glucose tolerance in obesity and diabetes mellitus (NIDDM) Eur J Clin Pharmacol. 1991;40(1):23–26. [PubMed: 2060541]
  995. Pontiroli AE, Perfetti MG, Pozza G. Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance. Horm Metab Res Suppl. 1992;26:32–34. [PubMed: 1490690]
  996. Pontiroli AE, Galli L. Duration of obesity is a risk factor far non-insulin dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia. Acta Diabetol. 1998;35(3):130–136. [PubMed: 9840448]
  997. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E. et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87(8):3555–3561. [PubMed: 12161474]
  998. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 2002;51(3):334–342. [PubMed: 11887170]
  999. Pories WJ, MacDonald KG Jr.,, Morgan EJ, Sinha MK, Dohm GL, Swanson MS. et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992;55(2 Suppl):582S–585S. [PubMed: 1733132]
  1000. Poulton J, Brown MS, Cooper A, Marchington DR, Phillips DI. A common mitochondrial DNA variant is associated with insulin resistance in adult life. Diabetologia. 1998;41(1):54–58. [PubMed: 9498630]
  1001. Power MJ, Fullerton KJ, Stout RW. Blood glucose and prognosis of acute stroke. Age & Ageing. 1988;17(3):164–170. [PubMed: 3389245]
  1002. Poykko S, Ukkola O, Kauma H, Savolainen MJ, Kesaniemi YA. Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects. Diabetologia. 2003;46(4):455–458. [PubMed: 12739020]
  1003. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected South Indian population: the Chennai Urban Population Study. Diabetes Care. 2000;23(9):1295–1300. [PubMed: 10977021]
  1004. Prince MJ, Deeg MA. Do n-3 fatty acids improve glucose tolerance and lipemia in diabetics? Current Opinion in Lipidology. 1997;8(1):7–11. [PubMed: 9127704]
  1005. Proctor CA. Abnormal insulin levels and vertigo. Laryngoscope. 1981;91(10):1657–1662. [PubMed: 7026944]
  1006. Puavilai G, Tiewtranon V, Pensuwan S, Sriphrapradaeng A, Asawakul W, Supitak V. et al. Impaired glucose tolerance in Thai adults: status of glucose tolerance after 2-year follow up. J Med Assoc Thai. 1987;70(Suppl 2):68–76. [PubMed: 3298521]
  1007. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract. 1999;44(1):21–26. [PubMed: 10414936]
  1008. Pyorala K. Hyperinsulinaemia as predictor of atherosclerotic vascular disease: epidemiological evidence. Diabete Metab. 1991;17(1 Pt 2):87–92. [PubMed: 1834487]
  1009. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle- aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98(5):398–404. [PubMed: 9714089]
  1010. Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I. et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation. 2000;69(7):1275–1283. [PubMed: 10798741]
  1011. Qiao Q, Keinanen K, Kivela SL. Haemoglobin A(1c) measurement for diabetes among subjects with a previous history of impaired glucose tolerance. Diabetes Res Clin Pract. 1995;30(3):189–194. [PubMed: 8861458]
  1012. Qiao Q, Keinanen-Kiukaanniemi S, Rajala U, Uusimaki A, Kivela S-L. Risk for diabetes and persistent impaired glucose tolerance among middle-aged Finns. Diabetes Res Clin Pract. 1996;33(3):191–198. [PubMed: 8922541]
  1013. Qiao Q, Rajala U, Keinanen-Kiukaanniemi S. Hypertension, hyperinsulinaemia and obesity in middle-aged Finns with impaired glucose tolerance. J Hum Hypertens. 1998;12(4):265–269. [PubMed: 9607697]
  1014. Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y. et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000;43(12):1470–1475. [PubMed: 11151755]
  1015. Qiao Q, Larsen S, Borch-Johnsen K, Nissinen A, Pekkanen J, Tuomilehto J. et al. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397–405. [PubMed: 11176766]
  1016. Qiao Q, Tuomilehto J. Diagnostic criteria of glucose intolerance and mortality. Minerva Medica. 2001;92(2):113–119. [PubMed: 11323573]
  1017. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R. et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose.[see comment] Eur Heart J. 2002;23(16):1267–1275. [PubMed: 12175663]
  1018. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care. 2003;26(10):2910–2914. [PubMed: 14514600]
  1019. Qiao Q, Hu G, Tuomilehto J, Borch-Johnsen K, Ramachandran A, Mohan V. et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003;26(6):1770–1780. [PubMed: 12766108]
  1020. Qiao Q, Lindstrom J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med. 2003;20(12):1027–1033. [PubMed: 14632705]
  1021. Quatraro A, Giugliano D, De Rosa N, Minei A, Ettorre M, Donzella C. et al. Is a family history of diabetes associated with an increased level of cardiovascular risk factors? Studies in healthy people and in subjects with different degree of glucose intolerance. Diabete Metab. 1993;19(2):230–238. [PubMed: 8339854]
  1022. Quinn L. Glucose monitoring in the acutely III patient with diabetes mellitus. Critical Care Nursing Quarterly. 1998;21(3):85–96. [PubMed: 10646424]
  1023. Racette SB, Kohrt WM, Landt M, Holloszy JO. Response to serum leptin concentrations to 7 d of energy restriction in centrally obese African Americans with impaired or diabetic glucose tolerance. Am J Clin Nutr. 1997;66(1):33–37. [PubMed: 9209166]
  1024. Racette SB, Weiss EP, Obert KA, Kohrt WM, Holloszy JO. Modest lifestyle intervention and glucose tolerance in obese African Americans. Obes Res. 2001;9(6):348–355. [PubMed: 11399781]
  1025. Rado JP, Banos C, Gercsak G, Molnar Z, Pato E, Csabuda M. Glucose-induced hyperkalemia developing in the upright position in captopril-treated hypertensives. Research Communications in Chemical Pathology & Pharmacology. 1982;38(1):161–164. [PubMed: 6755590]
  1026. Rahman Al-Nuaim A. High prevalence of metabolic risk factors for cardiovascular diseases among Saudi population, aged 30-64 years. Int J Cardiol. 1997;62(3):227–235. [PubMed: 9476683]
  1027. Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: Antecedent or consequence? Metabolism. 2002;51(12):1573–1577. [PubMed: 12489070]
  1028. Rajala U, Laakso M, Qiao Q, Keinanen-Kiukaanniemi S. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes Care. 1998;21(10):1664–1669. [PubMed: 9773727]
  1029. Rajala U, Qiao Q, Laakso M, Keinanen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2000;50(3):231–239. [PubMed: 11106838]
  1030. Rajala U, Koskela P, Keinanen-Kiukaanniemi S. Hyperglycemia as a risk factor of mortality in a middle-aged Finnish population. J Clin Epidemiol. 2001;54(5):470–474. [PubMed: 11337209]
  1031. Rakotoambinina B, Delaisi B, Laborde K, Silly C, De Blic J, Lenoir G. et al. Insulin responses to intravenous glucose and the hyperglycemic clamp in cystic fibrosis patients with different degrees of glucose tolerance. Pediatr Res. 1994;36(5):667–671. [PubMed: 7877889]
  1032. Rakotoambinina B, Timsit J, Deschamps I, Laborde K, Gautier D, Jos J. et al. Insulin responses to intravenous glucose, intravenous arginine and a hyperglycaemic clamp in ICA-positive subjects with different degrees of glucose tolerance. Diabetes Metab. 1997;23(1):43–50. [PubMed: 9059765]
  1033. Ramachandran A, Snehalatha C, Naik RA, Mohan V, Shobana R, Viswanathan M. Significance of impaired glucose tolerance in an Asian Indian population: a follow-up study. Diabetes Res Clin Pract. 1986;2(3):173–178. [PubMed: 3527626]
  1034. Ramachandran A, Mohan V, Snehalatha MC, Chinnikrishnudu M, Viswanathan M. Use of metformin in selected cases of NIDDM. A clinical trial. Journal of the Diabetic Association of India. 1988;28(4):137–139.
  1035. Ramachandran A, Snehalatha C, Shyamala P, Vijay V, Viswanathan M. High prevalence of NIDDM and IGT in an elderly south Indian population with low rates of obesity. Diabetes Care. 1994;17(10):1190–1192. [PubMed: 7821141]
  1036. Ramachandran A, Snehalatha C, Clementina M, Sasikala R, Vijay V. Foetal outcome in gestational diabetes in south Indians. Diabetes Res Clin Pract. 1998;41(3):185–189. [PubMed: 9829347]
  1037. Ramachandran A, Snehalatha C, Satyavani K, Vijay V. Effects of genetic predisposition on proinsulin responses in Asian Indians. Diabetes Res Clin Pract. 1998;41(1):71–77. [PubMed: 9768375]
  1038. Ramachandran A, Snehalatha C, Latha E, Manoharan M, Vijay V. Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract. 1999;44(3):207–213. [PubMed: 10462144]
  1039. Ramachandran A, Snehalatha C, Shobana R, Vidyavathi P, Vijay V. Influence of life style factors in development of diabetes in Indians--scope for primary prevention.[see comment] J Assoc Physicians India. 1999;47(8):764–766. [PubMed: 10778617]
  1040. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK. et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia. 2001;44(9):1094–1101. [PubMed: 11596662]
  1041. Ramachandran A, Snehalatha C, Vijay V, King H. Impact of the poverty on the prevalence of diabetes and its complications in urban southern India. Diabet Med. 2002;19(2):130–135. [PubMed: 11874429]
  1042. Ramaiya KL, Swai AB, McLarty DG, Alberti KG. Improvement in glucose tolerance after one year of follow-up in a Hindu community in Africa. Diabetes Res Clin Pract. 1990;10(3):245–255. [PubMed: 2073872]
  1043. Ramaiya KL, Swai AB, McLarty DG, Bhopal RS, Alberti KG. Prevalences of diabetes and cardiovascular disease risk factors in Hindu Indian subcommunities in Tanzania. BMJ. 1991;303(6797):271–276. [PMC free article: PMC1670456] [PubMed: 1888926]
  1044. Ramaiya KL, Denver E, Yudkin JS. Diabetes, impaired glucose tolerance and cardiovascular disease risk factors in the Asian Indian Bhatia community living in Tanzania and in the United Kingdom. Diabet Med. 1995;12(10):904–910. [PubMed: 8846682]
  1045. Rao CA, Snehalatha C. Hyper insulinism and decreased insulin sensitivity in nonobese healthy offspring of conjugal diabetic parents and individuals with IGT and NIDDM. Indian J Physiol Pharmacol. 1996;40(2):139–144. [PubMed: 9062808]
  1046. Rapoport JL. Effects of dietary substances in children. [Review] [15 refs] J Psychiatr Res. 1982;17(2):187–191. [PubMed: 6764936]
  1047. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R. et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46(2):182–189. [PubMed: 12627316]
  1048. Ratner RE. Type 2 diabetes mellitus: The grand overview. Diabet Med. 1998;15(SUPPL. 4):S4–S7. [PubMed: 9868984]
  1049. Ratzman K-P, Strese J, Rjasanowski I. Prevalence of islet cell antibodies (ICA) and islet cell surface antibodies (ICSA) in children and adolescents with antecedent mumps infection. Exp Clin Endocrinol. 1984;83(2):199–202. [PubMed: 6539220]
  1050. Ratzmann KP, Witt S, Ziegler M, Schulz B. Changes in carbohydrate tolerance and early insulin response to glucose in potential diabetics: a follow–up study of 2--4 years. Endokrinologie. 1980;75(1):89–97. [PubMed: 6989593]
  1051. Ratzmann KP, Besch W, Witt S, Schulz B. Evaluation of insulin resistance during inhibition of endogenous insulin and glucagon secretion by somatostatin in non-obese subjects with impaired glucose tolerance. Diabetologia. 1981;21(3):192–197. [PubMed: 6117492]
  1052. Ratzmann KP, Besch W, Witt S, Schulz B. Discrepant effect of the prostaglandin synthesis inhibitor acetylsalicylic acid on insulin and C-peptide response to glucose in man. Horm Metab Res. 1982;14(10):508–512. [PubMed: 6757082]
  1053. Ratzmann KP, Witt S, Schulz B. The effect of long-term glibenclamide treatment on glucose tolerance, insulin secretion and serum lipids in subjects with impaired glucose tolerance. Diabete Metab. 1983;9(2):87–93. [PubMed: 6413265]
  1054. Ratzmann ML, Rjasanowski I, Bruns W, Ratzmann KP. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. Exp Clin Endocrinol. 1983;82(2):216–221. [PubMed: 6354731]
  1055. Rau H, Althoff P-H, Schmidt K, Badenhoop K, Usadel KH. Bromocriptine treatment over 12 years in acromegaly: Effect on glucose tolerance and insulin secretion. Clin Investig. 1993;71(5):372–378. [PubMed: 8508007]
  1056. Ravelli ACJ, van der Meulen JHP, Michels RPJ, Osmond C, Barker DJP, Hales CN. et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet. 1998;351(9097):173–177. [PubMed: 9449872]
  1057. Reaven GM, Hollenbeck CB, Chen Y-D. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia. 1989;32(1):52–55. [PubMed: 2651188]
  1058. Reeves S, Howard R. Atypical antipsychotics and diabetes. Irish–Journal-of-Psychological-Medicine. 2002;19(2):63–65.
  1059. Regensteiner JG, Shetterly SM, Mayer EJ, Eckel RH, Haskell WL, Baxter J. et al. Relationship between habitual physical activity and insulin area among individuals with impaired glucose tolerance. Diabetes Care. 1995;18(4):490–497. [PubMed: 7497858]
  1060. Reiser S, Bohn E, Hallfrisch J, Michaelis OE, Keeney M, Prather ES. Serum insulin and glucose in hyperinsulinemic subjects fed three different levels of sucrose. Am J Clin Nutr. 1981;34(11):2348–2358. [PubMed: 7030048]
  1061. Resnick HE, Shorr RI, Kuller L, Franse L, Harris TB. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol. 2001;54(9):869–876. [PubMed: 11520645]
  1062. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab. 2001;86(3):1149–1153. [PubMed: 11238500]
  1063. Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr. 1981;34(12):2670–2678. [PubMed: 7032273]
  1064. Ribstein J, Du CG, Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive patients. J Hypertens. 2001;19(12):2257–2264. [PubMed: 11725171]
  1065. Riccardi G, Vaccaro O, Rivellese A, Pignalosa S, Tutino L, Mancini M. Reproducibility of the new diagnostic criteria for impaired glucose tolerance. Am J Epidemiol. 1985;121(3):422–429. [PubMed: 4014132]
  1066. Richard JL, Sultan A, Daures JP, Vannereau D, Parer-Richard C. Diagnosis of diabetes mellitus and intermediate glucose abnormalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabet Med. 2002;19(4):292–299. [PubMed: 11943000]
  1067. Riggio O, Merli M, Cangiano C. Glucose intolerance in liver cirrhosis. Metabolism. 1982;31(6):627–634. [PubMed: 7043186]
  1068. Riley WJ, Maclaren NK, Spillar RS. Reversal of deteriorating glucose tolerance with azathioprine in prediabetics. Transplant Proc. 1986;18(4):819–822.
  1069. Ritenbaugh C, Teufel-Shone NI, Aickin MG, Joe JR, Poirier S, Dillingham DC. et al. A lifestyle intervention improves plasma insulin levels among Native American high school youth. Prev Med. 2003;36(3):309–319. [PubMed: 12634022]
  1070. Rjasanowski I, Michaelis D, Besch W, Keilacker H, Ziegler B, Hildmann W. Glucose tolerance behaviour before the onset of type I (insulin-dependent) diabetes in young people as a predictor of the further course of the disease: a retrospective analysis of 33 cases. Diabetes Res Clin Pract. 1991;11(2):107–115. [PubMed: 2022175]
  1071. Rjasanowski I, Vogt L, Michaelis D, Keilacker H, Kohnert K. The frequency of diabetes in children of type 1 diabetic parents. Diabete Metab. 1993;19(1 Pt 2):173–177. [PubMed: 8314422]
  1072. Roberts RN, Henriksen JE, Hadden DR. Insulin sensitivity in pre-eclampsia. Br J Obstet Gynaecol. 1998;105(10):1095–1100. [PubMed: 9800933]
  1073. Roberts WL, De BK, Brown D, Hanbury CM, Hoyer JD, John WG. et al. Effects of hemoglobin C and S traits on eight glycohemoglobin methods. Clin Chem. 2002;48(2):383–385. [PubMed: 11805029]
  1074. Rodriguez-Villar C, Conget I, Casamitjana R, Ercilla G, Gomis R. Effects of insulin administration in a group of high-risk, non-diabetic, first-degree relatives of Type 1 diabetic patients: an open pilot trial. Diabet Med. 1999;16(2):160–163. [PubMed: 10229311]
  1075. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K. et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care. 1999;22(8):1262–1265. [PubMed: 10480768]
  1076. Rogers MA, Yamamoto C, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Improvement in glucose tolerance after 1 wk of exercise in patients with mild NIDDM. Diabetes Care. 1988;11(8):613–618. [PubMed: 3065001]
  1077. Rolandsson O, Hagg E, Nilsson M, Hallmans G, Mincheva-Nilsson L, Lernmark A. Prediction of diabetes with body mass index, oral glucose tolerance test and islet cell autoantibodies in a regional population. J Intern Med. 2001;249(4):279–288. [PubMed: 11298847]
  1078. Rolny P, Jagenburg R. Exocrine pancreatic function, fecal fat, and blood glucose in patients with pancreatitis. Scand J Gastroenterol. 1980;15(6):727–732. [PubMed: 7209383]
  1079. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest. 2002;25(6):502–507. [PubMed: 12109620]
  1080. Rosenbaum M, Hirsch J, Murphy E, Leibel RL. Effects of changes in body weight on carbohydrate metabolism, catecholamine excretion, and thyroid function. Am J Clin Nutr. 2000;71(6):1421–1432. [PubMed: 10837281]
  1081. Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK. Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes. Diabetes. 1982;31(5 Pt 1):385–387. [PubMed: 6759254]
  1082. Rosenbloom AL, Hunt SS. Prognosis of imparied glucose tolerance in children with stress hyperglycemia, symptoms of hypoglycemia, or asymptomatic glucosuria. J Pediatr. 1982;101(3):340–344. [PubMed: 7108655]
  1083. Rosenfalck AM, Hendel H, Rasmussen MH, Almdal T, Anderson T, Hilsted J. et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab. 2002;4(1):19–28. [PubMed: 11890163]
  1084. Rowe BR, Barnett AH. Pre-conception counselling in Asian women with non insulin dependent diabetes and impaired glucose tolerance. Diabetes Research. 1988;8(1):35–38. [PubMed: 3224493]
  1085. Rubin, R R., Fujimoto, W.Y., Marrero, D.G. et al. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials. 2002;23(2):157–171. [PubMed: 11943442]
  1086. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ. et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT) Arch Intern Med. 2002;162(22):2597–2604. [PubMed: 12456232]
  1087. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699–713. [PubMed: 9588440]
  1088. Ruige JB, De Neeling JND, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care. 1997;20(4):491–496. [PubMed: 9096967]
  1089. Ruige JB, Batstra MR, Aanstoot HJ, Bouter LM, Bruining GJ, De Neeling JN. et al. Low prevalence of antibodies to GAD65 in a 50- to 74-year-old general Dutch population. The Hoorn Study. Diabetes Care. 1997;20(7):1108–1110. [PubMed: 9203445]
  1090. Russell-briefel R, Ezzati TM, Perlman JA, Murphy RS. Impaired glucose tolerance in women using oral contraceptives: United States, 1976-1980. J Chronic Dis. 1987;40(1):3–11. [PubMed: 3805231]
  1091. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB. et al. Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function. Circulation. 2003;107(3):448–454. [PubMed: 12551870]
  1092. Ruzsa C, Fiegler M, Nagy L. Effect of indomethacin on glucose absorption and insulin release in patients with impaired glucose tolerance. Int J Clin Pharmacol Res. 1986;6(2):87–91. [PubMed: 3522445]
  1093. Ryan DH, Diabetes Prevention Program Research Group. Diet and exercise in the prevention of diabetes. [Review][35 refs]. Int J Clin Pract 2003; Supplement.(134):28–35. [PubMed: 12793595]
  1094. Ryle AJ, Davie S, Gould BJ, Yudkin JS. A study of the effect of diet on glycosylated haemoglobin and albumin levels and glucose tolerance in normal subjects. Diabet Med. 1990;7(10):865–870. [PubMed: 1963125]
  1095. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Bennett PH. Transient impaired glucose tolerance in Pima Indians: is it important? BMJ. 1988;297(6661):1438–1441. [PMC free article: PMC1835114] [PubMed: 3147006]
  1096. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med. 1988;319(23):1500–1506. [PubMed: 3054559]
  1097. Sacks DB. Implications of the revised criteria for diagnosis and classification of diabetes mellitus. Clin Chem. 1997;43(12):2230–2232. [PubMed: 9439437]
  1098. Sacks FM, Pfeffer MA, Moye' L, Brown LE, Hamm P, Cole TG. et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) Am J Cardiol. 1991;68(15):1436–1446. [PubMed: 1746424]
  1099. Sacks FM. Dyslipidemia, prediabetes, and type 2 diabetes: clinical implications of the VA-HIT subanalysis. Advanced Studies in Medicine. 2003;3(4A):S228–S233.
  1100. Saikawa T, Arita M, Yamaguchi K, Ito M. Hypoglycemic effect of cibenzoline in patients with abnormal glucose tolerance and frequent ventricular arrhythmias. Cardiovascular Drugs & Therapy. 2000;14(6):665–669. [PubMed: 11300368]
  1101. Salemans TH, Dieijen-Visser MP, Brombacher PJ. The value of HbA1 and fructosamine in predicting impaired glucose tolerance--an alternative to OGTT to detect diabetes mellitus or gestational diabetes. ANN CLIN BIOCHEM. 1987;24(Pt 5):447–452. [PubMed: 3662394]
  1102. Salobir B, Prezelj J, Kocijancic A, Meden-Vrtovec H. Basal glucose level as an independent predictor of fertilization rate in patients without polycystic ovary syndrome included in an in-vitro fertilization program. Wien Klin Wochenschr. 2002;114(12):454–457. [PubMed: 12422580]
  1103. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Glucose tolerance and blood pressure: long term follow up in middle aged men [published erratum appears in BMJ 1991 Apr 20;302(6782):939] BMJ. 1991;302(6775):493–496. [PMC free article: PMC1669625] [PubMed: 2012844]
  1104. Salomaa VV, Tuomilehto J, Jauhiainen M, Korhonen HJ, Stengard J, Uusitupa M. et al. Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study. Diabetes Care. 1992;15(5):657–665. [PubMed: 1516486]
  1105. Saloranta C, Guitard C, Pecher E, Pablos-Velasco P, Lahti K, Brunel P. et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care. 2002;25(12):2141–2146. [PubMed: 12453951]
  1106. Salti IS, Khogali M, Alam S, Haidar NA, Masri A. Epidemiology of diabetes mellitus in relation to other cardiovascular risk factors in Lebanon. Eastern Mediterranean Health Journal 3(3):462–71, 1997 Dec (21 ref) 1997;(3):462–471.
  1107. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002;359(9319):1740–1745. [PubMed: 12049864]
  1108. Sane T, Taskinen MR. Does familial hypertriglyceridemia predispose to NIDDM? Diabetes Care. 1993;16(11):1494–1501. [PubMed: 8299439]
  1109. Sann L, Morel Y, Lasne Y. Effect of hydrocortisone on intravenous glucose tolerance in small-for-gestational-age infants. Helv Paediatr Acta. 1983;38(56):475–482. [PubMed: 6365846]
  1110. Santer R, Hillebrand G, Steinmann B, Schaub J. Intestinal glucose transport: Evidence for a membrane traffic-based pathway in humans. Gastroenterology. 2003;124(1):34–39. [PubMed: 12512027]
  1111. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ. et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48(9):1836–1841. [PubMed: 10480616]
  1112. Sarioglu B, Ozerkan E, Can S, Yaprak I, Topcuoglu R. Insulin secretion and insulin resistance determined by euglycemic clamp. J Pediatr Endocrinol Metab. 1998;11(1):27–33. [PubMed: 9642626]
  1113. Sarkkinen E, Schwab U, Niskanen L, Hannuksela M, Savolainen M, Kervinen K. et al. The effects of monounsaturated-fat enriched diet and polyunsaturated-fat enriched diet on lipid and glucose metabolism in subjects with impaired glucose tolerance. Eur J Clin Nutr. 1996;50(9):592–598. [PubMed: 8880038]
  1114. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29(1):41–49. [PubMed: 7380107]
  1115. Sas T, Muinck Keizer–Schrama S, Aanstoot HJ, Stijnen T, Drop S. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections. Clin Endocrinol (Oxf) 2000;52(6):741–747. [PubMed: 10848879]
  1116. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M. et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 2001;54(2):243–251. [PubMed: 11207640]
  1117. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab. 2000;85(2):769–775. [PubMed: 10690889]
  1118. Sasaki A, Suzuki T, Horiuchi N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow-up study. Diabetologia. 1982;22(3):154–157. [PubMed: 7075915]
  1119. Sasaki A. Assessment of the new diagnostic criteria for diabetes mellitus according to a long-term follow-up study. Tohoku J Exp Med. 1983;141 Suppl:99–104. [PubMed: 6680553]
  1120. Sasaki S, Kuwahara N, Kunitomo K, Harada S, Yamada T, Azuma A. et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol. 2002;89(4):386–389. [PubMed: 11835916]
  1121. Sasaki TM, Gray RS, Ratner RE, Currier C, Aquino A, Barhyte DY. et al. Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels. Transplantation. 1998;65(11):1510–1512. [PubMed: 9645815]
  1122. Saukkonen T, Vaisanen S, Akerblom HK, Savilahti E, Tuomilehto J, Lounamaa R. et al. Coeliac disease in children and adolescents with type 1 diabetes: A study of growth, glycaemic control, and experiences of families. Acta Paediatr. 2002;91(3):297–302. [PubMed: 12022302]
  1123. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447–453. [PubMed: 11289466]
  1124. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care. 2001;24(8):1397–1402. [PubMed: 11473076]
  1125. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003;157(12):1092–1100. [PubMed: 12796045]
  1126. Sayeed MA, Hussain MZ, Banu A, Rumi MA, Azad Khan AK. Prevalence of diabetes in a suburban population of Bangladesh. Diabetes Res Clin Pract. 1997;34(3):149–155. [PubMed: 9069566]
  1127. Sayeed MA, Banu A, Malek MA, Khan AK. Blood pressure and coronary heart disease in NIDDM subjects at diagnosis: prevalence and risks in a Bangladeshi population. Diabetes Res Clin Pract. 1998;39(2):147–155. [PubMed: 9597385]
  1128. Scarpello JHB. Will prevention of type 2 diabetes reduce the future burden of cardiovascular disease? The evidence-base today. Medscape 2004.
  1129. Schaefer-Graf UM, Kjos SL, Kilavuz O, Plagemann A, Brauer M, Dudenhausen JW. et al. Determinants of fetal growth at different periods of pregnancies complicated by gestational diabetes mellitus or impaired glucose tolerance.[erratum appears in Diabetes Care. 2003 Apr;26(4):1329] Diabetes Care. 2003;26(1):193–198. [PubMed: 12502680]
  1130. Schafer-Graf UM, Dupak J, Vogel M, Dudenhausen JW, Kjos SL, Buchanan TA. et al. Hyperinsulinism, neonatal obesity and placental immaturity in infants born to women with one abnormal glucose tolerance test value. J Perinat Med. 1998;26(1):27–36. [PubMed: 9595364]
  1131. Scheen A.J. [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study] Rev Med Liege. 2002;57(9):617–621. [PubMed: 12440353]
  1132. Scheen AJ, Letiexhe MR, Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med. 1995;12(11):985–989. [PubMed: 8582131]
  1133. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. [Review] [91 refs] Diabetes Metab. 2002;28(6 Pt 1):437–445. [PubMed: 12522323]
  1134. Scheen AJ. Is there a role for a-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs. 2003;63(10):933–951. [PubMed: 12699398]
  1135. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edelstein SL. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol. 1991;133(6):565–576. [PubMed: 2006643]
  1136. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain. 2002;18(6):350–354. [PubMed: 12441828]
  1137. Schmid S, Molteni A, Fuchtenbusch M, Naserke HE, Ziegler A-G, Bonifacio E. Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes. Diabetologia. 2002;45(5):677–685. [PubMed: 12107748]
  1138. Schmidt MI, Duncan BB, Vigo A, Pankow J, Ballantyne CM, Couper D. et al. Detection of undiagnosed diabetes and other hyperglycemia states: The atherosclerosis risk in communities study. Diabetes Care. 2003;26(5):1338–1343. [PubMed: 12716785]
  1139. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP. et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;19(13):1147–1154. [PubMed: 10393723]
  1140. Schranz A, Tuomilehto J, Marti B, Jarrett RJ, Grabauskas V, Vassallo A. Low physical activity and worsening of glucose tolerance: results from a 2-year follow-up of a population sample in Malta. Diabetes Res Clin Pract. 1991;11(2):127–136. [PubMed: 2022178]
  1141. Schranz AG. Abnormal glucose tolerance in the Maltese. A population-based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Res Clin Pract. 1989;7(1):7–16. [PubMed: 2752891]
  1142. Schranz AG, Savona-Ventura C. Long-term significance of gestational carbohydrate intolerance: a longitudinal study. Experimental & Clinical Endocrinology & Diabetes. 2002;110(5):219–222. [PubMed: 12148085]
  1143. Schultz-Larsen K, Avlund K, Kreiner S. Functional ability of community dwelling elderly. Criterion-related validity of a new measure of functional ability. J Clin Epidemiol. 1992;45(11):1315–1326. [PubMed: 1432011]
  1144. Schultz SK, Arndt S, Ho BC, Oliver SE, Andreasen NC. Impaired glucose tolerance and abnormal movements in patients with schizophrenia. American-Journal-of-Psychiatry. 1999;156(4):640–642. [PubMed: 10200749]
  1145. Schulz B, Ratzmann KP, Heinke P, Besch W. A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance (IGT) Exp Clin Endocrinol. 1983;82(2):222–231. [PubMed: 6354732]
  1146. Schulz B, Witt S, Hildmann W, Ratzmann KP, Strese J, Keilacker H. Islet cell antibodies in individuals at increased risk for IDDM. Exp Clin Endocrinol. 1984;83(2):192–198. [PubMed: 6373322]
  1147. Schulz LO, Weidensee RC. Glucose tolerance and physical activity in a Mexican indigenous population. Diabetes Care. 1995;18(9):1274–1276. [PubMed: 8612443]
  1148. Schutz Y, Golay A, Felber JP, Jequier E. Decreased glucose-induced thermogenesis after weight loss in obese subjects: a predisposing factor for relapse of obesity? Am J Clin Nutr. 1984;39(3):380–387. [PubMed: 6695838]
  1149. Schwab IR, Dawson CR, Hoshiwara I, Szuter CF, Knowler WC. Incidence of cataract extraction in Pima Indians. Diabetes as a risk factor. Arch Ophthalmol. 1985;103(2):208–212. [PubMed: 3883967]
  1150. Schwab US, Sarkkinen ES, Lichtenstein AH, Li Z, Ordovas JM, Schaefer EJ. et al. The effect of quality and amount of dietary fat on the susceptibility of low density lipoprotein to oxidation in subjects with impaired glucose tolerance. Eur J Clin Nutr. 1998;52(6):452–458. [PubMed: 9683400]
  1151. Schwartz GG, Il'yasova D, Ivanova A. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care. 2003;26(2):468–470. [PubMed: 12547882]
  1152. Schwarz J-M, Mulligan K, Lee J, Lo JC, Wen M, Noor MA. et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2002;87(2):942–945. [PubMed: 11836345]
  1153. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KGMM, Gray CS. Prevalence of unrecognised diabetes mellitus and impaired glucose tolerance in acute stroke patients with hyperglycaemia. Cerebrovascular Diseases. 1999;9(Suppl 1):16.
  1154. Scott RD, Kritz-Silverstein D, Barrett-Connor E, Wiederholt WC. The association of non-insulin-dependent diabetes mellitus and cognitive function in an older cohort. Journal of the American Geriatrics Society 46(10):1217-22, 1998 Oct (39 ref) 1998;(10):1217-1222. [PubMed: 9777902]
  1155. Seccia TM, Vulpis V, Ricci S, Pirrelli A. The effects of nitrendipine on glucose tolerance and immunoreactive insulin levels in hypertensive patients. Current Therapeutic Research, Clinical & Experimental. 1994;55(11):1323–1334.
  1156. Seibaek M, Sloth C, Vallebo L, Hansen T, Urhammer SA, Burchardt H. et al. Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. Am Heart J. 1997;133(6):622–629. [PubMed: 9200389]
  1157. Sermer M, Naylor CD, Gare DJ, Kenshole AB, Ritchie JW, Farine D. et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. Am J Obstet Gynecol. 1995;173(1):146–156. [PubMed: 7631672]
  1158. Shaten BJ, Smith GD, Kuller LH, Neaton JD. Risk factors for the development of type II diabetes among men enrolled in the usual care group of the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(10):1331–1339. [PubMed: 8269790]
  1159. Shaw JE, Hodge AM, de Court, Dowse GK, Gareeboo H, Tuomilehto J. et al. Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract. 1998;42(2):131–139. [PubMed: 9886750]
  1160. Shaw JE, Hodge AM, de Court, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999;42(9):1050–1054. [PubMed: 10447514]
  1161. Shaw JE, Zimmet PZ, de Court, Dowse GK, Chitson P, Gareeboo H. et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care. 1999;22(3):399–402. [PubMed: 10097917]
  1162. Shaw JE, Zimmet PZ, Hodge AM, de Court, Dowse GK, Chitson P. et al. Impaired fasting glucose: How low should it go? Diabetes Care. 2000;23(1):34–39. [PubMed: 10857965]
  1163. Shelgikar KM, Hockaday TD, Yajnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabet Med. 1991;8(8):712–717. [PubMed: 1838061]
  1164. Shelgikar KM, Naik SS, Khopkar M, Bhat DS, Raut KN, Joglekar CV. et al. Circulating lipids and cardiovascular risk in newly diagnosed non-insulin-dependent diabetic subjects in India. Diabet Med. 1997;14(9):757–761. [PubMed: 9300225]
  1165. Shera AS, Rafique G, Khwaja IA, Ara J, Baqai S, King H. Pakistan national diabetes survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. Diabet Med. 1995;12(12):1116–1121. [PubMed: 8750223]
  1166. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J. et al. The prevention or delay of type 2 diabetes. Diabetes Care. 2003;26(SUPPL. 1):S62–S69. [PubMed: 12502620]
  1167. Shetty A, Wilson S, Kuo P, Laurin JL, Howell CD, Johnson L. et al. Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation. 2000;69(11):2451–2454. [PubMed: 10868659]
  1168. Shimizu H, Shouzu A, Nishikawa U, Omoto S, Hayakawa T, Miyake Y. et al. Serum concentration and renal handling of 1,5-anhydro-D-glucitol in patients with chronic renal failure. ANN CLIN BIOCHEM. 1999;36(6):749–754. [PubMed: 10586312]
  1169. Shimizu S, Kawata Y, Kawakami N, Aoyama H. Effects of changes in obesity and exercise on the development of diabetes and return to normal fasting plasma glucose levels at one-year follow-up in middle-aged subjects with impaired fasting glucose. Environmental Health & Preventive Medicine. 2001;6(2):127–131. [PMC free article: PMC2723249] [PubMed: 21432250]
  1170. Shimokata H, Muller DC, Fleg JL, Sorkin J, Ziemba AW, Andres R. Age as independent determinant of glucose tolerance. Diabetes. 1991;40(1):44–51. [PubMed: 2015973]
  1171. Shinohara R, Ohta Y, Yamauchi M, Ishiguro I. Improved fluorometric enzymatic sorbitol assay in human blood. Clin Chim Acta. 1998;273(2):171–184. [PubMed: 9657347]
  1172. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M. et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation. 1995;92(7):1749–1757. [PubMed: 7671357]
  1173. Shinozaki K, Naritomi H, Shimizu T, Suzuki M, Ikebuchi M, Sawada T. et al. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke. 1996;27(1):37–43. [PubMed: 8553400]
  1174. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new a-glucosidase inhibitor, Voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996;45(6):731–737. [PubMed: 8637448]
  1175. Shionoiri H, Miyakawa T, Takasaki I. Glucose tolerance during chronic captopril therapy in patients with essential hypertension. J Cardiovasc Pharmacol. 1987;9(2):160–164. [PubMed: 2435993]
  1176. Shionoiri H, Sugimoto KI, Minamisawa K, Ueda S-I, Ebina T, Matsukawa T. et al. Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. J Cardiovasc Pharmacol. 1990;15(6):933–938. [PubMed: 1694916]
  1177. Shionoiri H, Gotoh E, Ito T, Hata T, Iwatsubo H, Takegawa K. et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci. 1994;307(Suppl 1):S91–S95. [PubMed: 7908168]
  1178. Shionoiri H, Takasaki I, Naruse M, Nagamoti I, Himeno H, Ito T. et al. Effect of cilazapril therapy on glucose and lipid metabolism in patients with hypertension. Clin Ther. 1995;17(6):1126–1135. [PubMed: 8750404]
  1179. Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther. 1997;19(3):527–536. [PubMed: 9220217]
  1180. Sicree RA, Zimmet PZ, King H, Coventry JS. Weight change amongst Nauruans over 6.5 years: extent, and association with glucose intolerance. Diabetes Res Clin Pract. 1987;3(6):327–336. [PubMed: 3665732]
  1181. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among nauruans. Diabetes. 1987;36(2):179–185. [PubMed: 3542644]
  1182. Sievenpiper JL, Jenkins DJA, Josse RG, Leiter LA, Vuksan V. Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance. Am J Clin Nutr. 2001;73(3):567–573. [PubMed: 11237933]
  1183. Sigurdsson G, Gottskalksson G, Thorsteinsson T, Davidsson D, Olafsson O, Samuelsson S. et al. Community screening for glucose intolerance in middle-aged Icelandic men. Deterioration to diabetes over a period of 71/2 years. Acta Medica Scandinavica. 1981;210(12):21–26. [PubMed: 7293824]
  1184. Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A. Lipid metabolic studies in oophorectomised women: Effects on serum lipids and lipoproteins of three synthetic progestogens. Maturitas. 1982;4(2):103–111. [PubMed: 6811837]
  1185. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers: relationship to fetal hyperinsulinism. Diabetes Care. 1995;18(5):611–617. [PubMed: 8585997]
  1186. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care. 1998;21(Suppl 2):B142–B149. [PubMed: 9704242]
  1187. Simmons D, Powell MJ. Metabolic and clinical characteristics of south Asians and Europeans in Coventry. Diabet Med. 1993;10(8):751–758. [PubMed: 8261758]
  1188. Simpson HCR, Sturley R, Stirling CA, Reckless JPD. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure Type 2 diabetic patients. Diabet Med. 1990;7(2):143–147. [PubMed: 2137755]
  1189. Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes - lifestyle change or pharmacotherapy? A challenge for the 21st century. [Review] [126 refs] Diabetes Res Clin Pract. 2003;59(3):165–180. [PubMed: 12590013]
  1190. Singh MM, Biswas SK, Shah A. Impaired glucose tolerance in active pulmonary tuberculosis. Indian Journal of Tuberculosis. 1984;31(3):118–121.
  1191. Singh RB, Niaz MA, Ghosh S. Effect on central obesity and associated distrubances of low-energy, fruit- and vegetable-enriched prudent diet in North Indians. Postgrad Med J. 1994;70(830):895–900. [PMC free article: PMC2398005] [PubMed: 7870637]
  1192. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle & Nerve. 2001;24(9):1225–1228. [PubMed: 11494277]
  1193. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346(11):802–810. [PubMed: 11893791]
  1194. Sirtori CR, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A. et al. n-3 Fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Am J Clin Nutr. 1997;65(6):1874–1881. [PubMed: 9174486]
  1195. Sirtori CR, Crepaldi G, Manzato E, Mancini M, Rivellese A, Paoletti R. et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis. 1998;137(2):419–427. [PubMed: 9622285]
  1196. Skouby SO, Molsted-Pedersen L, Kuhl C. Low dosage oral contraception in women with previous gestational diabetes. Obstet Gynecol. 1982;59(3):325–328. [PubMed: 6804901]
  1197. Slabber M, Barnard HC, Kuyl JM, Dannhauser A, Schall R. Effects of a low-insulin-response, energy-restricted diet on weight loss and plasma insulin concentrations in hyperinsulinemic obese females. Am J Clin Nutr. 1994;60(1):48–53. [PubMed: 8017337]
  1198. Slama G. The potential of metformin for diabetes prevention. Diabetes Metab. 2003;29(4):104–111. [PubMed: 14502107]
  1199. Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001;57(9):1701–1704. [PubMed: 11706115]
  1200. Smith DA. Review: hyperglycemia after myocardial infarction increases the risk for death in patients with and without diabetes mellitus... commentary on Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. LANCET 2000 Mar 4;355:773-8. ACP Journal Club 133(3):116, 2000 Nov-Dec (3 ref) 2000;(3):116.
  1201. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol. 1992;136(9):1110–1114. [PubMed: 1462971]
  1202. Smith NL, Savage PJ, Heckbert SR, Barzilay JI, Bittner VA, Kuller LH. et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50(3):416–423. [PubMed: 11943034]
  1203. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH. et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly. Arch Intern Med. 2002;162(2):209–216. [PubMed: 11802755]
  1204. Smith SM, Davis-Street JE, Fontenot TB, Lane HW. Assessment of a portable clinical blood analyzer during space flight. Clin Chem. 1997;43(6):1056–1065. [PubMed: 9191561]
  1205. Smith SM, Holohan J, McAuliffe A, Firth RG. Irish diabetes detection programme in general practice. Diabet Med. 2003;20(9):717–722. [PubMed: 12925050]
  1206. Smutok MA, Reece C, Kokkinos PF, Farmer CM, Dawson PK, DeVane J. et al. Effects of exercise training modality on glucose tolerance in men with abnormal glucose regulation. Int J Sports Med. 1994;15(6):283–289. [PubMed: 7822064]
  1207. Snehalatha C, Ramachandran A, Satyavani K, Vijay V, Haffner SM. Specific insulin and proinsulin concentrations in nondiabetic South Indians. Metabolism. 1998;47(2):230–233. [PubMed: 9472976]
  1208. Snehalatha C, Ramachandran A, Saltyamurthy I, Satyavani K, Sivasankari S, Misra J. et al. Association of proinsulin and insulin resistance with coronary artery disease in non-diabetic south Indian men. Diabet Med. 2001;18(9):706–708. [PubMed: 11606167]
  1209. Snehalatha C, Vijay V, Suresh MR, Satyavani K, Sivasankari S, Megha T. et al. Lack of association of insulin resistance and carotid intimal medial thickness in non-diabetic Asian Indian subjects. Diabetes Metab Res Rev. 2001;17(6):444–447. [PubMed: 11757080]
  1210. Snehalatha C, Ramachandran A, Sivasankari S, Satyavani K, Vijay V. Insulin secretion and action show differences in impaired fasting glucose and impaired glucose tolerance in Asian Indians. Diabetes Metab Res Rev. 2003;19(4):329–332. [PubMed: 12879411]
  1211. Soeldner JS, Srikanta S, Eisenbarth GS, Gleason RE. Pre-hyperglycemic diabetes mellitus. [Review] [30 refs] Clin Chem. 1986;32(10 Suppl):B7–18. [PubMed: 3530543]
  1212. Solano MP, Perry AC, Wang X, Ross R, Goldberg RB. Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. Int J Obes. 2003;27(1):82–87. [PubMed: 12532158]
  1213. Soliman AT, Al Suwaid AR, Gamil H, Asfour M. Prevalence and significance of acanthosis nigricans in children and adolescents. Annals of Saudi Medicine. 1996;16(4):424–428. [PubMed: 17372496]
  1214. Solnica B, Naskalski JW. Evaluation of analytical performance of Super G1, Super G2+ and Biosen 5030 glucose amperometric analyzers. Clinical Laboratory. 2003;49(56):233–238. [PubMed: 15285179]
  1215. Solomon CG, Graves SW, Greene MF, Seely EW. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension. 1994;23(6 Pt 1):717–721. [PubMed: 8206568]
  1216. Solomon MP, Wilson DC, Corey M, Kalnins D, Zielenski J, Tsui L. et al. Glucose intolerance in children with cystic fibrosis. J Pediatr. 2003;142(2):128–132. [PubMed: 12584532]
  1217. Solymoss BC, Bourassa MG, Campeau L, Lesperance J, Marcil M, Varga S. Incidence, coronary risk profile and angiographic characteristics of prediabetic and diabetic patients in a population with ischemic heart disease. Canadian Journal of Cardiology. 2003;19(10):1155–1160. [PubMed: 14532941]
  1218. Sosenko JM, Kato M, Soto R, Goldberg RB. Sensory function at diagnosis and in early stages of NIDDM in patients detected through screening [see comments] Diabetes Care. 1992;15(7):847–852. [PubMed: 1516503]
  1219. Spiller HA, Weber JA, Winter ML, Klein-Schwartz W, Hofman M, Gorman SE. et al. Multicenter case series of pediatric metformin ingestion. Ann Pharmacother. 2000;34(12):1385–1388. [PubMed: 11144693]
  1220. Sprafka JM, Xue S, Bushhouse SA, French LR, Martinez AM, Goetz FC. Cardiovascular disease risk factors and glucose tolerance: The Wadena City Health Study. Ann Epidemiol. 1992;2(5):647–656. [PubMed: 1342316]
  1221. Srinivasan SR, Myers L, Berenson GS. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: The Bogalusa Heart Study. Diabetes. 2002;51(1):204–209. [PubMed: 11756342]
  1222. Statistics Canada. National Center for Health Statistics.http://www​.cdc.gov/nchs​/products/pubs/pubd​/hestats/overwght99.htm. 2001. Ref Type: Report.
  1223. Stefan N, Stumvoll M, Bogardus C, Tataranni PA. Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am J Physiol Endocrinol Metab. 2003;284(6):E1156–E1161. [PubMed: 12582008]
  1224. Steffen LM, Jacobs DR Jr., Murtaugh MA, Moran A, Steinberger J, Hong CP. et al. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. Am J Epidemiol. 2003;158(3):243–250. [PubMed: 12882946]
  1225. Steinmueller T, Konrad T, Jonas S, Tullius S, Bechstein WO, Mueller A. et al. The effect of cyclosporine vs FK 506 on glucose metabolism. Transplant Proc. 1999;31(12):1129–1130. [PubMed: 10083504]
  1226. Stengard JH, Tuomilehto J, Pekkanen J, Kivinen P, Kaarsalo E, Nissinen A. et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia. 1992;35(8):760–765. [PubMed: 1511803]
  1227. Stengard JH, Pekkanen J, Tuomilehto J, Kivinen P, Kaarsalo E, Tamminen M. et al. Changes in glucose tolerance among elderly Finnish men during a five-year follow-up: the Finnish cohorts of the Seven Countries Study. Diabete Metab. 1993;19(1 Pt 2):121–129. [PubMed: 8314414]
  1228. Stern MP, Morales PA, Valdez RA, Monterrosa A, Haffner SM, Mitchell BD. et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes. 1993;42(5):706–714. [PubMed: 8482427]
  1229. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Annals of Internal Medicine. 2002;136(8):575–581. [PubMed: 11955025]
  1230. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR, Cherokee DS. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care. 2002;25(6):1009–1014. [PubMed: 12032107]
  1231. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A, Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol. 1997;145(1):24–32. [PubMed: 8982019]
  1232. Stone LM, Kahn SE, Deeb SS, Fujimoto WY, Porte JD. Glucokinase gene variations in Japanese-Americans with a family history of NIDDM. Diabetes Care. 1994;17(12):1480–1483. [PubMed: 7882822]
  1233. Storgaard H, Jensen CB, Vaag AA, Volund A, Madsbad S. Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism. 2003;52(7):885–894. [PubMed: 12870166]
  1234. Stowers JM, Sutherland HW, Kerridge DF. Long-range implications for the mother. The Aberdeen experience. Diabetes. 1985;34(Suppl 2):106–110. [PubMed: 3888735]
  1235. Strand CL, Garcia H, Costales F. Hyponatremia in spontaneous hyperglycemia: Correlation studies in 100 patients. Clin Chem. 1987;33(10):1941–1942. [PubMed: 3665062]
  1236. Su CC, Chen H-S, Lin H-D. Glycemic control with different premixed insulin in Taiwanese people with type two diabetes mellitus. Journal of the Chinese Medical Association: JCMA. 2003;66(3):155–159. [PubMed: 12779035]
  1237. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canadian-Journal-of-Psychiatry. 2003;48(5):345–347. [PubMed: 12866342]
  1238. Suematsu C, Hayashi T, Fujii S, Endo G, Tsumura K, Okada K. et al. Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Diabetes Care. 1999;22(2):228–232. [PubMed: 10333938]
  1239. Sugarman JR, Gilbert TJ, Weiss NS. Prevalence of diabetes and impaired glucose tolerance among Navajo Indians. Diabetes Care. 1992;15(1):114–120. [PubMed: 1737528]
  1240. Sum C-F, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in Type 2 diabetes. Diabet Med. 1992;9(1):61–65. [PubMed: 1551312]
  1241. Sumino HI. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res. 2003;60(3):134–142. [PubMed: 12931041]
  1242. Sun B, Wang X, Song Q, Wang Y, Xue L, Wang C. et al. Prospective studies on the relationship between the 50 g glucose challenge test and pregnant outcome. Chin Med J (Engl) 1995;108(12):910–913. [PubMed: 8728943]
  1243. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Meta-analysis in medical research. Rexdale, Ontario, Canada: Wiley, 2000.
  1244. Suvd J, Gerel B, Otgooloi H, Purevsuren D, Zolzaya H, Roglic G. et al. Glucose intolerance and associated factors in Mongolia: results of a national survey. Diabet Med. 2002;19(6):502–508. [PubMed: 12060063]
  1245. Suzuki H, Jae HR. Effect of samgyetang feeding on plasma lipids, glucose, glycosylated hemoglobin, and stress-induced gastric ulcers in mice. Nutrition Research. 2000;20(4):575–584.
  1246. Suzuki M, Nishizaki M, Arita M, Kakuta T, Numano F. Impaired glucose tolerance with late hypersecretion of insulin during oral glucose tolerance test in patients with vasospastic angina. J Am Coll Cardiol. 1996;27(6):1458–1463. [PubMed: 8626958]
  1247. Suzuki S, Kawasaki H, Satoh Y, Ohtomo M, Hirai M, Hirai A. et al. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care. 1994;17(12):1465–1468. [PubMed: 7882818]
  1248. Swai ABM, McLarty DG, Kitange HM, Kilima PM, Masuki G, Mtinangi BI. et al. Study in Tanzania of impaired glucose tolerance: Methodological myth? Diabetes. 1991;40(4):516–520. [PubMed: 2010053]
  1249. Swinburn BA, Woollard GA, Chang EC, Wilson MR. Effects of reduced-fat diets consumed ad libitum on intake of nutrients, particularly antioxidant vitamins. Journal of the American Dietetic Association. 1999;99(11):1400–1405. [PubMed: 10570677]
  1250. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care. 2001;24(4):619–624. [PubMed: 11315819]
  1251. Swinn RA, Wareham NJ, Gregory R, Curling V, Clark PM, Dalton KJ. et al. Excessive secretion of insulin precursors characterizes and predicts gestational diabetes. Diabetes. 1995;44(8):911–915. [PubMed: 7621996]
  1252. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC. et al. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation. 2002;106(21):2680–2686. [PubMed: 12438293]
  1253. Tahvanainen E, Molin M, Vainio S, Tiret L, Nicaud V, Farinaro E. et al. Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants. Atherosclerosis. 2000;152(2):317–325. [PubMed: 10998459]
  1254. Tai ES, Lim SC, Tan BY, Chew SK, Heng D, Tan CE. Screening for diabetes mellitus - A two-step approach in individuals with impaired fasting glucose improves detection of those at risk of complications. Diabet Med. 2000;17(11):771–775. [PubMed: 11131101]
  1255. Tajra LC, Dubernard JM, Dawhara M, Lefrancois N, Badet L, Martin X. Long-term metabolic control and pancreatic graft survival according to surgical technique. Transplant Proc. 1999;31(8):3192–3193. [PubMed: 10616436]
  1256. Takasaki I, Shionoiri H, Hiroto S, Yasuda G, Gotoh E, Umemura S. et al. Long-term captopril therapy with no effect on glucose metabolism in patients with essential hypertension. Am J Hypertens. 1988;1(3 III):217S–220S. [PubMed: 3046627]
  1257. Takata Y, Ou O, Nishida H, Sakagami K. Impact of self-monitoring of blood glucose on the lifestyles of subjects with fasting hyperglycemia: A randomized controlled trial. Journal of Occupational Health. 2002;44(1):28–33.
  1258. Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Experimental & Clinical Endocrinology & Diabetes. 2003;111(6):351–357. [PubMed: 14520602]
  1259. Takemura Y, Kikuchi S, Inaba Y, Yasuda H, Nakagawa K. The protective effect of good physical fitness when young on the risk of impaired glucose tolerance when old. Prev Med. 1999;28(1):14–19. [PubMed: 9973583]
  1260. Takeuchi M, Kanazawa A, Suzuki M, Hasegawa M, Kimura Y, Kodama K. et al. Evaluation of factors during OGTT to correlate insulin resistance in non-diabetic subjects. Endocr J. 2000;47(5):535–542. [PubMed: 11200932]
  1261. Takino H, Okuno S, Uotani S, Yano M, Matsumoto K, Kawasaki E. et al. Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res Clin Pract. 1994;24(3):167–172. [PubMed: 7988348]
  1262. Tan ECTH, De Keijzer MH, Goris RJA. Capillary blood gas analysis in complex regional pain syndrome: A pilot study. ANN CLIN BIOCHEM. 2003;40(5):569–571. [PubMed: 14503998]
  1263. Tan KCB, Wat NMS, Tam SCF, Janus ED, Lam TH, Lam KSL. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care. 2003;26(8):2323–2328. [PubMed: 12882856]
  1264. Tan YY, Yeo GS. Impaired glucose tolerance in pregnancy--is it of consequence? Aust N Z J Obstet Gynaecol. 1996;36(3):248–255. [PubMed: 8883744]
  1265. Taniguchi A, Nakai Y, Doi K, Fukushima M, Nagata I, Kawamura H. et al. Glucose effectiveness in two subtypes within impaired glucose tolerance. Diabetes. 1994;43(10):1211–1217. [PubMed: 7926290]
  1266. Taniguchi A, Nakai Y, Fukushima M, Imura H, Kawamura H, Nagata I. et al. Insulin sensitivity, insulin secretion, and glucose effectiveness in subjects with impaired glucose tolerance: A minimal model analysis. Metabolism. 1994;43(6):714–718. [PubMed: 8201959]
  1267. Tankova T, Dakovska L, Kirilov G, Koev D. Insulin secretion and anti-GAD65 antibodies in subjects with impaired glucose tolerance. Experimental & Clinical Endocrinology & Diabetes. 2001;109(7):355–360. [PubMed: 11573145]
  1268. Tapp RJ, Shaw JE, Harper CA, de Court, Balkau B, McCarty DJ. et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26(6):1731–1737. [PubMed: 12766102]
  1269. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood.[see comment] Lancet. 2000;356(9234):993–997. [PubMed: 11041401]
  1270. Tate DF, Jackvony EH, Wing RR. Effects of Internet behavioral counseling on weight loss in adults at risk for type 2 diabetes: a randomized trial. JAMA. 2003;289(14):1833–1836. [PubMed: 12684363]
  1271. Tavintharan S, Chew LS, Heng DM. A rational alternative for the diagnosis of diabetes mellitus in high risk individuals. Ann Acad Med Singapore. 2000;29(2):213–218. [PubMed: 10895342]
  1272. Teixeira CC, Fuchs FD, Blotta RM, Knijnik J, Delgado IC, Netto MS. et al. Effect of tea prepared from leaves of Syzygium jambos on glucose tolerance in nondiabetic subjects. Diabetes Care. 1990;13(8):907–908. [PubMed: 2209336]
  1273. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W. et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.[see comment] Metabolism. 2002;51(6):743–749. [PubMed: 12037728]
  1274. Temelkova-Kurktschiev T, Koehler C, Henkel E, Hanefeld M. Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiovasc Res. 2002;56(2):277–283. [PubMed: 12393098]
  1275. Ten Boekel E, De Kieviet W, Bartels PCM. Subjects with a shortened activated partial thromboplastin time show increased in-hospital mortality associated with elevated D-dimer, C-reactive protein and glucose levels. Scand J Clin Lab Invest. 2003;63(6):441–448. [PubMed: 14594325]
  1276. Tenenbaum A, Motro M, Fisman EZ, Boyko V, Mandelzweig L, Reicher-Reiss H. et al. Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease. Am J Cardiol. 2000;86(12):1363–1366. [PubMed: 11113414]
  1277. Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L. et al. Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. Am J Cardiol. 2002;90(5):529–532. [PubMed: 12208417]
  1278. Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Ryden L. et al. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care. 2003;26(10):2770–2776. [PubMed: 14514578]
  1279. Tesfaye S. Diabetic neuropathy: Current treatment and potential therapeutic approaches. Diabetes Nutr Metab. 1994;7(6):375–379.
  1280. Testori GP, Ferrari C, Lepore R, Boghen M. Effect of gemfibrozil treatment on glucose tolerance in hypertriglyceridemic patients with normal or impaired glucose tolerance. Current Therapeutic Research, Clinical & Experimental. 1990;47(2):390–395.
  1281. Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care. 1988;11(3):246–251. [PubMed: 3416678]
  1282. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23):2981–2997. [PubMed: 12479763]
  1283. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000; 23(11) 1619–1629. [PMC free article: PMC1360735] [PubMed: 11092283]
  1284. Thong FSL, Graham TE. Caffeine-induced impairment of glucose tolerance is abolished by beta-adrenergic receptor blockade in humans. J Appl Physiol. 2002;92(6):2347–2352. [PubMed: 12015346]
  1285. Thorburn AW, Crapo PA, Griver K, Wallace P, Henry RR. Long-term effects of dietary fructose on carbohydrate metabolism in non-insulin-dependent diabetes mellitus. Metabolism. 1990;39(1):58–63. [PubMed: 2403621]
  1286. Thrainsdottir S, Malik RA, Dahlin LB, Wiksell P, Eriksson KF, Rosen I. et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes. 2003;52(10):2615–2622. [PubMed: 14514647]
  1287. Todoroki I, Shinchi K, Kono S, Imanishi K. Lifestyle and glucose tolerance: A cross-sectional study of Japanese men. Ann Epidemiol. 1994;4(5):363–368. [PubMed: 7981843]
  1288. Toeller M, Gries FA, Dannehl K. Natural history of glucose intolerance in obesity. A ten year observation. Int J Obes. 1982;6 Suppl 1:145–149. [PubMed: 6749720]
  1289. Toivonen AM, Kulmala P, Savola K, Akerblom HK, Knip M. Soluble adhesion molecules in pre-clinical Type 1 diabetes: a prospective study. Diabetologia. 2003;46(4):492–495. [PubMed: 12684750]
  1290. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22(6):920–924. [PubMed: 10372242]
  1291. Tomiyama H, Kimura Y, Okazaki R, Kushiro T, Abe M, Kuwabara Y. et al. Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension. 2000;36(2):245–249. [PubMed: 10948085]
  1292. Tong PCY, Lee ZSK, Sea M, Chow C, Ko GTC, Chan W. et al. The effect of Orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascualr risk factors and insulin sensitivity in young obese Chinese subjects with or without Type 2 Diabetes. Arch Intern Med. 2002;162(21):2428–2435. [PubMed: 12437401]
  1293. Top C, Cingozbay BY, Terekeci H, Kucukardali Y, Onde ME, Danaci M. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res. 2002;30(1):15–20. [PubMed: 11921494]
  1294. Topic E, Pavlicek I, Brinar V, Korsic M. Glycosylated haemoglobin in clarification of the origin of hyperglycaemia in acute cerebrovascular accident. Diabet Med. 1989;6(1):12–15. [PubMed: 2522367]
  1295. Torella R, Salvatore T, Spiezia R. Is the common presence of glucose intolerance in old age a reliable index for the subsequent occurrence of fasting hyperglycemia. Acta Diabetol Lat. 1986;23(1):57–61. [PubMed: 3716750]
  1296. Torgerson JSH. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161. [PubMed: 14693982]
  1297. Toyota T, Oikawa S, Abe R, Sano R, Suzuki N, Hisamichi S. et al. Effect of cilostazol on lipid, uric acid and glucose metabolism in patients with impaired glucose tolerance or type 2 diabetes mellitus a double-blind, placebo-controlled study. Clinical Drug Investigation. 2001;21(5):325–335.
  1298. Trinick TR, Duly E. Experience of a quality assessment scheme for non-laboratory glucose meters. J Clin Pathol. 1992;45(1):77–78. [PMC free article: PMC495825] [PubMed: 1740522]
  1299. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen M-R, Tuomi T. et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: Lessons from the Botnia Study. Diabetes. 2000;49(6):975–980. [PubMed: 10866050]
  1300. Trivedi N, Mithal A, Gupta SK, Godbole MM. Reversible impairment of glucose tolerance in patients with endemic fluorosis. Diabetologia. 1993;36(9):826–828. [PubMed: 8405753]
  1301. Troisi RJ, Cowie CC, Harris MI. Hormone replacement therapy and glucose metabolism. Obstetrics & Gynecology 96(5 part 1):665–70, 2000 Nov (19 ref) 2000;(5 part 1):665–670. [PubMed: 11042298]
  1302. Tsai S-T, Li C-L, Chen C-H, Chou P. Community-based epidemiological study of glucose tolerance in Kin-Chen, Kinmen: Support for a new intermediate classification. J Clin Epidemiol. 2000;53(5):505–510. [PubMed: 10812323]
  1303. Tsao PS, Niebauer J, Buitrago R, Lin PS, Wang B-Y, Cooke JP. et al. Interaction of diabetes and hypertension on determinants of endothelial adhesiveness. Arteriosclerosis Thrombosis & Vascular Biology. 1998;18(6):947–953. [PubMed: 9633936]
  1304. Tschritter O, Fritsche A, Shirkavand F, Machicao F, Haring H, Stumvoll M. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care. 2003;26(4):1026–1033. [PubMed: 12663568]
  1305. Tsutsu N, Nunoi K, Kodama T, Nomiyama R, Iwase M, Fujishima M. Lack of association between blood pressure and insulin in patients with insulinoma. J Hypertens. 1990;8(5):479–482. [PubMed: 2163424]
  1306. Tuffnell DJ, West J, Walkinshaw SA. Treatments for gestational diabetes and impaired glucose tolerance in pregnancy. [Review][61 refs]. Cochrane Database Syst Rev 2003;(3):CD003395. [PubMed: 12917965]
  1307. Tunbridge FKE, Newens A, Home PD, Davis SN, Murphy M, Burrin JM. et al. Double-blind crossover trial of isophane (NPH) - and lente-based insulin regimens. Diabetes Care. 1989;12(2):115–119. [PubMed: 2649324]
  1308. Tunbridge FKE, Home PD, Murphy M, Alberti KGMM. Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen? Diabet Med. 1991;8(9):833–838. [PubMed: 1837510]
  1309. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A. et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999;48(1):150–157. [PubMed: 9892237]
  1310. Tuomilehto-Wolf E, Tuomilehto J, Hitman GA, Nissinen A, Stengard J, Pekkanen J. et al. Genetic susceptibility to non-insulin dependent diabetes mellitus and glucose intolerance are located in HLA region [see comments] BMJ. 1993;307(6897):155–159. [PMC free article: PMC1678370] [PubMed: 8343743]
  1311. Tuomilehto J, Zimmet P, Kankaanpaa J, Wolf E, Hunt D, King H. et al. Prevalence of ischaemic ECG abnormalities according to the diabetes status in the population of Fiji and their associations with other risk factors. Diabetes Res Clin Pract. 1988;5(3):205–217. [PubMed: 3219991]
  1312. Tuomilehto J, Schranz A, Aldana D, Pitkaniemi J. The effect of diabetes and impaired glucose tolerance on mortality in Malta. Diabet Med. 1994;11(2):170–176. [PubMed: 8200202]
  1313. Tuomilehto J, Qiao Q, Borch-Johnsen K, Balkau B. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354(9179):617–621. [PubMed: 10466661]
  1314. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P. et al. Lifestyle changes can prevent the development of diabetes mellitus. CMAJ: Canadian Medical Association Journal. 2001;164(13):1885.
  1315. Tuomilehto J, Lindstrom J, Eriksson JG. Changes in diet and physical activity prevented type 2 diabetes mellitus in people with impaired glucose tolerance. Evidence Based Medicine. 2001;6(6):176.
  1316. Tuomilehto J, Qiao Q, Balkau B, Borch-Johnson K. Glucose tolerance and all-cause mortality. Cardiology Review. 2001;18(2):28–32.
  1317. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. [PubMed: 11333990]
  1318. Tuomilehto J, Borch-Johnsen K, Tajima N, Cockram CS, Nakagami T. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals - An evaluation of the World Health Organization two-step strategy: The DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) Diabet Med. 2002;19(7):549–557. [PubMed: 12099957]
  1319. Turk Z, Mesic R, Benko B. Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A(1c) for the assessment of diabetic control. Clin Chim Acta. 1998;277(2):159–170. [PubMed: 9853699]
  1320. Turpeinen AK, Haffner SM, Louheranta AM, Niskanen LK, Miettinen H, Uusitupa MI. Serum leptin in subjects with impaired glucose tolerance in relation to insulin sensitivity and first-phase insulin response. Int J Obes Relat Metab Disord. 1997;21(4):284–287. [PubMed: 9130025]
  1321. Turpeinen AK, Kuikka JT, Vanninen E, Uusitupa MIJ. Abnormal myocardial kinetics of 123I-heptadecanoic acid in subjects with impaired glucose tolerance. Diabetologia. 1997;40(5):541–549. [PubMed: 9165222]
  1322. Turpeinen AK, Takala TO, Nuutila P, Axelin T, Luotolahti M, Haaparanta M. et al. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Diabetes. 1999;48(6):1245–1250. [PubMed: 10342811]
  1323. Uchida K, Jikko A, Yamato T. Relationship of glucose intolerance and indocyanine green clearance to respiratory enzyme levels in human cirrhotic liver. Am J Med Sci. 1985;290(1):19–27. [PubMed: 2994474]
  1324. Unwin N, Harland J, White M, Bhopal R, Winocour P, Stephenson P. et al. Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK. Journal of Epidemiology & Community Health. 1997;51(2):160–166. [PMC free article: PMC1060438] [PubMed: 9196645]
  1325. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19(9):708–723. [PubMed: 12207806]
  1326. Uusitupa M, Louheranta A, Lindstrom J, Valle T, Sundvall J, Eriksson J. et al. The Finnish Diabetes Prevention Study. Br J Nutr. 2000;83(Suppl 1):S137–S142. [PubMed: 10889804]
  1327. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstrom J, Tuomilehto J. et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52(10):2532–2538. [PubMed: 14514637]
  1328. Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P. et al. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr. 1992;68(1):209–216. [PubMed: 1390605]
  1329. Uusitupa MI. Early lifestyle intervention in patients with non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Ann Med. 1996;28(5):445–449. [PubMed: 8949977]
  1330. Vaccaro O, Rivellese A, Riccardi G, Capaldo B, Tutino L, Annuzzi G. et al. Impaired glucose tolerance and risk factors for atherosclerosis. Arteriosclerosis. 1984;4(6):592–597. [PubMed: 6391444]
  1331. Vaccaro O, Pauciullo P, Rubba P. Peripheral arterial circulation in individuals with impaired glucose tolerance. Diabetes Care. 1985;8(6):594–597. [PubMed: 4075946]
  1332. Vaccaro O, Ruth KJ, Stamler J. Relationship of postload plasma glucose to mortality with 19-yr follow-up. Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. Diabetes Care. 1992;15(10):1328–1334. [PubMed: 1425098]
  1333. Vaccaro O, Imperatore G, Iovino V, Iovine C, Rivellese AA, Riccardi G. Does impaired glucose tolerance predict hypertension? A prospective analysis. Diabetologia. 1996;39(1):70–76. [PubMed: 8720605]
  1334. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.[see comment] Diabetes Care. 1999;22(9):1490–1493. [PubMed: 10480514]
  1335. Vajo Z, Szekacs B, Dachman W. Evidence for genetic variability in venous responsiveness. Acta Physiol Hung. 1996;84(4):353–360. [PubMed: 9328607]
  1336. Valerio G, Franzese A, Carlin E, Pecile P, Perini R, Tenore A. High prevalence of stress hyperglycaemia in children with febrile seizures and traumatic injuries. Acta Paediatr. 2001;90(6):618–622. [PubMed: 11440092]
  1337. van Dam RM, Schuit AJ, Feskens EJM, Seidell JC, Kromhout D. Physical activity and glucose tolerance in elderly men: the Zutphen elderly study. Medicine & Science in Sports & Exercise 34(7):1132–6, 2002 Jul (22 ref) 2002;(7):1132–1136. [PubMed: 12131253]
  1338. Van der MMT, Crowther NJ, Schlaphoff GP, Gray IP, Joffe BI, Lonnroth PN. Evidence for insulin resistance in black women from South Africa. Int J Obes. 2000;24(10):1340–1346. [PubMed: 11093297]
  1339. Van der MMT, Schlaphoff GP, Crowther NJ, Boyd IH, Gray IP, Joffe BI. et al. Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa. J Clin Endocrinol Metab. 2001;86(7):3296–3303. [PubMed: 11443204]
  1340. van Dijk RA, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Brachial artery pulse pressure and common carotid artery diameter: mutually independent associations with mortality in subjects with a recent history of impaired glucose tolerance. Eur J Clin Invest. 2001;31(9):756–763. [PubMed: 11589717]
  1341. Van Dijk RAJM, Nijpels G, Twisk JWR, Steyn M, Dekker JM, Heine RJ. et al. Change in common carotid artery diameter, distensibility and compliance in subjects with a recent history of impaired glucose tolerance: A 3-year follow-up study. J Hypertens. 2000;18(3):293–300. [PubMed: 10726716]
  1342. Van Kempen AAMW, Romijn JA, Ruiter AFC, Ackermans MT, Endert E, Hoekstra JH. et al. Adaptation of glucose production and gluconeogenesis to diminishing glucose infusion in preterm infants at varying gestational ages. Pediatr Res. 2003;53(4):628–634. [PubMed: 12612212]
  1343. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM. et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: The Hoorn study. Arch Ophthalmol. 2003;121(2):245–251. [PubMed: 12583792]
  1344. Van Mieghem W. Evaluation of glucose tolerance during treatment with celiprolol in patients with Mild Arterial Hypertension without diabetes mellitus. Acta Clin Belg. 1997;52(6):360–366. [PubMed: 9489131]
  1345. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Drop SL. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J Clin Endocrinol Metab. 2002;87(12):5442–5448. [PubMed: 12466334]
  1346. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Rodgers H. et al. The incidence of diabetes mellitus in an English community: a 20-year follow-up of the Whickham Survey. Diabet Med. 1996;13(8):741–747. [PubMed: 8862950]
  1347. Vangen S, Stoltenberg C, Holan S, Moe N, Magnus P, Harris JR. et al. Outcome of pregnancy among immigrant women with diabetes. Diabetes Care. 2003;26(2):327–332. [PubMed: 12547857]
  1348. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Notkola IL, Takala JK. Hyperinsulinemia and clustering of cardiovascular risk factors in middle-aged hypertensive Finnish men and women. J Hypertens. 1997;15(5):475–481. [PubMed: 9169999]
  1349. Vanhala MJ, Pitkajarvi TK, Keinanen-Kiukaanniemi SM, Kumpusalo EA, Takala JK. Hyperinsulinaemia in hypertensive subjects: validity of a test for the detection of insulin resistance in clinical practice. J Hum Hypertens. 1998;12(7):463–467. [PubMed: 9702932]
  1350. Vanhanen M, Koivisto K, Kuusisto J, Mykkanen L, Helkala E, Hanninen T. et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care. 1998;21(3):398–402. [PubMed: 9540022]
  1351. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia. 1991;34(2):93–102. [PubMed: 2065854]
  1352. Vasankari T, Hamalainen H, Aunola S, Rastas M, Marniemi J, AM Reduced oxidized LDL after two years dietary and exercise intervention in IGT subjects. European Journal of Endocrinology. 1999;140(Suppl. 1):21.
  1353. Velho G, Blanche H, Vaxillaire M, Bellanne-Chantelot C, Pardini VC, Timsit J. et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia. 1997;40(2):217–224. [PubMed: 9049484]
  1354. Vella A, Reed AS, Charkoudian N, Shah P, Basu R, Basu A. et al. Glucose-induced suppression of endogenous glucose production: Dynamic response to differing glucose profiles. Am J Physiol Endocrinol Metab. 2003;285(1 481):E25–E30. [PubMed: 12637258]
  1355. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Circulation. 2003;107(9):1291–1296. [PubMed: 12628950]
  1356. Verrillo A, de Teresa A, Pinto M, Rucco E. Diurnal variation in the effect of exogenous insulin on blood sugar, growth hormone and free fatty acids in subjects with various degrees of glucose intolerance. IRCS Medical Science. 1983;11(10):913–914.
  1357. Verschoor L, Lamberts SWJ, Uitterlinden P, Del Pozo E. Glucose tolerance during long term treatment with a somatostatin analogue. British Medical Journal. 1986;293(6558):1327–1328. [PMC free article: PMC1342048] [PubMed: 2878704]
  1358. Vijayakumar T, Vasudevan DM. Effect of ascorbic acid administration on glucose tolerance and serum cholesterol in normal and in diabetic subjects. Indian Medical Gazette. 1980;114(3):96–100.
  1359. Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med. 1996;13(8):715–719. [PubMed: 8862945]
  1360. Vinceti M, Rovesti S, Pacchioni C, Ropa G, Roncaia R, Benedetti P. et al. Diet as a risk factor for abnormal glucose tolerance in subjects with and without family history of diabetes mellitus. Diabetes Nutr Metab. 1994;7(1):21–28.
  1361. Viswanathan M, Mohan V, Snehalatha C, Ramachandran A. High prevalence of Type 2 (non-insulin-dependent) diabetes among the offspring of conjugal Type 2 diabetic parents in India. Diabetologia. 1985;28(12):907–910. [PubMed: 4092859]
  1362. von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab. 2000;85(9):3101–3108. [PubMed: 10999793]
  1363. Von Mach M-A, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Experimental & Clinical Endocrinology & Diabetes. 2002;110(8):416–419. [PubMed: 12518253]
  1364. Voors AW, Radhakrishnamurthy B, Srinivasan SR, Webber LS, Berenson GS. Plasma glucose level related to blood pressure in 272 children, ages 7–15 years, sampled from a total biracial population. Am J Epidemiol. 1981;113(4):347–356. [PubMed: 7211820]
  1365. Vuksan V, Sievenpiper JL, Koo VYY, Francis T, Beljan-Zdravkovic U. American Ginseng (Panax quinqefolius L) Reduces Postprandial Glycemia in Nondiabetic Subjects and Subjects with Type 2 Diabetes Mellitus. Arch Intern Med. 2000;160(7):1009–1013. [PubMed: 10761967]
  1366. Vuksan V, Sievenpiper JL, Owen R, Swilley JA, Spadafora P, Jenkins DJ. et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care. 2000;23(1):9–14. [PubMed: 10857960]
  1367. Wagenaar LJ, Kuck EM, Hoekstra JBL. Troglitazone. Is it all over? Neth J Med. 1999;55(1):4–12. [PubMed: 10431549]
  1368. Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM. et al. The insulin resistance atherosclerosis study (iris): Objectives, design, and recruitment results. Ann Epidemiol. 1995;5(6):464–472. [PubMed: 8680609]
  1369. Wagenknecht LEZ. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol. 2003;23(6):1035–1041. [PubMed: 12702517]
  1370. Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R. et al. Nepsilon-(Carboxymethyl) lysine levels in patients with type 2 diabetes: Role of renal function. Am J Kidney Dis. 2001;38(4):785–791. [PubMed: 11576882]
  1371. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40(10):1748–1754. [PubMed: 12446057]
  1372. Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, Tracy RP. Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification.[see comment] Lancet. 1998;352(9133):1012–1015. [PubMed: 9759743]
  1373. Walker EA, Paduano DJ, Shamoon H. Quality assurance for blood glucose monitoring in health-care facilities. Diabetes Care. 1991;14(11):1043–1049. [PubMed: 1797485]
  1374. Wall U, Bergbrant A, Jern S. Impaired glucose tolerance at five-year follow-up of young men with borderline hypertension. Blood Pressure. 1996;5(3):139–147. [PubMed: 8790924]
  1375. Wareham NJ, Byrne CD, Carr C, Day NE, Boucher BJ, Hales CN. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism. 1997;46(10):1171–1177. [PubMed: 9322802]
  1376. Wareham NJ, Franks PW, Harding AH. Establishing the role of gene–environment interactions in the etiology of type 2 diabetes. [Review] [75 refs] Endocrinol Metab Clin North Am. 2002;31(3):553–566. [PubMed: 12227119]
  1377. Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabet Med. 1996;13(9 Suppl 6):S40–S45. [PubMed: 8894480]
  1378. Wasada T, Kuroki H, Arii H, Maruyama A, Saito S, Watanabe Y. et al. Physiological increase in plasma insulin concentration suppresses proinsulin secretion in normal controls but not in subjects with glucose intolerance. Endocr J. 1994;41(2):183–188. [PubMed: 7951567]
  1379. Wat NM, Lam TH, Janus ED, Lam KS. Central obesity predicts the worsening of glycemia in southern Chinese. Int J Obes Relat Metab Disord. 2001;25(12):1789–1793. [PubMed: 11781759]
  1380. Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens. 1999;17(8):1153–1160. [PubMed: 10466471]
  1381. Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N. et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999;22(1):152–156. [PubMed: 10333918]
  1382. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men.[erratum appears in Ann Intern Med 1999 Sep 7;131(5):394] Annals of Internal Medicine. 1999;130(2):89–96. [PubMed: 10068380]
  1383. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation. 2000;101(17):2047–2052. [PubMed: 10790345]
  1384. Wein P, Beischer N, Harris C, Permezel M. A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. Aust N Z J Obstet Gynaecol. 1999;39(2):162–166. [PubMed: 10755770]
  1385. Weinberger MH, Fineberg NS, Fineberg SE. The influence of blood pressure and carbohydrate tolerance on vascular compliance in humans. Am J Hypertens. 2002;15(8):678–682. [PubMed: 12160189]
  1386. Weiss HG, Klocker J, Labeck B, Nehoda H, Aigner F, Klingler A. et al. Plasma amine oxidase: a postulated cardiovascular risk factor in nondiabetic obese patients. Metabolism. 2003;52(6):688–692. [PubMed: 12800092]
  1387. Weiss PAM, Scholz HS, Haas J, Tamussino KF, Seissler J, Borkenstein MH. Long-term follow-up of infants of mothers with type 1 diabetes: Evidence for hereditary and nonhereditary transmission of diabetes and precursors. Diabetes Care. 2000;23(7):905–911. [PubMed: 10895839]
  1388. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC. et al. Prediabetes in obese youth: A syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003;362(9388):951–957. [PMC free article: PMC2995523] [PubMed: 14511928]
  1389. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW. et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350(23):2362–2374. [PubMed: 15175438]
  1390. Weitgasser R, Spitzer D, Kartnig I, Zajc M, Staudach A, Sandhofer F. Association of HELLP syndrome with autoimmune antibodies and glucose intolerance. Diabetes Care. 2000;23(6):786–790. [PubMed: 10840997]
  1391. Welborn TA, Reid CM, Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism. 1997;46(12 Suppl 1):35–39. [PubMed: 9439557]
  1392. Welin L, Eriksson H, Larsson B, Svardsudd K, Tibblin G, Wilhelmsen L. Triglycerides and blood glucose are the major coronary risk factors in elderly Swedish men. The study of men born in 1913. Ann Epidemiol. 1992;2(12):113–119. [PubMed: 1342252]
  1393. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia. 1992;35(8):766–770. [PubMed: 1511804]
  1394. Wells TG, Ulstrom RA, Nevins T. Hypoglycemia in pediatric renal allograft recipients. J Pediatr. 1988;113(6):1002–1007. [PubMed: 3057155]
  1395. Westgard JO. Cooking the books: is it happening in lab error budgets? Nothing but the truth about quality. Madison, WI: Westgard QC, 2004.
  1396. Weyer C, Bogardus C, Pratley RE. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes. Diabetes. 1999;48(8):1607–1614. [PubMed: 10426380]
  1397. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999;48(11):2197–2203. [PubMed: 10535454]
  1398. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24(1):89–94. [PubMed: 11194248]
  1399. Whelan J. Drug-induced islet growth: A novel treatment for diabetes? Drug Discovery Today. 2002;7(5):277–278. [PubMed: 11854042]
  1400. Widimsky JJ, Strauch B, Sindelka G, Skrha J. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res. 2001;50(6):603–607. [PubMed: 11829322]
  1401. Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Current Opinion in Investigational Drugs. 2003;4(4):412–420. [PubMed: 12808880]
  1402. Wiener K. Fasting plasma glucose as a diagnostic indicator of diabetes mellitus [see comments] Clin Chim Acta. 1995;238(2):199–208. [PubMed: 7586579]
  1403. Wijeyaratne CN, Sheriff R, Seneviratne HR, Sheriffdeen AH. Pregnancy following renal transplantation in Sri Lanka. Ceylon Med J. 2000;45(4):168–170. [PubMed: 11293964]
  1404. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. [PubMed: 15111519]
  1405. Wilks R, Rotimi C, Bennett F, McFarlane-Anderson N, Kaufman JS, Anderson SG. et al. Diabetes in the Caribbean: results of a population survey from Spanish Town, Jamaica. Diabet Med. 1999;16(10):875–883. [PubMed: 10547216]
  1406. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract. 2002;58(2):87–96. [PubMed: 12213349]
  1407. Williams DEM, Prevost AT, Whichelow MJ, Cox BD, Day NE, Wareham NJ. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr. 2000;83(3):257–266. [PubMed: 10884714]
  1408. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD. et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med. 1995;12(1):30–35. [PubMed: 7712700]
  1409. Williams DRR, Wareham NJ, Brown DC, Byrne CD, Clark PMS, Cox BD. et al. Undiagnosed glucose intolerance in the community: The Isle of Ely Diabetes Project. Diabet Med. 1995;12(1):30–35. [PubMed: 7712700]
  1410. Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care. 1998;21(3):350–359. [PubMed: 9540015]
  1411. Wingard DL, Barrett-Connor E. Family history of diabetes and cardiovascular disease risk factors and mortality among euglycemic, borderline hyperglycemic, and diabetic adults. Am J Epidemiol. 1987;125(6):948–958. [PubMed: 3578253]
  1412. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM: A population-based study. Diabetes Care. 1993;16(7):1022–1025. [PubMed: 8359095]
  1413. Wolever TM, Fernandes J, Rao VA, Chiasson JL, Josse RG, Leiter LA. Positive methane-producing status associated with increased serum cholesterol in subjects with impaired glucose tolerance. Diabetes Care. 1995;18(7):1010–1012. [PubMed: 7555532]
  1414. Wolever TM, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA. et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care. 1998;21(3):336–340. [PubMed: 9540012]
  1415. Wolever TM, Chiasson JL. Acarbose raises serum butyrate in human subjects with impaired glucose tolerance. Br J Nutr. 2000;84(1):57–61. [PubMed: 10961161]
  1416. Wolever TM, Mehling C. High-carbohydrate-low-glycaemic index dietary advice improves glucose disposition index in subjects with impaired glucose tolerance. Br J Nutr. 2002;87(5):477–487. [PubMed: 12010586]
  1417. Wolever TM, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr. 2003;77(3):612–621. [PubMed: 12600851]
  1418. Wolever TMS, Nguyen PM, Chiasson J-L, Hunt JA, Josse RG, Palmason C. et al. Determinants of diet glycemic index calculated retrospectively from diet records of 342 individuals with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994;59(6):1265–1269. [PubMed: 8198048]
  1419. Wolever TMS, Bentum-Williams A, Jenkins DJA. Physiological modulation of plasma free fatty acid concentrations by diet: Metabolic implications in nondiabetic subjects. Diabetes Care. 1995;18(7):962–970. [PubMed: 7555557]
  1420. Wolever TMS, Fernandes J, Rao VA, Chiasson JL, Josse RG, Leiter LA. Positive methane-producing status associated with increased serum cholesterol in subjects with impaired glucose tolerance. Diabetes Care. 1995;18(7):1010–1012. [PubMed: 7555532]
  1421. Wolever TMS, Chiasson J-L. Acarbose raises serum butyrate in human subjects with impaired glucose tolerance. Br J Nutr. 2000;84(1):57–61. [PubMed: 10961161]
  1422. Wolever TMS, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr. 2003;77(3):612–621. [PubMed: 12600851]
  1423. Won SP, Yun SC, Lee M. Effects of hyperglycemia or hypoglycemia on brain cell membrane function and energy metabolism during the immediate reoxygenation-reperfusion period after acute transient global hypoxia-ischemia in the newborn piglet. Brain Research. 2001;901(12):102–108. [PubMed: 11368956]
  1424. Wong M-S, Gu K, Heng D, Chew S-K, Chew L-S, Tai ES. The Singapore Impaired Glucose Tolerance Follow-Up Study: Does the ticking clock go backward as well as forward? Diabetes Care. 2003;26(11):3024–3030. [PubMed: 14578234]
  1425. Woo J, Ho SC, Sham A, Sea MM, Lam KS, Lam TH. et al. Diet and glucose tolerance in a Chinese population. Eur J Clin Nutr. 2003;57(4):523–530. [PubMed: 12700613]
  1426. Worrall G. Screening healthy people for diabetes: is it worthwhile? J Fam Pract. 1991;33(2):155–160. [PubMed: 1890396]
  1427. Yajnik CS, Naik SS, Bhat DS, Joshi VM, Shelgikar KM, Alberti KGMM. et al. The relationship between obesity, plasma immunoreactive insulin concentration and blood pressure in newly diagnosed Indian Type 2 diabetic patients. Diabet Med. 1993;10(2):146–151. [PubMed: 8458191]
  1428. Yajnik CS, Fall CH, Vaidya U, Pandit AN, Bavdekar A, Bhat DS. et al. Fetal growth and glucose and insulin metabolism in four-year-old Indian children. Diabet Med. 1995;12(4):330–336. [PubMed: 7600749]
  1429. Yamada N, Yoshinaga H, Sakurai N, Shimano H, Gotoda T, Ohashi Y. et al. Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care. 1994;17(2):107–114. [PubMed: 8137680]
  1430. Yamada T, Aizawa T, Nagasawa Y, Ishihara M, Komatsu M, Komiya I. et al. Ten-year follow-up of Japanese overweight subjects with impaired glucose tolerance: identification of a diabetes-prone subpopulation. Intern Med. 1992;31(7):877–884. [PubMed: 1450495]
  1431. Yamanouchi T, Inoue T, Ogata E, Kashiwabara A, Ogata N, Sekino N. et al. Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Colch ) 2001;101(3):227–233. [PubMed: 11524039]
  1432. Yamazaki Y, Takahashi K, Yagisawa T, Oba S, Teraoka S, Toma H. et al. Alterations in glucose tolerance and insulin release in renal transplant recipients receiving cyclosporine and corticosteroid. Transplant Proc. 1988;20(1 SUPPL. 1):158–159.
  1433. Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y. et al. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis. 1997;132(1):43–51. [PubMed: 9247358]
  1434. Yarnell JW, Pickering JE, Elwood PC, Baker IA, Bainton D, Dawkins C. et al. Does non-diabetic hyperglycemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol. 1994;47(4):383–388. [PubMed: 7730863]
  1435. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26(4):1277–1294. [PubMed: 12663610]
  1436. Yoshinaga H, Kosaka K. High glycosylated hemoglobin levels increase the risk of progression to diabetes mellitus in subjects with glucose intolerance. Diabetes Res Clin Pract. 1996;31(13):71–79. [PubMed: 8792104]
  1437. Young TK, Dean HJ, Flett B, Wood-Steiman P. Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr. 2000;136(3):365–369. [PubMed: 10700694]
  1438. Yu WK, Li WQ, Li N, Li JS. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol. 2003;9(8):1824–1827. [PMC free article: PMC4611552] [PubMed: 12918129]
  1439. Yuan X, Yamada K, Koyama K-I, Ichikawa F, Ishiyama S, Koyanagi A. et al. beta3-adrenergic receptor gene polymorphism is not a major genetic determinant of obesity and diabetes in Japanese general population. Diabetes Res Clin Pract. 1997;37(1):1–7. [PubMed: 9279471]
  1440. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988;2(8610):530–533. [PubMed: 2900920]
  1441. Zannolli R, Rebeggiani A, Chiarelli F, Morgese G. Hyperinsulinism as a marker in obese children. Am J Dis Child. 1993;147(8):837–841. [PubMed: 8352218]
  1442. Zargar AH, Shah NA, Masoodi SR, Laway BA, Dar FA, Khan AR. et al. Copper, zinc, and magnesium levels in non-insulin dependent diabetes mellitus. Postgrad Med J. 1998;74(877):665–668. [PMC free article: PMC2431594] [PubMed: 10197198]
  1443. Zargar AH, Masoodi SR, Khan AK, Bashir MI, Laway BA, Wani AI. et al. Impaired fasting glucose and impaired glucose tolerance - Lack of agreement between the two categories in a North Indian population. Diabetes Res Clin Pract. 2001;51(2):145–149. [PubMed: 11165694]
  1444. Zavaroni I, Bonini L, Gasparini R, Barilli AL, Zuccarelli A, Dall'Aglio E. et al. Hyperinsulinemia in a normal population as a predictor of non-insulin- dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla Factory revisited. Metabolism. 1999;48(8):989–994. [PubMed: 10459563]
  1445. Zawada Jr ET, Williams L, McClung DE. Renal-metabolic consequences of antihypertensive therapy with diltiazem versus hypochlorothiazide. Miner Electrolyte Metab. 1987;13(2):72–77. [PubMed: 3320720]
  1446. Zhang JL, Qin YW, Zheng X, Qiu JL, Zou DJ. Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med. 2003;20(10):828–831. [PubMed: 14510864]
  1447. Zimmer EZ, Paz Y, Goldstick O, Beloosesky R, Weiner Z. Computerized analysis of fetal heart rate after maternal glucose ingestion in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000;93(1):57–60. [PubMed: 11000505]
  1448. Zimmet P. When is diabetes?--a new look at diagnostic criteria for diabetes mellitus. Australian & New Zealand Journal of Medicine. 1980;10(3):346–350. [PubMed: 6931576]
  1449. Zimmet P, King H, Taylor R. The high prevalence of diabetes mellitus, impaired glucose tolerance and diabetic retinopathy in nauru - The 1982 survey. Diabetes Research. 1984;1(1):13–18. [PubMed: 6529880]
  1450. Zimmet PZ, Collins VR, Dowse GK, Knight LT. Hyperinsulinaemia in youth is a predictor of Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(6):534–541. [PubMed: 1612226]
  1451. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84(1):272–278. [PubMed: 9920095]
  1452. Zofkova I, Zamrazil V. Does exogenous hypermagnesaemia inhibit insulin secretion in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus? Horm Metab Res. 1994;26(3):157–159. [PubMed: 8005565]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...